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 Chronic pain leads neurological disorders in the US both in terms of numbers of 
cases and economic cost.  The understanding of sex differences in the sensory experience 
of pain is emerging.  For example, the incidence of many, but not all, chronic pain 
disorders is higher in women than men.  There is considerable evidence that sex steroids 
can modulate pain processing and may contribute to sex differences in chronic pain.  
However, there are no reports of direct, systematic investigation into the anatomical sites 
of action in the nervous system of the enhancement of pain by estrogen.  Thus, this 
research program aimed to determine the potential contribution of activational effects of 
sex hormones to pain sensation and was designed to test the overall hypothesis that sex 
differences in pain sensation are due, at least in part, to activational effects of sex 
hormones on peripheral, spinal and/or supraspinal sites involved in the transmission and 
perception of pain.  To test this hypothesis, established rodent models of pain were 
employed, and biochemical and behavioral end points were quantified. 
 Initial experiments used gonadectomy and testosterone supplementation to 
manipulate androgen status in adult, male rats, testing the impact of androgen 
manipulation on behavioral responses in several pain models.  Results revealed 
activational effects on pain of phasic thermal and persistent neuropathic origin, but 
perhaps not persistent inflammatory origin, providing evidence that androgens can 
contribute to sex differences in pain sensation.   
 Further experiments used ovariectomy and estradiol supplementation to 
manipulate estrogen status in adult, female rats, testing its impact on nociception-related 
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behavior and neuronal activation in response to formalin-evoked inflammatory 
nociception.  Results of behavioral analyses showed that estradiol increases persistent, 
inflammatory nociception in an activational manner.  Results of quantification of 
nociception-evoked neuronal activation (measurement of numbers of neurons expressing 
the protein Fos) showed that estrogen enhances inflammatory nociception primarily at 
higher brain centers, specifically the nucleus accumbens and the ventral hippocampal 
CA1 region.   
 These activational effects of estrogen may contribute to sex differences in pain 
sensation and/or the disproportionate severity or incidence of some pain syndromes in 
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BACKGROUND AND SIGNIFICANCE 
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1.1  Introduction 
 Chronic pain leads neurological disorders in the US in terms of the total number 
of cases and their annual economic cost (Carey, 2005; Loeser, 2001; Stucky et al., 2001).  
Interestingly, recently emerging studies have begun to characterize sex differences in the 
sensory experience of pain.  For example, the incidence of many chronic pain disorders, 
but not others, is higher in women than men, and for experimentally delivered stimuli, 
females have lower thresholds, higher pain ratings, and less tolerance of noxious stimuli 
than males (Berkley, 1997).  Many painful disorders show prevalence in women, and 
examples include migraine headache with aura, temporomandibular joint disorder, 
fibromyalgia, and pain of psychological origin (e.g. depression) (Berkley, 1997).  Women 
more often report multiple or recurrent pains than men, especially in certain body 
locations and at certain ages (James et al., 1991).  Many painful disorders vary in their 
incidence, disappearance, and prevalence as a function of menstrual stage, puberty, 
pregnancy, menopause, and age (Berkley, 1997).  For example, the incidence of migraine 
headaches and temporomandibular disorders varies with menstrual stage (Meisler, 1999).  
This is indirect clinical evidence that ovarian hormones such as estrogen may alter pain 
sensitivity.  There is also experimental evidence for this as well.  Female rats have 
heightened sensitivity to acute mechanical nociceptive stimuli during proestrus (Kayser et 
al., 1996), and the density of primary afferent innervation of the genitalia of female rats is 
greatest during proestrus (Robbins et al., 1992).  The formalin test is an established 
model of persistent inflammatory pain (Porro & Cavazzuti, 1993; Tjolsen et al., 1992).  
The pain response (nociceptive behaviors) to a formalin stimulus has previously been 
shown to be greater in female rats than males (Aloisi et al., 1994).  In addition, female 
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rats show less morphine-induced analgesia than males (Bodnar et al., 1988), and opioid 
receptor-mediated anti-nociception differs between men and women (Zubieta et al., 
2002), indicating the opioidergic system may play an important role in sex differences in 
pain.  Sex differences in analgesia are modulated by estrogen & other steroids (Berkley, 
1997).  Cicero et al. (1996) showed that male rats were more sensitive than females to 
morphine-induced anti-nociception, and that this difference was mediated by both spinal 
and supraspinal mechanisms.  They also concluded that this difference was due to 
organizational effects rather than acute, activational effects of gonadal steroids (see p. 28-
9).  However, other reports have concluded that gonadal steroids can affect morphine-
induced anti-nociception in an activational (acute) manner.  Highly relevant to this 
research proposal, responses to inflammatory pain, both clinically and experimentally, 
vary with the estrous cycle of the female (Bradshaw et al., 2000; Fillingim et al., 1997; 
Hellstrom & Anderberg, 2003; Isselee et al., 2002; Lautenbacher & Rollman, 1993; 
LeResche et al., 2003; Somerville, 1972; Tall & Crisp, 2004). 
 Depression is about twice as prevalent in women than men (Bromberger, 2004).  
This gender difference emerges at the onset of puberty (menarche), and indicates a 
possible role for gonadal steroids such as estrogen (Bromberger, 2004; Steiner et al., 
2003).  Women are at heightened risk of depression and other mental disorders during 
postpartum time periods (Steiner et al., 2003), and the apparent higher vulnerability of 
women to depression could, at least ostensibly, be explained by large or rapid changes in 
ovarian hormone levels that occur during puberty, postpartum, perimenopause, or 
premenstrually (Bromberger, 2004).  Since these large hormonal changes coincide with 
changes in mood, a causal link can logically be, and has been, suggested (Steiner et al., 
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2003).  However, there is little evidence directly linking these hormone levels and 
depressed mood (Bromberger, 2004).  There is an association of depression with pain, as 
discussed below.  Thus, estrogen could contribute to the incidence of depression by 
modulation of pain or through other mechanisms related to limbic system function (Allen 
& McCarson, 2005).  
 Pain is defined by the International Association for the Study of Pain as an 
unpleasant sensory and emotional experience associated with tissue damage or described 
in terms of such damage.  Thus, pain is a complex conscious experience that involves not 
only the transduction of noxious environmental stimuli, but also emotional and cognitive 
processing by the brain (Julius & Basbaum, 2001).  Pain normally serves as a warning 
mechanism to living beings of potential or real tissue damage.  The nervous system 
involved in the processing of nociceptive stimuli mediates protective mechanisms such as 
reflex withdrawal from the harmful stimuli.  This natural defense system is fast-acting 
and can be adaptive.  Sometimes the pain outlasts the injury, outliving its usefulness as a 
warning/protective system (Julius & Basbaum, 2001).  The pain can then become chronic 
and potentially debilitating, a maladaptive process involving changes in the brain, spinal 
cord, and primary sensory neuron (nociceptor) (Julius & Basbaum, 2001).  Chronic pain 
can result in anxiety, depression, and reduced quality of life (Hunt & Mantyh, 2001).  
Chronic pain often is accompanied by depression, and vice versa, indicating an 
association between the two disorders (Blackburn-Munro & Blackburn-Munro, 2001; 
Fishbain et al., 1997; King, 1991), and leading to speculation that chronic pain could be a 
variant of depression (Blumer & Heilbronn, 1982).  Fishbain et al. (1997) concluded that 
depression was more likely a consequence of chronic pain than vice versa, supporting the 
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consequence or scar (predisposition to depression) hypotheses of chronic pain-associated 
depression.  Recent studies have characterized hippocampal responses to pain that mimic 
those induced by stress and depression (Duric & McCarson, 2005, 2006a, 2006b). 
 Numerous reports have addressed the modulation by estrogen of biochemicals 
involved in nociceptive neuronal signaling or behavioral responses.  However, there are 
no reports of direct, systematic investigation into identification of the anatomical sites of 
action in the nervous system of the enhancement of nociception and pain by estrogen.   
 
1.2  Neuronal pain signaling 
1.2.1  Pathways - Overview 
 A complex system of many neurons is involved in the sensing and processing of 
noxious stimuli (See Figure 1 for a diagrammatic overview).  Noxious stimuli are 
detected by primary afferent neurons also known as nociceptors.  These neurons arise 
from the trigeminal or dorsal root ganglia (DRG) where their cell bodies reside.  The 
nociceptors then form synapses with secondary afferent neurons in the spinal cord.  These 
secondary spinal neurons make up the spinothalamic tract, or anterolateral system, which 
extend up the spinal cord and terminate in the thalamus and other midbrain centers.  The 
thalamus then acts as an integrator and relay for sensory information and sends third 
order neurons projecting to the cortex.  The spinothalamic tract also sends collateral 
branches to the lateral parabrachial nucleus in the pons, which in turn sends projections to 
the amygdala, one part of the limbic system. 
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Figure 1.  Neuronal pathways of nociception/pain. 
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1.2.2  Primary afferent nociceptors 
 Primary afferent neurons that innervate the head and body have their cell bodies 
in the trigeminal or DRG, respectively, and are the first nerves to be activated by noxious 
stimuli.  Primary afferent nociceptors are primarily made up of two types of nerve fibers: 
Aδ and C fibers.  They are described as being thinly or unmyelinated, respectively, and 
mediating fast and slow pain, respectively, a phenomenon related to their conduction 
velocities.  Fast (or first) pain is described as sharp or cutting, and slow (or second) pain 
described as more diffuse and dull.  Nociceptors are further characterized by the type of 
noxious stimulus they are most sensitive to (adequate stimulus).  Both Aδ and C fibers 
can be activated by mechanical stimuli.  Aδ fibers are further divided based on their 
differential abilities to also be stimulated by thermal stimuli.  Most C fibers are 
polymodal, responding to both thermal and mechanical stimuli.  Some are only activated 
by mechanical stimuli.  In addition, most C fibers are also activated by noxious chemicals 
such as acid or capsaicin.  There are also “silent” nociceptors that are recruited during 
sensitization due to tissue damage.  It is possible that this is attributable to recruitment of 
Aβ sensory fibers (Millan, 1999).    
 
1.2.3  Spinal cord pain processing 
 Processing of nociception is critical at the synapse between the primary afferent 
neuron and the secondary neuron residing in the dorsal horn of the spinal cord.  
Somatosensory and nociceptive neurons from the hind limbs (legs) terminate in the 
lumbar segments of the spinal cord.  Aδ fibers terminate primarily in laminae I and V of 
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the spinal cord dorsal horn on secondary fibers that project to the thalamus and lateral 
parabrachial nucleus.  C fibers are divided into two classes based on their content of 
neuropeptides, substance P (SP) and calcitonin gene-related peptide (CGRP).  C fibers 
that contain these peptide neurotransmitters synapse in the most superficial layers of the 
dorsal horn, lamina I and outer lamina II, largely on second order neurons that project to 
higher pain processing centers in the brain, including the amygdala via a synapse in the 
lateral parabrachial nucleus.  The other, nonpeptidergic C fibers synapse in the inner 
lamina II, primarily on interneurons, which have short, intraspinal projections. Wide 
dynamic range neurons, with their cell bodies in lamina V, receive input from Aδ and C 
nociceptors, as well as Aα/β somatosensory fibers.  These wide dynamic range neurons 
then project up to the thalamus. 
 
1.2.4  Spinal nociceptive reflexes 
 The spinal cord serves a protective role by mediating the flexor (and crossed-
extension) reflex.  This spinal nociceptive reflex is mediated by polysynaptic pathways 
involving interneurons.  In this phenomenon, cutaneous Aδ nociceptors are activated by a 
noxious stimulus, and synapse on interneurons in the dorsal horn.  Several interneurons 
are activated sequentially, which leads to an excitatory synapse onto flexor motor 
neurons, which causes withdrawal of the body part from the noxious stimulus.  There is 
also reciprocal innervation of the extensor muscle via inhibitory interneurons to facilitate 
the movement.  Sometimes there is innervation to a contralateral limb to mediate what is 
referred to as the crossed-extension reflex.  Spinal animals have been used in the 
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laboratory to demonstrate these simple reflexes so they are not obscured by modulation 
from higher CNS levels.   
 
1.2.5  Thalamic nociceptive relays 
 Spinothalamic neurons are heavily myelinated and project up the spinal cord to 
the intralaminar nuclei of the thalamus via the paleospinothalamic tract.  This tract also 
sends collateral branches to the amygdala via the parabrachial nucleus of the pons and to 
the hypothalamus.  There are nociceptive projections from the spinal cord to the nucleus 
reticularis gigantocellularis (NGC) in the medulla, which relays projections to the 
thalamus (Peschanski & Besson, 1984).  The thalamus acts as an integrator and relay for 
sensory information and sends (“third order”) neurons projecting to the primary sensory 
cortex and cingulate gyrus, as well as diffuse areas of the cortex associated with a poorly 
localized sensation of pain.  In addition, the thalamus has reciprocal communication with 
the hypothalamus.   
 
1.2.6  Limbic system contributions to the negative affective component of pain 
 The limbic system is the key center for processing the affective, or emotional, 
component of pain.  It is integrally involved in the regulation of many emotions, such as 
love, fear, and depression, and their autonomic responses.  This system has many 
components, including cortical areas, the hippocampal formation, septal complex nuclei, 
the amygdala, nucleus accumbens, and hypothalamus.  The hypothalamus coordinates 
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and mediates mental and physiological, and especially autonomic, responses associated 
with emotions.  The amygdala is needed for expression of emotions, and evokes both 
emotional feeling and autonomic responses.  Projections from the amygdala have a 
prominent effect on hypothalamic function.  The hippocampal formation plays a 
predominant role in stress responses.  There are extensive connections feeding back from 
the cortex to limbic structures, especially direct projections from the prefrontal areas to 
the amygdala and hypothalamus.  Much of the behavioral information known about 
emotions pertains to the amygdala and prefrontal cortex.  There is also extensive 
communication of the hippocampus with cortical areas and hypothalamus.   
 
1.2.7  Descending modulation of pain 
 There is much documented knowledge of descending inhibition of spinal 
nociceptive transmission from supraspinal centers.  Major centers in the descending 
inhibitory pathways include the periaqueductal grey (PAG), nucleus raphe magnus 
(NRM), nuclei reticularis gigantocellularis (NGC), gigantocellularis pars alpha (NGCα), 
paragigantocellularis (NPG), and anterior pretectal nucleus (APtN).  Of these, the PAG 
and NRM are the most thoroughly described.  The PAG receives input from the frontal 
and insular cortex, amygdala, and hypothalamus (Beitz, 1982b; Mantyh, 1983).  Major 
brainstem inputs that activate PAG neurons come from the nucleus cuneiformis and 
pontine reticular formation (Basbaum & Fields, 1984).  The PAG sends serotonin (5HT) 
and neurotensin projections to the rostral medulla (Beitz, 1982a, 1982c).  The rostral 
ventromedial medulla (RVM) in particular is a major site for projecting neurons to the 
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dorsal horn, mainly via the dorsolateral funiculus (DLF), making it an important relay for 
the descending inhibition.  The NRM is one important part of the RVM, and sends 5HT-
neurons, which may also contain substance P (Hokfelt et al., 1978), to the spinal cord 
(Basbaum & Fields, 1984).  The NGC, NGCα, and NPG also project to the spinal cord, 
possibly releasing 5HT or norepinephrine (NE), although the neuronal sources for NE 
from the brainstem to the spinal cord are not well known (Basbaum & Fields, 1984).  The 
PAG also has direct connections with the spinal cord (Mantyh & Peschanski, 1982), but 
the medullary relays are necessary for descending inhibition.  Descending neurons 
impinge upon inhibitory interneurons in the spinal dorsal horn that release opioids, 
especially enkephalins but also endorphins (Basbaum & Fields, 1984).  These opioids 
have both presynaptic and postsynaptic inhibitory effects on primary afferent and 
secondary spinothalamic projection neurons, respectively.   
 There is also supraspinal descending facilitation of nociceptive neurotransmission 
in the spinal cord that has been reported, especially for rodent hind paw responses.  Zhuo 
and Gebhart (1992) showed that electrical or glutamate stimulation of the NGC and 
NGCα can produce facilitation or inhibition of spinal transmission in response to noxious 
heating of the hind paw, depending on intensity of stimulation of the nuclei.  Mustard oil-
induced mechanical allodynia in rat hind paws was blocked by spinalization or lidocaine 
injection into the nucleus raphe magnus (NRM) or lateral reticular nucleus (LRN) of the 
medulla (Mansikka & Pertovaara, 1997).  Spinalization also raised mechanical thresholds 
for hind paw withdrawal reflexes in inflamed and non-inflamed paws (Mansikka & 
Pertovaara, 1997).  It is also evident that the hind limb and tail reflexes are differentially 
modulated by supraspinal influences, a phenomenon which may be further dependent on 
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the type of noxious stimulus (Aimone & Gebhart, 1986; Bian et al., 1998; Mansikka & 
Pertovaara, 1997).  This information robustly implicates supraspinal sites (including the 
NRM, LRN, NGC, and NGCα) in descending facilitation of nociceptive signaling in the 
spinal cord (particularly the lumbar region).   
 
1.3  Molecules & mechanisms 
1.3.1  Peripheral nociceptor activation 
 Primary afferent nociceptors detect noxious thermal, mechanical, and chemical 
stimuli.  They do this via receptors on their distal terminal.  The main receptor 
responsible for detection of noxious heat is transient receptor potential vanilloid 1 
(TRPV1), a member of the transient receptor potential (TRP) family.  The TRPV1 
channel is a non-selective cation channel that spans the cell membrane, and is activated 
by capsaicin as well.  It is expressed on C and type II Aδ fibers, which respond to heat 
with a threshold of ~45 °C as well as to capsaicin (Julius & Basbaum, 2001).  Type I Aδ 
fibers have a higher thermal threshold, ~52 °C, and do not respond to capsaicin (Julius & 
Basbaum, 2001).  It is not clear what receptor(s) is responsible for high-threshold thermal 
detection in these fibers; it is apparently not TRPV1, but could be a similar vanilloid 
receptor-like channel, TRPV2 (a.k.a. VRL-1) (Caterina et al., 1999).  There are also 
noxious cold-activated fibers, but their mechanism of activation is unknown and different 
than that of heat detection.  Alterations in sodium, potassium, or calcium currents have 
been speculated as potential mechanisms for this activation (Askwith et al., 2001; Reid & 
Flonta, 2001; Suto & Gotoh, 1999).   
13 
 Receptors for mechanical sensation have been extensively studied in Drosophila 
and C. elegans (Syntichaki & Tavernarakis, 2004).  These studies have provided 
promising candidates for receptors of noxious mechanical stimulation in mammals, most 
likely in the degenerin/epithelial sodium channel (DEG/ENaC) family.  Also, TRPV4 is a 
mechanosensitive channel in mammals that has been implicated in hypotonic nociceptive 
detection (Alessandri-Haber et al., 2003).   
 Other receptors on nociceptors can be activated by chemicals such as protons 
(H
+
).  For example, TRPV1 and members of the acid sensing ion channel (ASIC) family 
are important H
+
 receptors.  Protons also potentiate responses to capsaicin and heat, and, 
thus, take part in the phenomenon of convergence at the molecular level by modulating 
TRPV1.  This is an important part of the inflammatory sensitization that follows tissue 
damage, as tissue acidosis ensues.  Receptors for many other chemicals exist on the nerve 
terminal that excite or sensitize (decrease threshold of) the neuron.  Such chemicals that 
are important for mediating (peripheral) inflammatory sensitization make up the so-called 
“inflammatory soup,” and include bradykinin, prostaglandins, 5HT, ATP, and nerve 
growth factor (NGF).  Part of this sensitization is neurogenic inflammation, which is an 
efferent function of the nociceptors.  This involves the release of SP and CGRP, which 
causes vasodilation and extravasation.  Substance P also activates mast cells or 
neutrophils to release inflammatory mediators such as histamine.  Activation of cAMP-
dependent protein kinase (PKA) and protein kinase C (PKC) pathways also contributes to 
peripheral sensitization by enhancement of TRPV1 function (Varga et al., 2006).  
Following inflammation, TRPV1 and sensory neuron-specific sodium channel (SNS) 
expression is up-regulated in the primary afferent (Michael & Priestley, 1999; Tate et al., 
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1998).  Extracellular signal-regulated kinase (ERK) may also be involved in peripheral 
sensitization of primary afferent nociceptors (Dai et al., 2002).   
 
1.3.2  Neurotransmission and intracellular signaling 
 Glutamate and its receptors, as well as the tachykinin substance P and its 
neurokinin-1 (NK-1) receptor, are perhaps the most important signaling molecules for 
synaptic transmission of nociception.  Glutamate is the major excitatory neurotransmitter 
of the peripheral and central nervous system, and has many receptors that are 
metabotropic or ionotropic.  Glutamate and SP are released by the primary afferent 
nociceptors at their synapses in the spinal cord.  NK-1 is expressed mainly in the 
superficial laminae (I and II) of the spinal cord (Mantyh et al., 1989; Moussaoui et al., 
1992), and is a G-protein coupled receptor that signals through Gαq/11.  This activates 
phospholipase C (Hanley et al., 1980), which in turn mobilizes internal Ca
2+
 stores (Streb 
et al., 1983) and activates protein kinase C (Kishimoto et al., 1980).  The Ca
2+
, via 
interaction with Ca-calmodulin kinases, may also activate phosphorylation of other 
proteins, such as cyclic AMP response element binding protein (CREB), and, thus, 
stimulate the immediate early gene c-fos (Miyamoto, 2006).  Gamma-amino butyric acid 
(GABA) and type A & B GABA receptors are important for pre- and postsynaptic 
inhibition of signal transmission via interneurons, and opioid receptors (OR) are 
important for pre- and postsynaptic descending inhibition of nociceptive signaling.   
 Cell-surface receptors that mediate neuronal transduction can be either ionotropic 
or metabotropic [the G-protein coupled receptors (GPCR)].  Ionotropic receptors are ion 
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channels that directly regulate ion flux across the cell membrane.  Metabotropic receptors 
have indirect effects on ion flux via second messengers that modulate ion channels.  Once 
excitatory neuronal cell-surface receptors are activated, they depolarize the cell 
membrane potential, or electrochemical gradient.  This is done by altering the 
permeability/flux of ions across the membrane through ion channels.  If the stimulus is 
great enough, the depolarization is sufficient to raise the membrane potential to the 
threshold, the point at which voltage-gated ion channels open.  Especially important for 
this are voltage-gated sodium (Na
+
) channels, which further depolarize the neuron and 
propagate an action potential (AP) by allowing Na
+
 inflow.  Voltage-gated potassium 
(K
+
) channels then open, allowing K
+
 to flow out, deactivating Na
+
 channels, and 
repolarizing the cell.  When the AP reaches the synaptic terminal, the depolarization 
opens voltage-gated Ca
2+
 channels, followed by Ca
2+
 activation of soluble N-
ethylmaleimide-sensitive factor attachment protein receptors (SNARE) such as 
synaptobrevin.  Synaptobrevin works with synapsin to mediate exocytosis of vesicles 
containing neurotransmitters.  The neurotransmitter then binds to post-synaptic receptors 
on the secondary neurons and produces either an excitatory or inhibitory post-synaptic 
potential.  Neurotransmitters can also bind to pre-synaptic “autoreceptors” that regulate 
neurotransmitter release.   
 The immediate early gene c-fos is rapidly and transiently expressed in neurons 
following stimulation.  The protein product of c-fos, Fos, forms dimers with Jun proteins 
to make activator protein-1 (AP-1) complexes, which act as transcription factors 
regulating expression of downstream genes.  Fos has been used extensively as a neuronal 
marker of nociceptive activation in brain and spinal cord pathways (Bon et al., 2002; 
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Ceccarelli et al., 1999; Doyle & Hunt, 1999; Harris, 1998; Herrera & Robertson, 1996; 
Kaneko et al., 2000; Khanna et al., 2004; Kovacs, 1998; Menetrey et al., 1989; Presley et 
al., 1990; Sandner et al., 1993)  Fos expression in neurons is most effectively manifested 
by robust, prolonged and/or repeated activation.  The expression of Fos in the spinal 
dorsal horn following noxious simulation is mainly in lamina I, IIo, V, and VI, 
corresponding to the distribution of nociceptor terminals, and is different than that 
following non-noxious stimulation (Harris, 1998).  In addition, the number of Fos-
positive neurons in the spinal cord follows a dose-response relationship with formalin 
injection into the hind paw of rats (Kaneko et al., 2000). 
 ERK is a mitogen-acitvated protein kinase (MAPK), with phospho-ERK (pERK) 
being an indicator of cellular activation, and can be activated by, among other things, 
inflammatory cytokines (Alberts et al., 2002).  ERK1 and ERK2 are activated by the 
upstream mitogen-activated ERK kinase (MEK) (Cano & Mahadevan, 1995; Seger & 
Krebs, 1995).  They mediate short-term effects by phosphorylating kinases, receptors, 
and ion channels, and long-term effects by activating transcription factors such as CREB 
(Impey et al., 1999).  The Src family of cytoplasmic tyrosine kinases includes Src itself 
and, via phosphorylation, activates kinase pathways, including ERK (Alberts et al., 









1.3.3  Central sensitization 
 The phenomenon of central sensitization occurs during persistent inflammatory or 
neuropathic pain, and consists of facilitation of excitatory signaling and decreased 
inhibition (Woolf & Salter, 2000).  This produces pain responses to normally innocuous 
stimuli (allodynia) and hyperalgesia in areas outside the tissue injury.  A major 
component of this central sensitization is up-regulation of the N-methyl-D-aspartate 
(NMDA) receptor for glutamate.  The enhancement of NMDA activity in the spinal cord 
could be due to the tyrosine kinase Src (Yu et al., 1997) or PKC, for example.  Two 
mechanisms contribute to NMDA-mediated sensitization: 1.  Reduced Mg
2+
 blockade of 
NMDA channels, which is done by PKC, and 2.  Enhanced NMDA function by 
converging signaling cascades from GPCRs, such as NK-1 or mGlu receptors, and 
receptor tyrosine kinases, for example the trkB receptor for brain-derived neurotrophic 
factor (BDNF) (Woolf & Salter, 2000).  A point of convergence for these may be PKC, 
which indirectly potentiates NMDA currents in hippocampal neurons by activating Src 
(Lu et al., 1999).  The MAPK pathway is also implicated in NMDA-mediated central 
sensitization (Woolf & Salter, 2000).  In addition, PKC regulates α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) (glutamate receptor) channel membrane 
insertion in the spinal cord (Li et al., 1999).  Another component of central sensitization 
is decreased spinal inhibition, which may be largely mediated by GABAergic 
interneurons (Woolf & Salter, 2000).  In addition to modulation of central neurons, 
following inflammation, A-fibers begin expressing substance P and BDNF, which may 
increase the ability of stimulation of peripheral neurons to contribute to central 
sensitization (Woolf & Salter, 2000).    
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1.4  Experimental models of persistent pain 
 Subcutaneous injection of formalin is a commonly used model of persistent 
inflammatory pain (Tjolsen et al., 1992).  It is usually used in mice and rats, and may 
provide a better approximation of clinical chronic pain than traditional phasic nociceptive 
tests, such as acute radiant thermal, hot-plate, or mechanical paw withdrawal tests.  
Formalin is a dilute solution of formaldehyde, and, therefore, is a cross-linking agent at 
amino groups, disrupting proteins (Harvey, 1975; Metz et al., 2004).  This induces tissue 
changes that are typical of inflammation such as mast cell degranulation, edema, and 
invasion of granulocytes.  Formalin induces a biphasic pain-related behavioral response, 
separated by a quiescent interphase.  The first (early) phase is due to C-fiber activation, 
while the second (late) phase is due to peripheral inflammation and central sensitization. 
This central sensitization is instigated by C-fiber activity, and is due to functional 
changes in the spinal cord (Coderre et al., 1990; Hunskaar & Hole, 1987).  The 
behavioral responses that can be evaluated include lifting, licking, biting, and flinching of 
the injected paw.  The flinching response seems to be a consistent component of the 
response, and is easy to observe and quantify.  The other behavioral responses have been 
more problematic, and it has been suggested that flinching is less influenced by 
conditions that affect non-nociceptive behavior, and, thus, is a better end-point (Tjolsen 
et al., 1992).   
  
20 
1.5  Therapeutic approaches to the control of pain 
 Current therapies for pain by and large still consist of either opioids (narcotics) or 
non-steroidal anti-inflammatory drugs (NSAIDs).  Opioids target the opioid receptors, 
and their primary sites of analgesia are thought to be in the PAG and NRM.  NSAIDs 
inhibit the cyclooxygenase (COX) enzymes, and newer NSAIDs are selective for certain 
subtypes of COX enzymes.  Despite their wide use as analgesics, opioids and NSAIDs 
have quite a few deficiencies and problematic adverse effects (Schmidt, 2003).  Opioids 
carry with them adverse effects such as drowsiness, dizziness, and vomiting, as well as 
significant toxicity and propensity for tolerance and addiction (Schmidt, 2003).  NSAIDs 
can cause gastrointestinal ulcers and bleeding, and long-term use can produce liver and 
kidney toxicity.  In addition, NSAIDs and opioids are sometimes ineffective at providing 
complete analgesia, especially for moderate-severe pain, and opioids can be cross-
tolerant to morphine for chronic pain (Schmidt, 2003).  Thus, there are significant needs 
for development of analgesics that have reduced adverse effects and provide more 
personalized treatment of specific pain states.  Clinical treatment with “antidepressants” 
such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants 
(TCAs) has provided analgesia for some chronic pain conditions, regardless of presence 
of depression (Guay, 2001).  Many analgesics, anti-inflammatory drugs, and anti-
migraine drugs are currently under development, some of which have novel mechanisms 
of action.  Some of these emerging therapeutic strategies may be more appropriate for 
treating women with pain or depression. 
 
21 
1.6  Estrogen and its mechanistic contribution to pain sensation 
1.6.1  Biology of estrogen 
 Estrogens are endogenous steroid hormones that have various physiological 
functions.  In females, these functions include developmental effects such as sexual 
differentiation, control of ovulation, and actions on processes that effect body 
composition, for example mineral, carbohydrate, protein, and lipid metabolism (Loose-
Mitchell & Stancel, 2001).  The most abundant and potent estrogen occurring in humans 
is 17β-estradiol (estradiol, E2), followed by estrone and estriol.  The most common 
pharmacological uses of estrogens are oral contraception and hormone replacement 
therapy in postmenopausal women (Loose-Mitchell & Stancel, 2001).   
 
1.6.2  Estrogen metabolism 
 Steroid hormones are made from cholesterol (See Figure 3), and synthesis of 
steroids (steroidogenesis) takes place in the adrenal gland, ovaries, testes and placenta.  
Cholesterol can come from the diet or can be synthesized from acetate.  Androstenedione 
is a common precursor for the sex hormones (androgens and estrogens), and can be 
converted into testosterone, an androgen, or estrone and then estradiol.  Testosterone then 
can be converted into 5α-dihydrotestosterone (DHT) or E2.  The conversion of 
adrostenedione to estrone and of testosterone to E2 is catalyzed by aromatase.  Aromatase 
is a cytochrome P450 monooxygenase enzyme complex (CYP19A1), which uses 
NADPH and molecular oxygen as cofactors (Simpson et al., 1994).  Aromatase is located 
in the endoplasmic reticulum of ovarian granulosa cells, testicular sertoli and leydig cells, 
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stromal cells of adipose tissue, placental syncytiotrophoblasts, bone, skin, hair, and most 
areas of the brain (Simpson et al., 1999).  Aromatase is expressed in neurons but not glial 
cells (Lephart, 1996).  Since aromatase is found in the nervous system, circulating 








 Ovaries are the primary source of estrogen in premenopausal women.  In the 
ovaries, theca cells secrete androgens, which are then converted to estrogens, especially 
E2, and secreted by the granulosa cells.  Gonadal hormone synthesis and aromatase 
activity is stimulated by gonadotropins luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) from the pituitary that bind to GPCRs that stimulate cAMP production.  
Secretion of LH and FSH is stimulated by release of gonadotropin releasing hormone 
(GnRH) from the hypothalamus, which is regulated by feedback of estrogen.  In men and 
postmenopausal women, the primary source of estrogen is the adipose tissue stroma, 
which produces estrone (Loose-Mitchell & Stancel, 2001).   
 Most circulating estrogens are bound to serum albumin with low affinity, or sex 
hormone-binding globulin (SHBG) with high affinity.  Rats do not express a protein 
equivalent to SHBG.  Estrogens are metabolized in the liver by oxidation or conversion 
to glucuronides or sulfates, and excreted in the urine.  In adult female rats, the half-life of 
serum estradiol is about 4 minutes (Noe et al., 1992).  This short half-life is consistent 
with the observation by Lesclous et al. (2001) that endogenous serum estradiol levels 
drop markedly within 4 days of ovariectomy (OVX) in adult Sprague-Dawley rats.   
 
1.6.3  Mechanisms of estrogen signaling 
 Two main mechanisms of estrogen action are “genomic” and “nongenomic.”  
Genomic actions are more delayed and prolonged, whereas nongenomic actions are rapid 
and more transient.  Classical estrogen actions are characterized as genomic and are 
carried out by the nuclear estrogen receptors (ERs), members of the nuclear 
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steroid/thyroid receptor superfamily.  Nongenomic actions may be carried out by ERs or 
a putative membrane-bound G-protein coupled estrogen receptor, mER (Qiu et al., 2003).  
Estrogen actions via second messengers may have either genomic or nongenomic 
mechanisms, each of which may be from classical ERs or the putative mER.  An 
overview of estrogen signaling mechanisms is shown in Figure 4. 
 Two subtypes of nuclear ER have been identified: ERα and ERβ.  These ERs are 
transcription factors that, upon ligand binding, form homo- or hetero-dimers, translocate 
to the nucleus, and regulate transcription of target genes by binding to specific DNA 
elements.  These DNA elements are called estrogen response elements (ERE), and are 
cis-acting enhancers located in promoter regions of target genes.  The DNA-bound ER 
dimer interacts with the transcription apparatus either directly or indirectly via cofactors 
(Hall et al., 2001).  The major functional domains of the ERs, from amino- to carboxyl-
terminus, are a ligand-independent transcription activation function-1 (AF-1) domain, a 
DNA binding domain with two zinc fingers essential for binding, a hinge, and a ligand-
dependent transcription activation function-2 (AF-2) (Nadal et al., 2001).  The ERs can 
also regulate transcription of genes at sites other than EREs.  This is done by interaction 
of the activated ER with other transcription factors, such as the activator protein-1 (AP-1) 
complex of Fos/Jun, thereby up-regulating transcription (Hall et al., 2001).  However, the 
human ERβ cannot activate transcription at AP-1 sites, due to its lack of the AF-2 domain 
(Hall et al., 2001).  In addition, ERs can be activated by phosphorylation due to 
extracellular growth factor activation of intracellular kinases, and this ligand-independent 
activation modulates binding to EREs and transcription (Hall et al., 2001).  The 
distribution of ERα and ERβ in the body differ greatly, with moderate to high expression 
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of ERα in pituitary, kidney, epididymis, and adrenal, moderate to high expression of ERβ 
in prostate, lung, and bladder, and overlapping high expression in brain, ovary, testis, and 
uterus (Kuiper et al., 1997; Kuiper et al., 1998; Shughrue et al., 1996).   
 There are limited and controversial findings on estrogen action at the cell 
membrane.  Some reports suggest the presence of a novel membrane-bound estrogen 
receptor, mER, while others demonstrate membrane locality and function of classical 
ERs.  Early studies showed antibody labeling of ERα at or near the cell surface, and in 
membranes of Chinese hamster ovarian cells transfected with ERα and ERβ, estradiol 
activated Gαq and Gαs, which rapidly stimulated inositol phosphate production and 
adenylyl cyclase activity (McEwen & Alves, 1999).  Also, ERα and ERβ have 
nongenomic activity in caveolae, stimulating eNOS activity (Chambliss et al., 2002).  In 
contrast, there are reports of a novel mER that is coupled to Gαq and stimulates 
phospholipase C, leading to stimulation of PKCδ and PKA (Qiu et al., 2003; Qiu et al., 
2006).  This activity was coupled to rapid desensitization of GABAB and μ-opioid 
receptors in hypothalamic neurons (Qiu et al., 2003; Qiu et al., 2006).  Furthermore, a 
non-steroidal compound, STX, has been synthesized (Tobias et al., 2006), which 
selectively stimulates this mER and has no binding affinity for nuclear ERα or ERβ.  
STX was more potent than E2 at mediating this desensitization, and both E2 and STX 
were fully efficacious in ERα,β knock-out mice (Qiu et al., 2006).   
 In addition to these findings, there are several second messenger systems that 
could mediate estrogen effects.  One of these is increased cAMP.  Estrogen increased 
cAMP levels in MCF-7 or uterine cells in culture and, in some brain regions, increased 
phosphorylation of CREB via a cAMP-dependent mechanism (Aronica et al., 1994; Gu et 
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al., 1996; Zhou et al., 1996).  This represents a pathway for gene regulation by estrogen 
through phosphorylation of DNA-binding proteins such as CREB.  Mitogen activated 
protein kinase (MAPK) activity is another possible second messenger mechanism of 
estradiol action.  Several reports have shown that ERs (and androgen receptors) directly 
interact with and stimulate Src, and stimulate ERK phosphorylation (Harrington et al., 
2006; Kousteni et al., 2001; Migliaccio et al., 2000).  There is also evidence that 
estrogen-dependent ERK-1 and ERK-2 phosphorylation may not involve a classical ER 
(McEwen & Alves, 1999).  Yet another second messenger pathway for estrogen action is 
via calcium homeostasis.  In one example, estradiol rapidly inhibits L- and N-type high-
voltage-activated (HVA) Ca
2+
 channel currents (Lee et al., 2002; Mermelstein et al., 
1996).  This effect was nongenomic and seemed to be mediated by a unique ER on the 
cell surface (McEwen & Alves, 1999).  There are also reported estrogen effects on 
calcium currents that appear to be due to intracellular, genomic action, requiring protein 




Figure 4.  Estrogen signaling pathways/mechanisms.   
 
1.6.4  Estrogens and the nervous system 
 There are estrogen receptors (ER) (Kato et al., 1994) and androgen receptors (AR) 
distributed throughout the (rat) central and peripheral nervous system, largely in neurons 
(Melcangi et al., 2005; Patrone et al., 1999; Simerly et al., 1990).  The distribution of 
ERα and ERβ within the central nervous system is differential, and initial reports 
indicated that ERβ was more widely distributed, with overlapping areas (Shughrue et al., 
1997).  There is much higher expression of ERα mRNA in the amygdala and 
ventromedial hypothalamic nucleus, whereas ERβ mRNA has higher expression in 
cerebellum, hypothalamus, cerebral cortex, and hippocampus.  In the hippocampus, ERα 
is expressed, but at a much lower level, and both ERs are distributed evenly in the frontal 
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cortex (Shughrue et al., 1997).  The bed nucleus of the stria terminalis, preoptic area, and 
medial amygdala co-express ERα protein and ERβ mRNA, while in other regions such as 
the arcuate, ventromedial nucleus and cortical amygdala, co-expression of ERα and ERβ 
is very rare (Woolley, 1999).  A moderate amount of cells expressing ERβ were found in 
the spinal cord lamina II, and a scattered expression of ERα was found in laminae I, II, 
VI, VII, and X (Shughrue et al., 1997).  Sohrabji et al. (1994) showed that ERα is 
expressed in small DRG neurons, while ERβ is expressed in large, medium, and small 
DRG neurons (Taleghany et al., 1999).   
 Estrogens have numerous and varied effects on nervous system functions.  For 
instance, estrogens affect verbal and spatial memory, motor skills, and appear to have 
neuroprotective effects in culture and in conditions such as Alzheimer’s disease and 
Parkinson’s disease, among others (Gillies et al., 2004; McEwen & Alves, 1999).  Sex 
differences in and estrogen effects on the serotonergic, cholinergic, dopaminergic, and 
noradrenergic systems may all contribute to affective state, movement disorders, and 
cognitive function (McEwen & Alves, 1999).   
 There is permanent developmental sexual differentiation of the nervous system, 
influencing both neuronal wiring and responses to hormonal regulation of gene 
expression (McEwen & Alves, 1999; Morris et al., 2004).  Many of the effects of 
estrogens on the nervous system differ qualitatively or quantitatively between the sexes, 
implying that they may be due to sexual differentiation during pre- or post-natal 
development and/or by different levels of sex hormones (McEwen & Alves, 1999).  In 
fact, estrogen itself imparts many developmental (organizational) effects and transient 
(activational) effects during adulthood on the nervous system (Becker et al., 2005; Morris 
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et al., 2004).  In many regions of the developing and adult brain, estrogen has actions on 
structural development, synaptogenesis, and morphological plasticity (Beyer, 1999).  
Estrogen promotes neurite outgrowth, dendritic spine formation, and synapse formation 
(Murphy et al., 1998; Toran-Allerand, 1991; Woolley & McEwen, 1993).  Estrogen 
regulates neurogenesis in the dentate gyrus of the hippocampus, which produces new 
neurons in adulthood, and this effect fluctuates with the estrous cycle (Tanapat et al., 
1999; Woolley & McEwen, 1992).  A possible consequence of post-menopausal loss of 
estrogen in women is loss of synaptic connections in the hippocampus (Woolley & 
McEwen, 1992).  In the anteroventral periventricular nucleus, males express more 
preproenkephalin mRNA than females, and the opposite is true for prodynorphin; females 
that are androgen sterilized at birth have male patterns of neuropeptide gene expression, 
indicating an important organizational role of estrogen (McEwen & Alves, 1999).  On the 
other hand, expression of ERα in the hippocampus and dorsal raphe nucleus appears to be 
similarly regulated by estradiol in both sexes (Alves et al., 1998; Weiland et al., 1997).   
 There are numerous reports on the effects of gonadal hormones on sensory and 
nociceptive sensitivity, and the nervous system components that have these functions.  
Robinson and Short reported that the skin of the nipples, areolae, and breast had no sex 
differences in sensitivity prepubertally, while postpubertally sensitivity increased 
markedly in women but not men, indicating a role of increasing gonadal hormones 
(Robinson & Short, 1977).  In rodents, estrogen injection increased the receptive field 
size of trigeminal mechanoreceptors (Bereiter et al., 1980).  Estrogen and inflammation 
increases the excitability of rat temporomandibular joint afferent neurons in an additive 
manner (Flake et al., 2005).  Dina et al. (2001) showed gender differences in PKC, PKA, 
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and NO signaling in epinephrine-induced hyperalgesia that were estrogen dependent.  
Estrogen has a vasodilatory action in vascular endothelium, regulating synthesis of NO, 
and thus may have a vascular influence in syndromes such as migraine headache.  In the 
DRG, estrogen up-regulates expression of the trkA (tyrosine kinase) receptor for nerve 
growth factor (NGF), a neurotrophin, suggesting that estrogen may contribute to normal 
or pathological neuronal function (Sohrabji et al., 1994).  Lee et al. (2002) showed that 
estradiol rapidly inhibited L- and N-type high-voltage-activated (HVA) Ca
2+
 channel 
currents in DRG neurons, an effect that was greater in cells from female rats than males.   
 In the spinal cord, effects of gonadal hormones on pain have been mostly studied 
with relevance to pregnancy.  Increased pain thresholds during pregnancy in rats and 
humans appear to involve an opioid-mediated mechanism, activated by sex hormones 
(Dawson-Basoa & Gintzler, 1993).  Estradiol and progesterone activate a spinal 
dynorphin/κ-opioid analgesic system both pre-synaptically and post-synaptically (Aloisi, 
2000; Dawson-Basoa & Gintzler, 1993).  In female rats, ovariectomy and estradiol and/or 
progesterone treatment had variable effects on opioid anti-nociception, but E2 tended to 
decrease μ-opioid anti-nociception (Stoffel et al., 2005).  In intact male rats, 
intracerebroventricular estrogen decreased the formalin-induced paw jerk and increased 
the licking response; both effects were blocked by opioid receptor antagonists (Aloisi & 
Ceccarelli, 2000; Ceccarelli et al., 2004).  Amandusson et al. (1999) demonstrated that in 
female rats ERs are expressed in the same area of the spinal cord as enkephalin-
expressing neurons, and that estrogen increases enkephalin mRNA levels in the spinal 
cord of OVX rats.  Allen and McCarson (2005) demonstrated that estradiol potentiated 
increased BDNF gene expression in the spinal cord by formalin in OVX rats.   
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 Gonadal hormones appear to have a significant effect on thalamic transmission 
(Aloisi, 2000).  In certain areas of the brain, females exhibit greater activation from the 
same painful stimuli than males, suggesting differential supraspinal processing (Aloisi, 
2000).  Some effects of estrogen on pain processing may be due to actions at supraspinal 
sites, as discussed above.  Estrogen has also been reported to have rapid effects on 
neuronal activity in the hippocampus, hypothalamus, cerebellum, cortex, and amygdala 
(McEwen & Alves, 1999). 
 
1.7  Conclusion 
 Multiple sites may exist for the enhancement of pain by estrogen.  However, there 
is evidence to suggest that sex differences in, or estrogen modulation of, pain may be 
primarily due to supraspinal processes.  Limbic system sensitization plays an important 
role in conditions such as multiple chemical sensitivity and depression, which are more 
prevalent in women, as well as post-traumatic stress disorder.  The limbic system may 
similarly have a pivotal role in chronic pain, especially if levels of estrogen are associated 
with painful or stressful conditions.  The observation that pain of psychological origin is 
more prevalent in women may support the importance of estrogen in modulating the 
limbic processing of pain.  Importantly, the modulation of pain by estrogen appears to 
depend on the route of administration, dosing regimen, and pain model being used.   
 The major focus of this dissertation project was to determine the possible sites of 
action for estrogen contribution to sex differences in pain.  To anatomically distinguish 
sites of estrogen enhancement of nociception, estrogen replacement was used in OVX 
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female rats.  The formalin test was used as a model of persistent inflammatory pain, and 
biochemical and behavioral end-points were quantified.  The results of this study 
implicate possible locations for estrogen enhancement of inflammatory pain.  This 
information ultimately will shape the anatomical locations and biomolecular mechanisms 













STATEMENT OF PURPOSE 
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 This dissertation project had the purpose of testing the overall hypothesis 
that sex hormones have activational effects on pain that contribute to sex differences 
in the experience of chronic pain. 
 Chronic pain leads neurological disorders in the US in terms of the total number 
of cases and their annual economic cost (Carey, 2005; Loeser, 2001; Stucky et al., 2001).  
Sometimes pain outlasts its usefulness as a warning/protective system (Julius & 
Basbaum, 2001), and becomes chronic and potentially debilitating through maladaptive 
processes.  Chronic pain can result in anxiety, depression, and reduced quality of life 
(Hunt & Mantyh, 2001). 
 The incidence or severity of many chronic pain disorders, but not others, is higher 
in women than men, and for experimentally delivered stimuli, females have lower 
thresholds, higher pain ratings, and less tolerance of noxious stimuli than males (Berkley, 
1997).  In addition, chronic pain often is accompanied by depression, and vice versa, 
indicating an association between the two disorders (Blackburn-Munro & Blackburn-
Munro, 2001; Fishbain et al., 1997; King, 1991), and depression is about twice as 
prevalent in women than men (Bromberger, 2004). 
 Many painful disorders vary in their incidence, disappearance, and prevalence as 
a function of menstrual stage, puberty, pregnancy, menopause, and age (Berkley, 1997).  
This is indirect clinical evidence that ovarian hormones such as estrogen may alter pain 
sensitivity.  There is also experimental evidence for this as well.  Highly relevant to this 
research proposal, responses to inflammatory pain, both clinically and experimentally, 
vary with the estrous cycle of the female (Bradshaw et al., 2000; Fillingim et al., 1997; 
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Hellstrom & Anderberg, 2003; Isselee et al., 2002; Lautenbacher & Rollman, 1993; 
LeResche et al., 2003; Somerville, 1972; Tall & Crisp, 2004). 
 Numerous reports have addressed the modulation by estrogen of biochemicals 
involved in nociceptive neuronal signaling or behavioral responses.  However, there are 
no reports of direct, systematic investigation into identification of the anatomical sites of 
action in the nervous system of the enhancement of nociception and pain by estrogen.  
Thus, this research program had the purpose of determining the potential contribution of 
activational effects of sex hormones to sex differences in pain conditions, and was 
specifically designed to test the overall hypothesis that sex differences in pain sensation 
are due, at least in part, to activational effects of sex hormones on peripheral, spinal 
and/or supraspinal sites involved in the transmission and perception of nociceptive 
stimuli.  To test this hypothesis, established models of pain were employed, and 
biochemical and behavioral end points were quantified.  The resulting data provide novel 
and significant information pertaining to sex hormone modulation of nociceptive 
processing, and establish specific CNS sites where estrogen may enhance pain sensation 
in females.  Ultimately, these findings may have impact human health by helping identify 
novel strategies for the management of pain syndromes that are more prevalent or intense 
in women.   
2.1  Specific Aim #1:  Determine whether short-term exposure to androgens during 
adulthood alters pain-related behavior. 
 Several emerging lines of evidence support the existence of sex differences in the 
sensory experience of pain.  For example, the incidence or severity of many chronic pain 
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disorders is higher in women than men, but men experience gender-selective pain 
syndromes as well.  Additionally, sex differences in nociception and analgesia have been 
demonstrated, as has their modulation by estrogens, androgens and other steroids.  
Gonadal steroids such as estrogens and androgens may produce these differences through 
effects on sexual development or through activational effects in the adult animal.  
However, little is known about the activational effects of male gonadal hormones on 
nociception.  Previous reports have suggested that males are less sensitive to stimulus-
evoked nociception.  These observations suggest that male gonadal hormones have anti-
nociceptive, activational effects in males. 
 To test the activational effects of androgen on nociception, experiments in this 
aim investigated the activational effects of male gonadal hormones on nociception-related 
responses to phasic or persistent noxious stimuli in male rats.  We hypothesized that male 
gonadal hormones produce anti-nociceptive effects.  To this end, studies in this aim used 
adult male rats and evaluation of pain-related behavioral responses in several well-
characterized rodent models of phasic or persistent pain.  Concurrently, male gonadal 
hormones were manipulated by gonadectomy and/or testosterone replacement.  The goal 
of these experiments was to reveal what activational effects androgens have on pain of 
phasic or persistent origin.  Thus, these studies were carried out to gain insight into the 
specific contribution of male gonadal hormones to sex differences in pain sensation.   
2.2  Specific Aim #2:  Determine whether short-term exposure to estrogen during 
adulthood increases nociception. 
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 Estrogens have been demonstrated to have activational, often pro-nociceptive 
(pain-potentiating), effects on sensory function.  Previous results from our laboratory 
suggested that sustained, long-term estrogen replacement in ovariectomized females 
enhances formalin-induced pain-related behavior.  We hypothesized that short-term 
estrogen replacement in ovariectomized females would similarly enhance formalin-
evoked persistent inflammatory nociception.  Ultimately, this aim set out to provide 
supporting evidence of the overall hypothesis that sex differences in pain sensation are 
due, at least in part, to activational effects of estradiol.   
 To determine whether activation in response to inflammatory pain was increased 
by acute, activational effects of estrogen, experiments in this aim examined the intensity 
of nociceptive behaviors evoked by formalin (a model of persistent inflammatory pain).  
These nociception-related behaviors were measured as a biological proxy for the degree 
of the overall nociceptive state.  The formalin test is a well-established, widely used 
model of persistent inflammatory pain (Porro & Cavazzuti, 1993; Tjolsen et al., 1992).  
The noxious formalin stimulus results in peripheral inflammation and central 
sensitization that more closely approximates the persistent pain experienced with chronic 
inflammatory conditions than traditional phasic nociceptive tests.  These experiments 
quantified nociception-related behaviors, especially flinching of the inflamed hind paw, 
and other behaviors monitored by actometry, following formalin injection, and 
investigated whether short-term estrogen exposure increased these behavioral responses 
in adult, female rats. 
 Activational effects of estrogen on this persistent, inflammatory nociception were 
investigated using ovariectomy and a single injection of estradiol in adult female rats.  A 
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preliminary experiment was designed to establish the efficacy of a single injection of 
estradiol (by measuring uterus weight), which would be the estrogen manipulation model 
for experiments in this aim and future experiments.  Estrogen manipulation was designed 
to be relatively short-term with respect to timing prior to application of the formalin pain 
model.  These estrogen manipulations were designed with the purpose of emulating the 
short-term fluctuations in symptoms of chronic pain that occur in synchrony with the 
menstrual cycle. 
 The goal of experiments in this aim was to establish evidence for short-term, 
activational estradiol-mediated enhancement in the inflammatory pain model.  With this 
established, experiments could then move forward to investigate where in the nervous 
system this modulation takes place.   
2.3  Specific Aim #3:  Determine whether short-term exposure to estrogen during 
adulthood increases nociception in peripheral, spinal and/or supraspinal sites of the 
nervous system. 
 Previous reports and results from Specific Aim #2 suggest that elevated serum 
estrogen levels enhance persistent inflammatory nociception.  However, there were no 
reports of any direct, systematic investigation into identification of the anatomical sites of 
estrogens’ action in the nervous system to enhance nociception and pain.  We 
hypothesized that sex differences in pain sensation are due, at least in part, to 
activational effects of estradiol on peripheral, spinal and/or supraspinal sites involved in 
the transmission and perception of nociceptive stimuli.  Emphasis was placed on 
determining which specific sites largely contribute to estrogen-induced enhancement of 
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nociception.  Thus, studies in this aim had the purpose of determining whether estrogen 
increased neuronal activation in specific, nervous system sites driven by inflammatory 
nociception.   
 These experiments measured the levels of biomarkers of neuronal activation 
evoked by intraplantar formalin, a stimulus that models the persistent inflammatory pain 
experienced with chronic pain conditions.  Two widely-used biological proxies for the 
degree of nociceptive activation or throughput (Fos or phospho-ERK) were measured in 
the spinal cord, amygdala, hippocampus and nucleus accumbens as initial sites of 
investigation.  Initially, the spinal cord was chosen as a site of investigation because it is 
the site of the “first synapse” where signals from the primary afferent neurons are 
processed.  Subsequently, supraspinal sites were investigated based on their being limbic 
structures associated with the regulation of affect or nociception.   
 Activational effects of estrogen on this neuronal activation were investigated 
using ovariectomy and a single injection of estradiol in adult, female rats.  Estrogen 
manipulation was designed to be relatively short-term with respect to timing prior to 
application of the formalin pain model.  As in the previous aim, these estrogen 
manipulations were designed to emulate short-term cyclic fluctuations in chronic pain 








GONADECTOMY INCREASES MECHANICAL NOCICEPTION IN A 
NEUROPATHIC PAIN MODEL, AND TESTOSTERONE DECREASES 
THERMAL NOCICEPTION:  STUDIES IN MALE RATS 
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3.1  Abstract 
 Experiments in this chapter investigated the effect of male gonadal hormones on 
phasic or persistent noxious stimuli in male rats. 
 Little is known about the activational effects of male gonadal hormones on 
nociception.  Previous reports have suggested that males tend to be less sensitive to acute 
nociceptive stimuli.  We hypothesized that endogenous testosterone and/or its 
metabolites, dihydrotestosterone (DHT) or estradiol (E2), have anti-nociceptive, 
activational effects in males.  To test this hypothesis, persistent pain models used 
included spared nerve injury (SNI) and formalin injection; phasic stimuli were thermal 
(analgesiometer) and, following SNI, mechanical (von Frey).  To test the effect of 
androgen on phasic thermal sensitivity, adult male rats were placed into three groups: 1) 
gonadectomized (GDX); 2) GDX receiving 20 mg testosterone propionate (TP) pellets 
implanted subcutaneously (GDX + 20 mg TP); and 3) gonadally intact naïve controls.  
One week after GDX, behavioral evaluation of acute nociceptive thermal hind paw 
withdrawal thresholds was performed using a thermal analgesiometer.  Serum levels of 
DHT and E2 were subsequently determined.  In other experiments, the effect of 
gonadectomy was investigated in the formalin model and the spared nerve injury (SNI) 
model; male rats were either GDX or gonadally intact.  Dilute formalin was injected into 
the plantar hind paw, and paw flinches were quantified.  For SNI, mechanical thresholds 
were determined over several days following surgery.  Results of the testosterone 
replacement experiment, as well as a separate, one-week time-course experiment, showed 
no difference in thermal withdrawal latency between GDX and naïve rats.  However, 
GDX + 20 mg TP rats had longer withdrawal latencies than naïve or GDX rats.  Serum 
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DHT levels in naïve and GDX + 20 mg TP rats were not different, but were higher than 
GDX rats.  Importantly, serum E2 levels were not changed by any manipulation.  These 
results suggest that testosterone or DHT has an activational, hypoalgesic effect on acute 
thermal nociception in males that is not likely due to the effects of E2 produced by 
metabolism of testosterone.  No effect of androgen was observed on formalin-induced 
nociceptive behavior.  Also, gonadectomy in the context of the SNI model increased 
mechanical nociceptive sensitivity contralateral to the SNI, indicating an anti-nociceptive 
effect of male gonadal hormone(s) possibly through modulation of descending control.  
These observations taken together demonstrated androgen had a hypoalgesic effect on 
phasic thermal stimulus and an anti-nociceptive effect on phasic mechanical nociception 
contralateral to a persistent neuropathic pain model.  Thus, it is evident that androgen has 
activational effects on pain of phasic thermal and persistent neuropathic origin, but 
perhaps not persistent inflammatory origin.  These results provide evidence that 
androgens, as well as estrogens, may contribute to sex differences in pain sensation. 
3.2  Introduction 
 Chronic pain leads neurological disorders in the United States in terms of 
incidence and annual economic impact (Carey, 2005; Loeser, 2001; Stucky et al., 2001).  
Several emerging lines of evidence support the existence of sex differences in the sensory 
experience of pain.  For example, the incidence or severity of many chronic pain 
disorders is higher in women than men, and for experimentally delivered stimuli, females 
have lower thresholds, higher pain ratings, and develop less tolerance toward noxious 
stimuli than males (Berkley, 1997).  Many painful disorders show prevalence in women 
(e.g. migraine headache, fibromyalgia, irritable bowel syndrome, temporomandibular 
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joint disorder), but men experience gender-selective pain syndromes as well (e.g. cluster 
headache, Raeder’s paratrigeminal syndrome, post-herpetic neuralgia, ankylosing 
spondylitis) (Berkley, 1997).  Gonadal steroids such as estrogens and androgens may 
produce these differences through effects on sexual development or through activational 
effects in the adult animal.   
 While sex differences in the prevalence and intensity of pain syndromes have 
gained increased attention, very little is currently understood about the specific biological 
mechanisms underlying the modulatory roles of gonadal hormones such as androgens.  
Studies of gonadal steroid modulation of pain sensation to date have largely focused on 
the activational effects of estrogen in adult females; little is known about the activational 
effects of male gonadal hormones on nociception.  Sex differences in nociception and 
analgesia have been demonstrated, as has their modulation by estrogens, androgens and 
other steroids.  Previous reports suggest that males are less sensitive to stimulus-evoked 
nociception.  For example, Lautenbacher and Rollman (1993) reported women having 
lower pain thresholds and higher pain ratings than men for electrocutaneous stimuli, and 
Barrett et al. (2002) demonstrated that male rats had higher mechanical nociceptive 
thresholds than females.  Studies indicate that male rats develop more robust morphine-
induced anti-nociception than females (Cicero et al., 1996; Wang et al., 2006).  
Numerous other reports conclude that gonadal steroids can affect nociception or opioid-
induced anti-nociception in an activational manner.  Specifically, androgen manipulation 
activationally increases nociceptive withdrawal latencies of rats or birds receiving 
transient thermal stimuli (Edinger & Frye, 2005; Forman et al., 1989; Frye & Seliga, 
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2001; Hau et al., 2004), and testosterone administration alters morphine-evoked thermal 
anti-nociception in a sexually dimorphic manner in rats (Stoffel et al., 2003).   
 Androstenedione is a common precursor for the sex hormones (androgens and 
estrogens), and can be converted into testosterone (an androgen) via 17β-hydroxysteroid 
dehydrogenase or into estrone via aromatase and then estradiol (E2) via 17β-
hydroxysteroid dehydrogenase.  Testosterone then can be converted into either 5α-
dihydrotestosterone (DHT), the most potent androgen, via 5α-reductase or E2 via 
aromatase.  All of these steroids are found in circulating blood, and thus are available to 
affect all tissues, including all locations of the nervous system.  This arrangement of 
testosterone metabolism means that when testing the effects of testosterone, it is 
important to consider the possible effects of its major metabolites such as DHT and E2.   
 The above (and other) observations suggest that testosterone and/or its 
metabolites, DHT or E2, have anti-nociceptive, activational effects in males.  
Accordingly, the current study used adult male Sprague-Dawley rats and behavioral 
evaluation of acute nociceptive thermal hind paw withdrawal thresholds following 
gonadectomy and testosterone replacement to characterize the specific contribution of 
male gonadal hormones to sex differences in pain sensation.  The effect of gonadectomy 
on formalin-induced persistent nociception was investigated.  In addition, the effects of 
gonadectomy on thermal and mechanical sensitivity following the spared nerve injury 
(SNI) model were investigated. 
 The SNI model is a model of persistent neuropathic pain.  It was developed by 
Decosterd & Woolf (2000) as a modification of other partial denervation models.  The 
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model involves unilateral surgical transection of the common peroneal and tibial 
branches of the sciatic nerve, leaving the sural branch intact.  The SNI model produces 
immediate (next day) and long-lasting mechanical hyperalgesia on the affected hind paw 
(Decosterd & Woolf, 2000).  One study investigated sex differences in the SNI model, 
but reported no differences (Bourquin et al., 2006). 
 The formalin test is an established, widely used model of persistent inflammatory 
pain (Porro & Cavazzuti, 1993; Tjolsen et al., 1992).  It is usually used in mice and rats, 
and may provide a better approximation of clinical chronic pain than traditional phasic 
nociceptive tests, such as acute radiant thermal, hot-plate, or mechanical paw withdrawal 
tests.  Formalin induces a biphasic pain-related behavioral response, separated by a 
quiescent interphase.  The first (early) phase is due to C-fiber activation, while the second 
(late) phase is due to peripheral inflammation and central sensitization.  The behavioral 
responses that can be evaluated include lifting (flexing), licking, biting, and flinching of 
the injected paw. 
 Some previous studies have investigated sex differences or sex hormone effects 
on nociceptive behavior with the formalin model (Aloisi et al., 1994; Aloisi & Ceccarelli, 
2000; Aloisi et al., 2004; Aloisi et al., 2000; Aloisi et al., 1995; Ceccarelli et al., 2004; 
Nayebi & Ahmadiani, 1999), with mixed results; some reported no effect, whereas some 
reported effects that were contradictory to each other.   
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3.3  Materials & methods 
 This study was conducted using male Sprague-Dawley rats (Harlan, Indianapolis, 
IN).  Animal facilities were temperature- and humidity-controlled with a 12-h dark–light 
cycle and food and water ad libitum.  All surgical procedures and animal handling were 
performed in accordance with National Institutes of Health laboratory care standards and 
were approved by the University of Kansas Medical Center Animal Care and Use 
Committee.  All testing, surgical procedures and handling of rats were performed during 
the light cycle.   
 In one experiment, male Sprague-Dawley rats (~10-13 weeks old, 290-360 g, 
Harlan, Indianapolis, IN) were randomly assigned to three groups: 1) gonadectomized 
(GDX; n = 4); 2) GDX receiving 20 mg testosterone propionate (TP) pellets implanted 
subcutaneously at the nape of the neck (GDX + 20 mg TP; n = 3); and 3) gonadally intact 
naïve controls (n = 5).  One week after gonadectomy and hormone manipulation, 
behavioral evaluation of acute thermal nociceptive withdrawal threshold was performed 
using a thermal paw analgesiometer.  Rats were housed one per cage beginning at least 
three days before nociceptive testing.  Immediately following behavioral evaluation, rats 
were decapitated and trunk blood collected for serum steroid (DHT and E2) analysis.  
Results from rats in this experiment are included in the report of DHT levels in naïve, 
GDX and GDX + TP rats in the text and Figure 7. 
 A separate pilot experiment was conducted to determine the testosterone dose that 
yielded serum DHT concentrations similar to normal endogenous levels.  Sixteen male 
Sprague-Dawley rats (~10-13 weeks old, 290-360 g, Harlan, Indianapolis, IN) were left 
48 
gonadally intact (naïve; n = 4) or were gonadectomized and received either no further 
hormonal manipulation (n = 3) or subcutaneous doses of 1, 5 or 10 mg TP (GDX + TP; n 
= 3 per group) in pelleted form.  One week after gonadectomy and hormone 
manipulation, rats were decapitated and trunk blood collected for serum DHT analysis.  
Results from rats in this experiment are included in the report of DHT levels in naïve, 
GDX and GDX + TP rats in the text and Figure 7.   
 In a separate experiment, male Sprague-Dawley rats (~7-9 weeks old, 190-230 g, 
Harlan, Indianapolis, IN) were divided into two groups:  1) gonadectomized (GDX; n = 
6); and 2) gonadally intact naïve controls (n = 5).  A time-course of acute nociceptive 
thermal withdrawal threshold was conducted for one week following GDX using a 
thermal paw analgesiometer, as described below.  Naïve control rats were housed two per 
cage, and GDX rats were housed one per cage for days 1-4 post-surgery and two per cage 
otherwise.  Another set of rats was used for a similar time-course experiment, except the 
control group in this experiment received sham GDX surgery instead of being naïve.  
This set of rats was also used later for the spared nerve injury (SNI) experiment. 
3.3.1  Spared nerve injury (SNI) 
 Left-side spared nerve injury (SNI) surgery was performed on rats according to 
methods described by Decosterd & Woolf (2000).  Rats were anesthetized with a mixture 
of ketamine (64 mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 
mg/kg; i.p.), and an incision was made in the biceps femoris muscle exposing the sciatic 
nerve.  The common peroneal and tibial nerves were tight-ligated with 4.0 silk and cut 
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distal to the ligation, and 2-4 mm were removed from the remaining distal portion.  The 
sural nerve was left intact.  Muscle and skin were sutured closed separately. 
 Thermal withdrawal latencies for all four paws and tail were determined ~12 days 
after SNI using a thermal analgesiometer as described below.  Rats were gonadectomized 
or left intact 8-9 days before SNI. 
 A time course of mechanical paw withdrawal threshold was performed in nerve-
injured rats using Von Frey testing (described below).  One week prior to baseline 
measurements, rats were gonadectomized or left intact.  Baseline readings were taken 1 
or 2 days prior to SNI surgery, and days represented are relative to SNI surgery.  
Mechanical withdrawal thresholds for hind paws were determined daily (except Day 2) 
up to 8 days, beginning one day after SNI.  Mechanical withdrawal thresholds for all four 
paws were also determined ~12 days after SNI.  Hind paws were tested on the lateral 
aspect and front paws were tested on their central portion. 
3.3.2  Hormone manipulation 
 For gonadectomy (GDX), rats were anesthetized with a mixture of ketamine (64 
mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 mg/kg; i.p.).  
Under aseptic conditions, a ventral midline incision (~1.5 cm long) was made into the 
lower abdominal cavity.  Both testes were externalized, vas deferens and blood vessels 
ligated with suture just proximal to the testes, and testes removed with scissors.  Adipose 
tissue, vas deferens, and blood vessels were reinserted into the abdominal cavity.  Muscle 
and skin were closed with suture.  For rats receiving testosterone replacement, an incision 
(~0.5-1 cm) was made in the skin at the nape of the neck during the anesthesia procedure 
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for gonadectomy.  In these rats, pellets containing 1, 5, 10 or 20 mg testosterone 
propionate (TP; 21-day sustained release; Hormone Pellet Press, Leawood, KS) were 
inserted s.c., and skin closed with suture [method modified from Allen and McCarson 
(2005)].  The vehicle for 1, 5 or 10 mg TP pellets was cholesterol; the 20 mg TP pellet 
did not contain any vehicle.  Gonadectomized or gonadally intact naïve controls did not 
receive any sham surgeries or steroid/vehicle.  The day of GDX surgery was defined as 
day zero for all experiments, with the exception of the spared nerve injury (SNI) 
experiment.   
3.3.3  Determination of serum dihydrotestosterone and estradiol content 
 Serum levels of dihydrotestosterone (DHT) and estradiol (E2) were determined 
using radioimmunoassay kits according to the manufacturers’ instructions (DSL-9600, 
Diagnostic Systems Laboratories, Webster, TX; and KE2D1, Diagnostic Products 
Corporation, Los Angeles, CA, respectively).  Briefly, DHT was extracted from serum 
with 98% n-hexane: 2% ethanol, dried under nitrogen gas, and reconstituted in sample 
diluent.  For E2, serum was added directly to assay tubes.  All steroid samples and 
standards were assayed in duplicate.  Both kits used 
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I-labeled steroid for competitive 
binding to an antibody.   
3.3.4  Nociceptive behavioral testing 
 3.3.4.1  Thermal withdrawal threshold 
 Rats were placed in a clear plastic chamber on a thermal analgesiometer 
(University of California San Diego) with the glass surface thermostatically controlled at 
30 °C and allowed to acclimate to the environment for approximately 10 minutes 
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[method adapted from Hargreaves et al. (1988)].  The radiant heat source of the 
analgesiometer was calibrated to elicit a latency time of approximately eight seconds for 
baseline or naïve rats, with a 20-second cut-off time to prevent tissue injury.  Rats from 
each group were randomized, and multiple rats were tested at the same time, all within an 
hour.  Three readings were taken on each body part plantar surface, allowing at least two 
minutes between testing of the same part.  Except where individual paws are specified, 
the left and right hind paws were tested, and the resulting six readings were then averaged 
into one latency value per rat.  For the testosterone replacement experiment, rats were 
tested on the seventh day after hormone manipulation.  For the time-course experiments, 
baseline readings were taken 1-3 days before GDX surgery.  Testing on the tail for the 
SNI experiment was done on approximately the middle 1/3 of the length of the tail.  
 3.3.4.2  Formalin testing 
 Male rats (the same set used in the thermal threshold time-course experiment) 
were gonadectomized (GDX) or left intact.  Fifteen to 17 days after GDX, rats were 
injected with 100 µL of 5% formalin into the plantar side of the right hind paw.  Flinches 
of the injected paw were counted 0-7 (“early” phase) and 30-41 (peak of the “late” phase) 
minutes post-injection.  Statistical testing for differences of GDX vs. Naïve was done for 
each minute or for the sums over each time period using Student’s t-test.  n = 5 Naïve, 6 
GDX. 
 3.3.4.3  Mechanical withdrawal threshold (Von Frey) 
 Rats were placed individually in plastic cages that allowed animals to move freely 
and that sat upon a wire mesh platform.  Semmes-Weinstein monofilaments were applied 
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perpendicularly to the plantar surface with sufficient force to cause a slight bending of the 
monofilament in increasing, then decreasing order of intensity, according to an up-down 
paradigm [adapted from Brennan et al., (1996)]  Monofilaments were applied 1-2 times 
and held for approximately five seconds.  A withdrawal of the paw indicated a positive 
response.  When a positive response was elicited 100% of the time from a monofilament, 
monofilaments were then presented in sequentially decreasing intensity.  The 
monofilament with an intensity that elicited a response ~50% of the time was considered 
the threshold. 
3.3.5  Data analyses 
 All data are shown as mean ± SEM.  For the time courses of thermal withdrawal 
latencies, data were analyzed using a two-way, repeated-measures ANOVA with a post 
hoc (Holm-Sidak) multiple comparisons test.  For DHT and E2 concentration data, and 
for data on the effects of testosterone treatment on thermal withdrawal latencies, data 
were analyzed using a one-way ANOVA with a post hoc (Tukey-Kramer) multiple 
comparisons test.  For data on the effect of GDX on the formalin test, and with SNI, 
single-day thermal and mechanical thresholds, data were analyzed by Student’s t-test.  
Data for the mechanical threshold time course with SNI were analyzed by two-way 
ANOVA with a post hoc (Holm-Sidak) multiple comparisons test.  For all analyses, the 
significance level was set to p ≤ 0.05. 
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3.4  Results 
 Thermal nociceptive testing was performed daily (except for day five) for one 
week following GDX.  Rats receiving sham GDX surgery (n = 6) did not show any 
change in thermal paw withdrawal latency at one day after surgery compared to the 
baseline latency of the same rats one day before surgery.  Two-way repeated measures 
ANOVA revealed a significant main effect of time (F[6, 70] = 12.89, p < 0.001), but not 
GDX (F[1, 75] = 0.47, p = 0.510) on paw withdrawal latency.  Results revealed a subtle 
but significant drift to longer thermal paw withdrawal latencies over the week-long time 
course for both naïve (n = 5) and GDX (n = 6) rats compared to their respective baseline 
latencies (Figure 6).  This drift in responsiveness could be due to habituation/adaptation 
to testing over the week, or physical growth of the rats or changes in hind paw 
skin/footpad thickness.  There was no difference in withdrawal latency between naïve 
and GDX rats on each day tested during the week-long time course.  This finding implies 
the presence or absence of gonads as a factor does not change the acute thermal 




Figure 6.  Time course of thermal paw withdrawal latency in gonadectomized (GDX) male rats.  Rats were 
gonadectomized or left intact (Naïve, left panel; Sham GDX, right panel).  Thermal withdrawal latencies 
were determined daily (except day 5) and averaged for left and right hind paws using a thermal 
analgesiometer.  Results revealed increasing thermal paw withdrawal latencies in both naïve (n = 5) and 
GDX (n = 6) rats compared to their respective baseline latencies.  Note that there was no difference in 
withdrawal latency between naïve and GDX rats on each day tested.  These data indicate GDX did not 
affect withdrawal latencies.  (*p ≤ 0.05 vs. respective baseline, two-way repeated-measures ANOVA, 
Holm-Sidak post-hoc test).    Data represent the mean ± SEM. 
 
 After one week of various hormonal manipulations, serum DHT and E2 
concentrations of the rats were determined (Figures 7 and 8, respectively).  The mean 
serum DHT concentration of naïve rats was 108.1 ± 27.2 pg/mL, which is in accordance 
with previously published levels for intact adult male rats (Overpeck et al., 1978).  One-
way ANOVA indicated a significant effect of treatment on serum DHT concentration 
(F[5, 22] = 4.40, p = 0.006).  Tukey-Kramer post hoc analysis revealed that the serum 
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DHT levels of GDX rats receiving 20 mg TP pellets (GDX + 20 mg TP; n = 3) were not 
different from the endogenous levels of naïve controls (n = 9), yet the serum DHT levels 
in GDX rats (n = 7) were lower than those of either naïve or GDX + 20 mg TP rats 
(Figure 7).   
 
Treatment: Serum DHT (pg/mL) 
Naïve 
GDX 
GDX + 1 mg TP 
GDX + 5 mg TP 
GDX + 10 mg TP 




25.6 ± 2.1* 
23.5 ± 2.5 
38.4 ± 8.2 





Figure 7.  Table of serum dihydrotestosterone (DHT) concentrations in gonadectomized (GDX) male rats 
following androgen manipulation.  After one week, results demonstrated that GDX reduced DHT levels 
compared to naïve.  Note that the DHT level in GDX rats receiving 20 mg testosterone propionate (TP) was 
not different from the endogenous level of naïve controls, but was higher than that of GDX rats.  These data 
indicate hormone manipulation significantly altered serum DHT levels.  (*p ≤ 0.05 vs. naïve.  †p ≤ 0.05 as 
compared vs. GDX, one-way ANOVA, Tukey-Kramer post hoc test; n = 9 naïve, n = 7 GDX, n = 3 each 
for all other groups).  Data represent the mean ± SEM. 
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 Analysis of serum estradiol levels revealed a mean serum E2 concentration in 
naïve rats of 3.96 ± 0.45 pg/mL, which is in accordance with previously published levels 
for intact adult male rats (Overpeck et al., 1978).  One-way ANOVA indicated no 
significant effect of treatment on serum E2 concentration (F[2, 9] = 2.93, p = 0.104) of 
naïve (n = 5), GDX (n = 4), or GDX + 20 mg TP (n = 3) rats (Figure 8).   
 
Figure 8.  Serum estradiol (E2) concentrations in gonadectomized (GDX) male rats following androgen 
manipulation.  Note that, after one week, serum E2 concentrations were not different for naïve (n = 5), 
GDX (n = 4), or GDX + 20 mg TP (n = 3) rats.  These results confirm hormone manipulation did not alter 
serum E2 levels.  (p > 0.05, one-way ANOVA). Data represent the mean ± SEM. 
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 After one week of hormone manipulation, there was no significant difference in 
hind paw thermal withdrawal latency between GDX (n = 4) and naïve (n = 5) rats 
(Figure 9).  One-way ANOVA indicated a significant effect of treatment on hind paw 
withdrawal latency (F[2, 9] = 11.09, p = 0.004), and Tukey-Kramer post hoc analysis 
revealed that GDX + 20 mg TP (n = 3) rats had a significantly longer thermal withdrawal 
latency (higher threshold) than naïve or GDX rats.   
 
Figure 9.  Thermal paw withdrawal latency in male rats of varying androgen status.  Results showed that, 
after one week, whereas there was no difference in latency between gonadectomized (GDX; n = 4) and 
naïve rats (n = 5), administration of testosterone propionate (TP) pellets to GDX rats (n = 3) significantly 
increased thermal withdrawal latency.  (*p ≤ 0.05 vs. naïve or GDX, one-way ANOVA, Tukey-Kramer 
post hoc test).  Data represent the mean ± SEM. 
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 Hind paw flinches in rats injected with formalin were quantified in the early phase 
and peak of the late phase (Figure 10).  Note there were no group differences between 
GDX (n = 6) and Naïve (n = 5) for any minute or summed over each time period 




Figure 10.  Effect of gonadectomy on flinching behavioral response in male rats during early (left) and late 
(right) phases following hind paw injection of 5% formalin.  Flinches of the injected hind paw were 
counted 0-7 and 30-41 minutes post-injection of 100 µL 5% formalin into the plantar right hind paw.  Note 
there were no group differences GDX vs. Naïve for any minute or summed over each time period 




 Thermal withdrawal latencies for all four paws and tail were determined ~12 days 
after SNI using a thermal analgesiometer (Figure 11).  Results revealed that there was no 
difference in withdrawal latency between Sham GDX (n = 6) and GDX (n = 6) rats.  
These data indicate GDX did not affect thermal withdrawal latencies (thresholds) in the 
SNI model (Student’s t-test). 
 
 
Figure 11.  Thermal withdrawal latency in gonadectomized (GDX) male rats with left-side spared nerve 
injury (SNI).  Rats were gonadectomized or left intact.  Thermal withdrawal latencies for all four paws and 
tail were determined ~12 days after SNI using a thermal analgesiometer.  Results revealed that there was no 
difference in withdrawal latency between Sham GDX (n = 6) and GDX (n = 6) rats.  These data indicate 
GDX did not affect withdrawal latencies.  (p > 0.05, Student’s t-test).  Data represent the mean ± SEM. 
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 Results of Von Frey testing on hind paws (Figure 12) revealed that, ipsilateral to 
SNI, there was no difference in mechanical threshold between Sham GDX and GDX rats 
on each day tested or overall (two-way ANOVA with Holm-Sidak post-hoc test; n per 
group by day: Baseline = 6, Day 1 = 5, Day 3 = 5, Days 4-8 = 6).  However, contralateral 
to the SNI, rats that received GDX overall had lower thresholds than Sham GDX.  Also, 
ipsilateral to the SNI, thresholds were lower overall vs. Baseline, while there was no 
difference on the contralateral side, indicating efficacy of the SNI model.  These data 
indicate GDX decreased withdrawal thresholds contralateral but not ipsilateral to SNI.  
Results of testing on day ~12 post-SNI revealed that there was no difference in 
withdrawal threshold between Sham GDX (n = 6) and GDX (n = 6) rats (Student’s t-test) 
for all four paws (Figure 13).  These data indicate no effect of GDX on mechanical 




Figure 12.  Time course of mechanical paw withdrawal threshold in gonadectomized (GDX) male rats with 
left-side spared nerve injury (SNI).  One week prior to Baseline readings, rats were gonadectomized or left 
intact.  Mechanical withdrawal thresholds for hind paws were determined daily (except Day 2), beginning 
one day after SNI, using Von Frey monofilaments.  Baseline readings were taken 1 or 2 days prior to SNI 
surgery, and days represented are relative to SNI surgery.  Results revealed that, ipsilateral to SNI, there 
was no difference in mechanical threshold between Sham GDX and GDX rats on each day tested or 
overall.  However, contralateral to the SNI, rats that received GDX overall had lower thresholds than Sham 
GDX.  Also, ipsilateral to the SNI, thresholds were lower overall vs. Baseline, while there was no 
difference on the contralateral side, indicating efficacy of the SNI model.  These data indicate GDX 
decreased withdrawal thresholds contralateral but not ipsilateral to SNI.  These data may indicate male 
gonadal hormones either inhibit descending facilitation or promote descending inhibition contralateral to 
SNI.  (Significance level set to p ≤ 0.05, two-way ANOVA with Holm-Sidak post-hoc test; n per group by 





Figure 13.  Mechanical withdrawal threshold in gonadectomized (GDX) male rats with left-side spared 
nerve injury (SNI).  Rats were gonadectomized or left intact.  Mechanical withdrawal thresholds for all four 
paws were determined ~12 days after SNI using Von Frey monofilaments.  Results revealed that there was 
no difference in withdrawal threshold between Sham GDX (n = 6) and GDX (n = 6) rats.  These data 
indicate GDX did not affect withdrawal threshold.  (p > 0.05, Student’s t-test).  HL = hind left; HR = hind 
right; FL = front left; FR = front right.  Data represent the mean ± SEM. 
  
63 
3.5  Discussion 
 Numerous previous studies have reported sex differences in nociception, with 
many reporting females as having lower thresholds or higher intensity of nociception [see 
reviews (Berkley, 1997; Bodnar et al., 1988)].  Women had lower thresholds and higher 
pain ratings compared with men for electrocutaneous stimulation (Lautenbacher & 
Rollman, 1993).  Female rats had lower mechanical nociceptive thresholds than males 
(Barrett et al., 2002).  On the contrary, there are reports of females having lower 
sensitivity to experimentally delivered stimuli.  For example, Tall et al. (2001) reported 
female rats as having longer paw withdrawal latency to radiant thermal stimulation than 
males, and Wang et al. (2006) reported female rats had less thermal hyperalgesia (longer 
paw withdrawal latency) in the complete Freund’s adjuvant (CFA) model than males.   
 There are reports of sex differences in opioid- and non-opioid-induced analgesia, 
the majority reporting opioid-induced analgesia as being greater in male than female 
rodents [see reviews (Craft, 2003a, 2003b)].  Morphine’s anti-nociceptive effect was 
greater in male than female rats on hot plate, tail flick, and abdominal constriction tests 
(Cicero et al., 1996), and morphine’s anti-hyperalgesic effect in the CFA model and anti-
nociceptive effect were greater in male than female rats with radiant thermal stimulus to 
the paw (Wang et al., 2006).  In mice as well, morphine anti-nociception on tail flick 
latencies was greater in males than females (Candido et al., 1992).   
 The differences in pain sensation and analgesia between the sexes may be due to a 
plethora of causal factors, but fewer research reports to date have focused on the effects 
of circulating androgens than estrogens in altering pain sensation.  This study was 
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designed to characterize the effects of exogenous testosterone replacement in 
gonadectomized adult male rats on acute nociceptive thermal hind paw withdrawal 
thresholds in order to explore specific components of sex differences in pain sensation 
contributed by male gonadal hormones.  This report provides the novel information of 
paw withdrawal latencies in male rats followed over a time course of one week after 
gonadectomy, and of the effect of testosterone replacement on paw withdrawal latencies 
using a radiant thermal analgesiometer.   
 Several studies addressing thermal nociception in males corroborate the 
hypothesis that testosterone can have hypoalgesic effects.  For example, GDX of adult 
male rats did not change thermal paw withdrawal latency, but neonatal GDX of male or 
testosterone androgenization of female rats indicated an organizational hypoalgesic effect 
of testosterone (LaCroix-Fralish et al., 2005).  However, that study did not directly 
investigate the activational effects of testosterone on thermal paw withdrawal latencies of 
adult rats, as did the current study.  Testosterone, DHT or 3α-androstanediol-3α-diol 
increased tail flick and hot plate latencies in GDX male rats (Edinger & Frye, 2005).  In 
male rats, testosterone fully reversed GDX-induced hyperalgesia on a tail flick test and 
partially reversed that of a hot plate test (Forman et al., 1989).  Similar to the findings of 
the current study, Frye and Seliga (2001) reported GDX itself did not affect nociceptive 
threshold, but testosterone replacement in GDX rats increased the tail flick threshold. 
 Activational effects of testosterone on anti-nociception have been observed as 
well.  Morphine anti-nociception was more potent on a hot plate test in gonadally intact 
male rats and testosterone-treated GDX than GDX rats (Stoffel et al., 2003), and 
morphine was more potent in intact than GDX male mice (Candido et al., 1992), although 
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inhibition of the 5α-reductase enzyme was found to potentiate morphine anti-nociception 
in the tail flick test (Verdi & Ahmadiani, 2007).  Also, Thompson et al. (2008) reported 
that testosterone was required for spinal α2-adrenoreceptor-mediated anti-nociception on 
a tail flick test in male rats.  Another report demonstrated GDX of male rats increased 
nociceptive behaviors in the formalin model of persistent inflammatory pain, indicating 
an anti-nociceptive effect of androgen (Aloisi & Ceccarelli, 2000).  However, in another 
study using the formalin model, testosterone had a pro-nociceptive effect in male rats 
(Nayebi & Ahmadiani, 1999).  Moreover, the formalin model – a persistent pain model – 
may employ additional or alternative mechanisms of nociceptive signaling than those of 
acute (phasic) thermal stimulation.  None of these studies on testosterone’s effect on 
nociception were done with radiant thermal stimulation of the paw, as was the current 
report.  The paw withdrawal test is a refinement of the tail flick test which possesses 
several distinctions from the tail flick test, including the following:  stimulation is on 
glabrous skin, the animal is not restrained, higher precision of stimulus location, and 
possible differences in the degree or nature of supraspinal modulation (Bennett, 2001). 
 Sex-related differences in acute nociceptive threshold have largely been attributed 
to mechanisms regulated by circulating estrogens, and many studies on the 
somatosensory effects of estrogens have reported pro-nociceptive effects.  Despite this 
prevalent interpretation, E2 reportedly can have anti-nociceptive effects as well.  For 
example, Forman et al. (1989) reported ovariectomized (OVX) rats receiving estradiol 
had longer tail flick latencies than OVX controls, and E2-treated OVX rats had lower 
thermal nociceptive sensitivity than OVX rats on a hot plate test (Stoffel et al., 2003), 
although this is somewhat contrary to results of a hot plate test reported by Forman et al. 
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(1989).  Nonetheless, the hypoalgesic effect on thermal nociception currently observed 
with testosterone replacement is opposite in direction to what is typically observed 
following E2 administration.  Serum E2 levels were measured in this study to exclude the 
possibility that the testosterone-evoked hypoalgesia was mediated via altered circulating 
estradiol levels (since TP can be metabolized into E2).  The results of this study showed 
that serum E2 concentrations were not significantly altered following hormone 
manipulation (Figure 8) , and remained at levels consistent with previous reports for 
adult male rats (Overpeck et al., 1978).  This observation, concurrent with the observed 
change in nociceptive withdrawal behavior (Figure 9), suggests that the hypoalgesic 
effect was not mediated by alteration of serum E2.   
 The hypoalgesic effect of testosterone observed in the current study could be due 
to direct (there are androgen receptors throughout the nervous system (Melcangi et al., 
2005; Simerly et al., 1990) or indirect (possibly via the hypothalamic-pituitary-gonadal 
and/or -adrenal axes (Viau, 2002) effects on the nervous system responsible for 
nociception.  Since gonadectomy itself did not alter withdrawal latencies, but testosterone 
replacement did, one possible interpretation is that androgen-induced hypoalgesic effects 
may be counterbalanced or masked by other endogenous gonadal factors.  For example, 
inhibin, activin and follistatin are known hormones produced in the testes that regulate 
endocrine function in the brain, such as levels of luteinizing hormone (LH) and follicle 
stimulating hormone (FSH).  It is possible that these or other (perhaps unknown) gonadal 
factors directly or indirectly affect nociception.  In fact, receptors for LH and activin are 
found in the brain, including the limbic system [reviewed by Vadakkadath Meethal and 
Atwood (2005)].  
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 Serum DHT concentrations in the 20 mg TP-supplemented rats were consistent 
with those previously reported for intact adult male rats (Overpeck et al., 1978).  Thus, 
the dose of TP supplementation results in serum DHT levels that mimic normal 
endogenous serum concentrations.  However, episodic, endogenous testosterone 
concentrations, as opposed to constant, exogenous release may make a difference in the 
net effect of androgens on nociceptive sensation.  Endogenous testosterone release in rats 
is pulsatile in manner, and serum levels are episodic, with a daily periodicity (Mock et 
al., 1978; Sodersten et al., 1980; Sodersten et al., 1983).  The testosterone pellets used in 
this study may produce androgen levels with less temporal variability than endogenous 
levels (i.e. that do not pulsate or fluctuate episodically over a day) and thus may produce 
different effects than the endogenous, episodic androgen levels (Hutchison & Goldman, 
1975; Moger, 1976).   
 As mentioned before, a previous report demonstrated a pro-nociceptive effect of 
testosterone in the formalin model of persistent inflammatory pain in male rats (Nayebi & 
Ahmadiani, 1999), and another study showed an anti-nociceptive effect of androgen 
(Aloisi & Ceccarelli, 2000).  However, the findings of the current study indicated no 
effect of male gonadal hormones on formalin-induced flinching behavior.  Compared to 
the current study, the previous reports used different formalin stimuli, longer periods 
during which rats were GDX before testing, and different pain scoring procedures than 
the current study, all of which may contribute to the contrast of the results of these 
studies.  In a gonadectomy study performed on male and female rats, Aloisi et al. (2000) 
reported that gonadal hormones in both sexes inhibited paw flexion duration following 
formalin, but did not affect the paw-jerk response.  They concluded that the effects of the 
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gonadal hormones on flexion posturing were independent of the [degree of] nociceptive 
[peripheral/spinal] input [to supraspinal processing and behavior], since flexion and 
licking are regarded as being more susceptible to supraspinal modulation than is 
flinching.  This indicated the hormones acted supraspinally.  The question – perhaps a 
rhetorical question – is which behavior(s) best represent the overall nociceptive 
experience.  Indeed, flinching is viewed as less influenced by conditions that affect non-
nociceptive behavior, and, thus, a more meaningful end point (Tjolsen et al., 1992).  
Another report found that GDX in males increased licking, flexion duration, and 
flinching in the formalin first phase and increased flexion duration in the second phase 
(Aloisi & Ceccarelli, 2000).  In yet another study (Aloisi et al., 2004), females had higher 
licking duration than males following formalin.  Licking duration was reduced by 
testosterone in females to a “male-like” level; the authors speculated that this was 
[indirect] evidence that testosterone limits the licking response in males.  
Supraphysiological testosterone added to intact males did not alter licking, but this 
negative result could be due to a ceiling effect.  Ultimately, the results of the current 
study do not support androgen activational effects as a contributing factor to sex 
differences in inflammatory nociception.   
 Since the introduction of the SNI model, there have been a very limited number of 
studies into sex differences or sex steroid effects on the mechanical hyperalgesia induced 
by SNI.  Bourquin et al. (2006) reported no sex difference in mechanical threshold 
following SNI.  They did find a slight sex difference in ipsilateral paw withdrawal 
frequency to the same stimulus over a range of intensities, with males being more 
sensitive.  However, this slight sex difference was present at baseline before SNI, and the 
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authors stated that the effect of SNI was equal for both genders.  They reported no sex 
difference for the contralateral paw.  The findings of the current study are different than 
the previous study in that they show an effect of gonadectomy.  Taken together, these 
studies imply that gonadectomy has effects on nociception that may not contribute to sex 
differences. 
 The current data indicate GDX decreased withdrawal thresholds contralateral but 
not ipsilateral to SNI.  These data may indicate male gonadal hormones either inhibit 
descending facilitation or promote descending inhibition contralateral to SNI.  However, 
the implications of this apparent androgen effect are limited by the lack of sex difference 
observed in the SNI model.  This lack of sex-difference context for the SNI model seems 
to extend to clinical observations, which have largely failed to demonstrate a sex 
difference in incidence of neuropathic pain following injury, [for example, see 
(Ciaramitaro et al., 2010)].  These observations suggest that pain of neuropathic origin is 
not typically altered by gender or sex hormones, despite the large body of evidence for 
women (and girls) having, in general, higher incidence, severity, and frequency of 
persistent body pains (Berkley, 1997; Unruh, 1996).  Gialloreti et al. (2010) reported the 
incidence of post-herpetic neuralgia in patients with herpes zoster was higher in females 
than males.  However, this neuropathic pain originates with viral infection and may 
sensitize the nervous system through different mechanisms than other injuries, such as 
the SNI model.  Thus, the current study adds novel evidence that androgen may have an 
anti-nociceptive effect in neuropathic pain states, at least in the SNI model.   
 The findings of the current study indicate GDX did not affect thermal withdrawal 
latencies (thresholds) in the SNI model.  This was no surprise because GDX itself did not 
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alter thermal thresholds in the absence of the SNI model (Figure 9), and the SNI model 
does not alter thermal thresholds (Decosterd & Woolf, 2000). 
 In conclusion, the results of this study demonstrate that exogenous replacement of 
testosterone in gonadectomized male rats increased thermal nociceptive withdrawal 
latencies over those observed in naïve or surgical control rats.  This finding suggests that 
testosterone or DHT has an activational, hypoalgesic effect on acute thermal nociception 
in males that is not likely mediated by metabolism of testosterone to estrogen. 
 The observations in this chapter, taken together, demonstrated androgen had a 
hypoalgesic effect on phasic thermal stimulus and an anti-nociceptive effect on phasic 
mechanical nociception contralateral to a persistent neuropathic pain model.  Thus, it is 
evident that androgen has activational effects on pain of phasic thermal and persistent 
neuropathic origin, but perhaps not persistent inflammatory origin.  These results provide 








ESTRADIOL INCREASES PERSISTENT NOCICEPTION-RELATED 
BEHAVIOR:  STUDIES CHARACTERIZING COMPLEX 




4.1  Abstract 
 These experiments characterized nociception-related behaviors, especially paw 
flinching, and actometry end points following formalin injection, and investigated the 
activational effect of estradiol upon them.  Many studies have demonstrated activational 
effects of estrogen, including modulation of pain sensation in females.  Previous results 
from our laboratory suggest that sustained, long-term estrogen replacement in 
ovariectomized females enhances formalin-induced pain-related behaviors.  We 
hypothesized that a single injection of estradiol, mimicking a proestrus surge, would 
similarly enhance formalin-evoked persistent inflammatory nociception.  Thus, adult 
female rats were ovariectomized and, six days later, injected subcutaneously with 10 
μg/kg estradiol benzoate or vehicle.  Twenty-four hours later, 100 μL of 5% or 50 μL of 
1.25% formalin was injected into the right hind paw.  Spontaneous hind paw flinches 
were then quantified, or behaviors were monitored by actometry.  A preliminary 
experiment verified that a single injection of estradiol, which would be the estrogen 
manipulation model for this and future experiments, had an uterotrophic effect.  Results 
revealed no difference due to estradiol in quantity of paw flinching at 1.25% formalin, 
but an estradiol-induced increase in flinching at 5% formalin.  Actometry revealed a 
nociception-related increase in behaviors in a 4.4–5.4 Hz frequency band (potentially 
reflecting increased licking, whisking, or respiration), and increased total distance 
traveled between formalin-injected and control groups at 5% but not 1.25% formalin.  
Estradiol injection reduced behaviors in a 0.3-1.5 Hz frequency band in rats receiving 
1.25% formalin; this may reflect alteration of locomotion during nociception.  Behaviors 
represented by these frequency and distance measures, or their detection, may be stimulus 
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intensity-dependent.  Taken together, these data indicate that a proestrus-like surge in 
serum estrogen can modify inflammatory nociception-related behaviors and, thus, 
presumably nociception in an activational manner.   
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4.2  Introduction 
 Estrogens appear to have activational, often pro-nociceptive (pain-potentiating), 
effects on innervation, synapse formation, and sensory function.  However, there are no 
reports of direct, systematic investigation into identification of the anatomical sites of 
action in the nervous system of the enhancement of nociception and pain by estrogens.  
Thus, we hypothesized that sex differences in pain sensation are due, at least in part, to 
activational effects of estradiol on peripheral, spinal and/or supraspinal sites involved in 
the transmission and perception of nociceptive stimuli.  To determine whether activation 
in response to inflammatory pain was increased by acute, activational effects of estrogen, 
the current study addressed the intensity of nociceptive behaviors evoked by formalin (a 
model of persistent inflammatory pain). 
 The formalin test is an established, widely used model of persistent inflammatory 
pain (Porro & Cavazzuti, 1993; Tjolsen et al., 1992).  It is usually used in mice and rats, 
and may provide a better approximation of clinical chronic pain than traditional phasic 
nociceptive tests, such as acute radiant thermal, hot-plate, or mechanical paw withdrawal 
tests.  Formalin induces a biphasic pain-related behavioral response, separated by a 
quiescent interphase.  The first (early) phase is due to C-fiber activation, while the second 
(late) phase is due to peripheral inflammation and central sensitization.  The behavioral 
responses that can be evaluated include lifting (flexing), licking, biting, and flinching of 
the injected paw.  The flinching response seems to be a consistent component of the 
response, and is easy to observe and quantify.  The other behavioral responses have been 
more problematic, and it has been suggested that flinching is less influenced by 
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conditions that affect non-nociceptive behavior, and, thus, is a better end-point (Tjolsen 
et al., 1992).   
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4.3  Materials & methods 
 Adult female Sprague-Dawley rats (~11 weeks old, 200-230 g, Harlan, 
Indianapolis, IN) were used in these experiments.  A set of formalin-only experiments 
was conducted in gonadally intact females and characterized the dose-response 
relationship and time course of the flinching response to formalin.  In addition, formalin-
only actometry experiments used rats that were OVX for a period of one week before 
nociceptive behavioral testing, but received no further manipulation.   
 For studies investigating effects of estrogen, rats were divided into two groups: 1) 
ovariectomized (OVX) receiving estradiol, and 2) OVX receiving an equivalent volume 
of vehicle.  Estradiol (E2) supplementation was followed 24 hours later by nociceptive 
behavioral evaluation.  Flinching behavior was quantified in rats that received 1.25% or 
5% formalin injection.  Another actometry experiment studied the effect of E2 on 1.25% 
formalin-induced behavior. 
 In a separate experiment, twenty-four hours after E2 injection (seven days after 
OVX), rats were weighed then decapitated, adipose tissue was removed from uteri, and 
uteri were excised at the base and weighed wet.   
4.3.1  Hormone manipulation 
 For ovariectomy (OVX), rats were anesthetized with a mixture of ketamine (64 
mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 mg/kg; i.p.).  
Under aseptic conditions, a ventral midline incision (~1.5 cm) was made into the lower 
abdominal cavity.  Both ovaries were externalized, fallopian tubes and blood vessels 
ligated with suture just proximal to the ovaries, and the ovaries excised.  Adipose tissue, 
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fallopian tubes, and blood vessels were reinserted into the abdominal cavity.  Muscle and 
skin layers were individually closed with suture.  Six days later, rats (except those in 
formalin-only actometry experiments) received a single subcutaneous injection into the 
left flank of 10 μg/kg estradiol benzoate (Sigma, E-9000) at 10 μg/mL in vehicle (10% 
ethanol/90% corn oil), or an equivalent volume of vehicle.  This dose of E2 was chosen 
to mimic the surge in E2 observed during proestrus in rats [see (Butcher et al., 1974; 
Medlock et al., 1991; Nag & Mokha, 2006; Viau & Meaney, 1991; Zoubina et al., 2001)].  
Rats in the formalin-only actometry experiments did not receive any injection of estradiol 
or vehicle.   
4.3.2  Nociceptive behavioral analysis 
 4.3.2.1  The Formalin Test 
 Approximately 24 hours after estradiol or vehicle injection (or seven days after 
OVX), rats received a unilateral injection of 100 μL of 5% or 50 μL of 1.25% formalin 
into the plantar hind paw as a model of persistent inflammatory pain.  Spontaneous hind 
paw flinches were quantified post-injection. 
 4.3.2.2  Actometry 
 For force plate actometry experiments, behavioral responses were recorded for 
one hour before, and for one hour immediately after formalin injection.  Detailed 
recordings of the rats’ movements were collected during these periods using a force-plate 
actometer (Bioanalytical Systems, Inc.).  Rats in the 1.25% formalin experiments were 
acclimated to the actometer environment over a 5 day period prior to the experiment.  
Rats in the 5% formalin experiments were not acclimated.  Rats in “Sham” groups were 
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manually restrained and hind paw handled as if injecting, but received no needle prick or 
injection.   
4.3.3  Data analyses 
 Force-plate actometry data were collected, and distance metrics and frequency 
spectra power analyses performed, using FPA analysis software provided by the 
manufacturer (Bioanalytical Systems, Inc.).  Frequency/power data were exported to 
Microsoft Excel to compile group values, for analysis of power spectra within selected 
frequency bands, and for general statistical analyses and plotting.  All data represent the 
mean ± SEM.  Data were analyzed by Student’s t-test or ANOVA statistical analyses 
with the significance level set to p ≤ 0.05.   
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4.4  Results 
 Results of the uterus measurement (Figure 14) revealed rats receiving estradiol 
(OVX + E2) had significantly higher uterus weight than controls receiving vehicle 
(OVX) (Student’s t-test, Welch-corrected; n: Vehicle = 17, E2 = 18). 
 Data in Figure 15 show the dose-response relationship of hind paw flinching 
behavioral response to formalin injection in gonadally intact female rats.  The number of 
flinches quantified during the 30-40 minute post-injection period were 37.6 ± 10.1, 104.3 
± 16.7 and 132.3 ± 15.9 for 1.25, 2.5 and 5%, respectively (n = 4 each).  These data 
demonstrate the degree of flinching response to different levels of formalin stimulus. 
 In the time-course experiment (Figure 16), gonadally intact rats (n = 8) were 
injected with 50 μL of 1.25% formalin into the right plantar hind paw, and paw flinches 
were quantified 0-60 minutes post-injection.  These data show the dynamic pattern of 
flinching response quantity over time.  These data are in accordance with previously 
published time courses of flinching behavior following formalin injection (Tjolsen et al., 
1992) and demonstrate the typical biphasic response. 
 Results of E2 manipulation revealed that, for 1.25% formalin (Figure 18), total 
flinches (in the 30-40 minute time frame) for rats receiving estradiol (OVX + E2) were 
not different than controls receiving vehicle (OVX) (Student’s t-test, n = 10 per group).  
In contrast, for 5% formalin (Figure 19), rats receiving estradiol (OVX + E2) had 
significantly more total flinches than controls receiving vehicle (OVX) (Student’s t-test, n 
= 12 per group). 
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 Further analysis was performed to examine the effect of E2 quantified hind paw 
flinches 0-60 minutes post-injection for 1.25% formalin.  Total flinches over the entire 60 
minutes were: Vehicle 286.4 ± 15.1; E2 289.6 ± 16.1.  When flinching behavior was 
broken down into Early (0-5 min), Inter- (5-15 min) and Late (15-60 min) phases, total 
flinches for rats receiving estradiol (OVX + E2) were not different than controls 
receiving vehicle (OVX) for any time period or for the entire 60 minutes (Data not 
shown; Student’s t-test, n = 10 per group). 
 
 
Figure 14.  Effect of estradiol on uterine weight in ovariectomized (OVX) female rats.  Rats were 
ovariectomized and, six days later, received a single s.c. estradiol (10 μg/kg) or vehicle injection.  Twenty-
four hours after estradiol (E2) injection (seven days after OVX), rats were weighed then decapitated, 
adipose tissue was removed from uteri, and uteri were excised at the base and weighed wet.  Note that rats 
receiving estradiol (OVX + E2) had significantly higher uterus weight than controls receiving vehicle 
(OVX).  These data demonstrate that the single dose of E2 produced an estrogenic effect.  (*p < 0.0001, 
unpaired Student’s t-test, Welch-corrected; n: Vehicle = 17, E2 = 18).  Data represent the mean ± SEM.  
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Figure 15.  Dose-response relationship of hind paw flinching behavioral response to formalin injection in 
female rats.  Rats were injected with 50 μL of 1.25, 2.5 or 5% formalin into the right plantar hind paw.  
Spontaneous hind paw flinches were quantified 30-40 minutes post-injection (during the peak of the late-
phase behaviors).  These data characterize the degree of flinching response to different levels of formalin 




Figure 16.  Time course of hind paw flinching behavioral response to formalin injection in female rats.  
Rats were injected with 50 μL of 1.25% formalin into the right plantar hind paw.  Spontaneous hind paw 
flinches were quantified 0-60 minutes post-injection.  These data characterize the flinching response over 




Figure 17.  Experimental timeline for studying the effect of estradiol on flinching behavior following 
formalin injection.  Rats were ovariectomized and, six days later, received a single s.c. estradiol (10 μg/kg) 
or vehicle injection.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), rats were 
injected with formalin into the right plantar hind paw.  Spontaneous hind paw flinches were quantified 30-
40 minutes post-injection.  Two hours after formalin injection, rats were anesthetized, perfused, and spinal 





Figure 18.  Effect of estradiol on 1.25% formalin-evoked spontaneous flinching behavior 30-40 minutes 
post-formalin.  Rats were ovariectomized and, six days later, received a single s.c. estradiol (10 μg/kg) or 
vehicle injection.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), rats were 
injected with 50 μL of 1.25% formalin into the right plantar hind paw.  Spontaneous hind paw flinches 
were quantified 30-40 minutes post-injection (during the peak of the late-phase behaviors).  Note that total 
flinches for rats receiving estradiol (OVX + E2) were not different than controls receiving vehicle (OVX).  






Figure 19.  Effect of estradiol on 5% formalin-evoked flinching behavior.  Rats were ovariectomized and, 
six days later, received a single s.c. estradiol (10 μg/kg) or vehicle injection.  Twenty-four hours after 
estradiol (E2) injection (seven days after OVX), rats were injected with 100 μL of 5% formalin into the 
right plantar hind paw.  Spontaneous hind paw flinches were quantified 30-40 minutes post-injection 
(during the peak of the late-phase behaviors).  Note that rats receiving estradiol (OVX + E2) had 
significantly more total flinches than controls receiving vehicle (OVX).  Data represent the mean ± SEM 




 Figure 20 shows representative force/time recordings from rats that were either 
injected with 50 μL 1.25% formalin into the left hind paw (right) or received sham 
restraint (left), then were placed in the actometer for one hour.  These force/time traces 
demonstrate activity of the rats and that the force on the plate changed over time as the 
subject manifested either restricted body movements (such as grooming) or moved about 
the behavioral arena (such as locomotion).  These changes in force over time are related 
to the specific patterns of movement that comprise behavior, and are the basis for 
Fourier-transformation of the data into frequency/power spectra.  . 
 Figure 21 shows Fourier-transformed power spectra of actometer force/time 
recordings of female rats that were either injected with 50 μL of 1.25% formalin into the 
right hind paw or received sham restraint, then were placed in the actometer for one hour.  
Rats had been acclimated to the actometer environment prior to the experiment.  Fourier-
transform power spectral analysis was performed on the force/time traces of actometry 
over the entire 60-minute period following formalin injection.  Results revealed similar 
power spectra for Sham (n = 20) and 1.25% formalin-treated (n = 20) rats (Figure 21).  
Data represent mean power spectra.  Rats in the Sham and Formalin groups were the 
same rats which were monitored in the actometer first without formalin (Sham) then after 
formalin injection (Formalin); rats in each treatment group were comprised of rats that 
had been OVX 7 days prior to the experiment, which received injection of either E2 (n = 
10) or vehicle (n = 10) 24 hours before the experiment. 
 Figure 22 shows Fourier-transformed power spectra of actometer force/time 
recordings of female rats that were either naïve or injected with 50 μL of 5% formalin 
into the left hind paw, then were placed in the actometer for one hour.  Results revealed 
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potentially qualitatively different power spectra for Naïve (n = 6) and 5% formalin-
treated (n = 6) rats.  Data represent mean power spectra.  Rats in the Naïve and Formalin 
groups were the same rats which were monitored in the actometer first without formalin 
(Naïve) then after formalin injection (Formalin).  Rats had not been acclimated to the 
actometer environment. 
 The mean power spectrum for Sham (n = 20) rats was subtracted from that of 
1.25% formalin-treated (n = 20) rats.  Results revealed a difference power spectrum with 
relatively small magnitudes (Figure 23).  The mean power spectrum for Naïve (n = 6) 
rats was subtracted from that of 5% formalin-treated (n = 6) rats.  Results revealed a 
difference power spectrum with relative larger magnitudes at some frequencies than those 
at 1.25% formalin (Figure 24). 
 Three categories of frequency band (range) were empirically designated for the 
power spectra, based on the difference power spectrum of 5% formalin.  The frequency 
band designations were:  Low:  0.3-1.5 Hz; Peak:  4.4-5.4 Hz; High:  2.4-9.3 Hz; they are 
represented by horizontal lines and shown with difference power spectra for 1.25% and 




Figure 20.  Representative actometer force/time recordings for rats without or with formalin injection.  
These are representative force/time recordings from rats that received either A) sham restraint or B) 




Figure 21.  Fourier-transformed power spectra of actometer force/time recordings of female rats following 
hind paw injection of 1.25% formalin.  Rats were either injected with 50 μL 1.25% formalin into the right 
hind paw or received sham restraint, then were placed in the actometer for one hour.  Rats had been 
acclimated to the actometer environment over a 5 day period prior to the experiment.  Results revealed 
similar power spectra for Sham (n = 20) and formalin-treated (n = 20) rats.  Data represent mean power 
spectra.  [Rats in the Sham and Formalin groups were the same rats which were monitored in the actometer 
first without formalin (Sham) then after formalin injection (Formalin); rats in each treatment group were 
comprised of rats that had been OVX 7 days prior to the experiment, which received injection of either E2 




Figure 22.  Fourier-transformed power spectra of actometer force/time recordings of female rats following 
hind paw injection of 5% formalin.  Rats were either naïve or injected with 50 μL 5% formalin into the left 
hind paw, then were placed in the actometer for one hour.  Results revealed potentially qualitatively 
different power spectra for Naïve (n = 6) and formalin-treated (n = 6) rats.  Data represent mean power 
spectra.  [Rats in the Naïve and Formalin groups were the same rats which were monitored in the actometer 





Figure 23.  Fourier-transformed difference power spectrum of actometer force/time recordings of female 
rats following hind paw injection of 1.25% formalin.  Rats were either injected with 50 μL 1.25% formalin 
into the right hind paw or received sham restraint, then were placed in the actometer for one hour.  Rats had 
been acclimated to the actometer environment over a 5 day period prior to the experiment.  The mean 
power spectrum for Sham (n = 20) rats was subtracted from that of formalin-treated (n = 20) rats.  Results 
revealed a difference power spectrum with relatively small magnitudes.  Data represent the mean power 
spectrum.  [Rats in the Sham and Formalin groups were the same rats which were monitored in the 
actometer first without formalin (Sham) then after formalin injection (Formalin); rats in each treatment 
group were comprised of rats that had been OVX 7 days prior to the experiment, which received injection 




Figure 24.  Fourier-transformed difference power spectrum of actometer force/time recordings of female 
rats following hind paw injection of 5% formalin.  Rats were either naïve or injected with 50 μL 5% 
formalin into the left hind paw, then were placed in the actometer for one hour.  The mean power spectrum 
for Naïve (n = 6) rats was subtracted from that of formalin-treated (n = 6) rats.  Results revealed a 
difference power spectrum with potentially significant magnitudes.  Data represent the mean power 
spectrum.  [Rats in the Naïve and Formalin groups were the same rats which were monitored in the 
actometer first without formalin (Naïve) then after formalin injection (Formalin).  Rats had not been 




Figure 25.  Designations of frequency bands of actometry power spectra for quantification of behaviors, 
superimposed on the difference power spectrum of 1.25% formalin.  Horizontal lines represent frequency 
band (range) designations of the power spectra, shown here with the Fourier-transformed difference power 
spectrum of actometer force/time recordings of female rats following hind paw injection of 1.25% 
formalin.  Bands designations were largely based on the difference power spectrum of 5% formalin.  The 




Figure 26.  Designations of frequency bands of actometry power spectra for quantification of behaviors, 
superimposed on the difference power spectrum of 5% formalin.  Horizontal lines represent frequency band 
(range) designations of the power spectra, shown here with the Fourier-transformed difference power 
spectrum of actometer force/time recordings of female rats following hind paw injection of 5% formalin.  
Band designations were largely based on the difference power spectrum of 5% formalin.  The frequency 




 Power spectra were summed over the designated frequency bands.  Results 
(Figure 27) revealed no differences in power for Sham (n = 20) vs. 1.25% formalin-
treated (n = 20) rats for Low, Peak or High frequency ranges (Student’s t-test).  In 
contrast, results for 5% formalin revealed a difference in power for Sham (n = 6) vs. 
formalin-treated (n = 6) rats at the Peak frequency band (Figure 28), but not at the Low 
or High frequency band (Student’s t-test).  These data demonstrate that 5% formalin 
induced an increase in a behavior(s) that is represented by power in the 4.4-5.4 Hz 
frequency band.   
 Figure 29 shows Fourier-transformed power spectra of actometer force/time 
recordings of female rats following hind paw injection of 1.25% formalin.  Rats had been 
acclimated to the actometer environment prior to the experiment.  Power spectra were 
summed over selected frequency bands, which were:  Low:  0.3-1.5 Hz; Peak:  4.4-5.4; 
Hz High:  2.4-9.3 Hz.  Results revealed lower power for E2-treated (n = 10) vs. vehicle-
treated (n = 10) rats in the Low frequency band, but no difference in the Peak or High 
frequency bands (Student’s t-test).  These data demonstrate estradiol decreased a 
behavior(s) that is represented by power in the Low frequency band.   
 Figure 30 shows representative spatial plots from actometer force/time recordings 
of female rats over one hour.  These data demonstrate movement of the rats across the 
force plate arena and that movement changed over time.  Movement across the (X,Y) 
coordinates of the force plate grid provide the basis for the analysis of total distance 
traveled.   
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 Analysis of total distance traveled from actometer recordings was performed, 
revealing no difference in total distance traveled for Sham (n = 20) vs. 1.25% formalin-
treated (n = 20) rats (Figure 31, panel A).  However, results revealed that 5% formalin-
treated (n = 6) rats had higher total distance traveled over Naïve (n = 6) rats (Figure 31, 




Figure 27.  Analysis of power over frequency bands in rats following 1.25% formalin.  Rats were either 
injected with 50 μL 1.25% formalin into the right hind paw or received sham restraint, then were placed in 
the actometer for one hour.  Rats had been acclimated to the actometer environment over a 5 day period 
prior to the experiment.  Power spectra were summed over the designated frequency bands.  The frequency 
band designations are:  Low:  0.3-1.5 Hz; Peak:  4.4-5.4; Hz High:  2.4-9.3 Hz.  Results revealed no 
differences in power for Sham (n = 20) vs. formalin-treated (n = 20) rats.  Data represent the mean ± SEM 
(Significance level set to p ≤ 0.05, unpaired Student’s t-test).  [Rats in the Sham and Formalin groups were 
the same rats which were monitored in the actometer first without formalin (Sham) then after formalin 
injection (Formalin); rats in each treatment group were comprised of rats that had been OVX 7 days prior 





Figure 28.  Analysis of power over frequency bands in rats following 5% formalin.  Rats were either 
injected with 50 μL 5% formalin into the left hind paw or were naïve, then were placed in the actometer for 
one hour.  Power spectra were summed over the designated frequency bands.  The frequency band 
designations are:  Low:  0.3-1.5 Hz; Peak:  4.4-5.4; Hz High:  2.4-9.3 Hz.  Results revealed a difference in 
power for Sham (n = 6) vs. formalin-treated (n = 6) rats at the Peak frequency band, but not at the Low or 
High frequency band.  These data suggest 5% formalin induced an increase in a behavior(s) that is 
represented by power in the Peak frequency band.  Data represent the mean ± SEM (*p ≤ 0.05, unpaired 
Student’s t-test).  [Rats in the Naïve and Formalin groups were the same rats which were monitored in the 
actometer first without formalin (Naïve) then after formalin injection (Formalin).  Rats had not been 




Figure 29.  Effect of estradiol on Fourier-transformed power spectra of actometer force/time recordings of 
female rats following hind paw injection of 1.25% formalin.  Rats were ovariectomized (OVX) and, six 
days later, received a single s.c. injection of 10 μg/kg estradiol (E2) or vehicle.  Twenty-four hours after 
estradiol (E2) injection (seven days after OVX), rats were injected with 50 μL 1.25% formalin into the right 
hind paw, then were placed in the actometer for one hour.  Rats had been acclimated to the actometer 
environment over a 5 day period prior to the experiment.  Power spectra were summed over the designated 
frequency bands.  The frequency band designations are:  Low:  0.3-1.5 Hz; Peak:  4.4-5.4; Hz High:  2.4-
9.3 Hz.  Results revealed a difference in power for vehicle (n = 10) vs. E2-treated (n = 10) rats in the Low 
frequency band, but not Peak or High frequency bands.  These data suggest estradiol decreased a 
behavior(s) that is represented by power in the Low frequency band.  Data represent the mean ± SEM (*p ≤ 




Figure 30.  Representative examples of recordings of position/time data of female rats for one hour.  Data 
were collected using a BASi force-plate actometer.  Analyses of total distance traveled was calculated 
based on the change in position of the center of force recordings over time.  Note that the position traces 
reflect the initial exploratory behavior in the force-plate arena, which diminishes over time.   
 
101 
A       B 
 
Figure 31.  Analysis of total distance traveled from actometer force/time recordings of female rats 
following hind paw injection of formalin.  A) 1.25% formalin:  Rats were either injected with 50 μL 1.25% 
formalin into the right hind paw or received sham restraint, then were placed in the actometer for one hour.  
Results revealed no difference in total distance traveled for Sham (n = 20) vs. formalin-treated (n = 20) rats.  
[Rats in the Sham and Formalin groups were the same rats which were monitored in the actometer first 
without formalin (Sham) then after formalin injection (Formalin); rats in each treatment group were 
comprised of rats that had been OVX 7 days prior to the experiment, which received injection of either E2 
(n = 10) or vehicle (n = 10) 24 hours before the experiment.  Rats had been acclimated to the actometer 
environment over a 5 day period prior to the experiment.]  B)  5% formalin:  Rats were either injected with 
50 μL 5% formalin into the right hind paw or were naïve, then were placed in the actometer for one hour.  
Results revealed 5% formalin-treated (n = 6) rats had higher total distance traveled over Naïve (n = 6) rats.  
Data represent the mean ± SEM (*p ≤ 0.05, paired Student’s t-test).  [Rats in the Naïve and Formalin 
groups were the same rats which were monitored in the actometer first without formalin (Naïve) then after 




4.5  Discussion 
 These experiments characterized nociception-related behaviors following 
formalin injection, and investigated the activational effect of estradiol upon these 
behaviors.  Behaviors examined were flinching of the inflamed hind paw and two force 
plate actometry end points:  total distance traveled and Fourier-transformed power 
spectra.  To test acute effects of estrogen, behavioral analyses with the formalin model 
were performed 24 hours after a single injection of estradiol. 
 Results of the uterus measurement (Figure 14) revealed that ovariectomized, 
adult rats receiving administration of a single dose of estradiol, which mimics the 
proestrus surge of estrogen in intact female rats [see (Butcher et al., 1974; Medlock et al., 
1991; Nag & Mokha, 2006; Viau & Meaney, 1991; Zoubina et al., 2001)], had 
significantly higher uterus weight than controls receiving vehicle.  These data 
demonstrated that the single dose of E2 produced an estrogenic (uterotrophic) effect, 
which was evident 24 hours after E2 injection (Student’s t-test, Welch-corrected; n: 
Vehicle = 17, E2 = 18).  The uterotrophic effect of this E2 dose in OVX rats has been 
reported previously (Zoubina et al., 2001).  These results confirmed the efficacy of using 
this estrogen dose and timing regimen for the experimental design. 
 Data in Figure 15 show the dose-response relationship of hind paw flinching 
behavioral response to formalin injection in gonadally intact female rats.  The number of 
flinches quantified during the 30-40 minute post-injection period were 37.6 ±10.1, 104.3 
±16.7 and 132.3 ±15.9 for 1.25, 2.5 and 5%, respectively (n = 4 each).  These data 
demonstrate the degree of flinching response to different levels of formalin stimulus. 
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 In the time-course experiment (Figure 16), gonadally intact rats (n = 8) were 
injected with 50 μL of 1.25% formalin into the right plantar hind paw, and paw flinches 
were quantified 0-60 minutes post-injection.  These data show the dynamic pattern of 
flinching response quantity over time.  These data are in accordance with previously 
published time courses of flinching behavior following formalin injection (Tjolsen et al., 
1992) and demonstrate the typical biphasic response. 
 Results of estradiol manipulation confirmed the hypothesis that a single injection 
of estradiol significantly enhances late-phase formalin-induced hind paw flinching at 5% 
formalin (Figure 19); in contrast, no difference was observed at 1.25% (Figure 18), even 
upon further investigation of an entire hour post-injection (data not shown).  These results 
showed that a proestrus-like surge in serum estradiol levels can increase pain-related 
behavior evoked by persistent inflammatory nociception.  This observation is consistent 
with several previous reports suggesting that elevated serum estrogen levels can enhance 
persistent inflammatory nociception (Bradshaw et al., 2000; Fillingim et al., 1997; 
Hellstrom & Anderberg, 2003; Isselee et al., 2002; Lautenbacher & Rollman, 1993; 
LeResche et al., 2003; Meisler, 1999; Somerville, 1972; Tall & Crisp, 2004). 
 Previous reports have investigated the effect of gonadal hormones on persistent 
inflammatory nociception, but few have directly manipulated estrogen.  In a 
gonadectomy study performed on male and female rats, Aloisi et al. (2000) reported that 
gonadal hormones in both sexes inhibited paw flexion duration following formalin, but 
did not affect the paw-jerk response.  They concluded that the effects of the gonadal 
hormones on flexion posturing were independent of the [degree of] nociceptive 
[peripheral/spinal] input [to supraspinal processing and behavior], since flexion and 
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licking are regarded as being more susceptible to supraspinal modulation than is 
flinching.  This indicated the hormones acted supraspinally.  Another report found that 
GDX in males increased licking, flexion duration, and flinching in the formalin first 
phase and increased flexion duration in the second phase (Aloisi & Ceccarelli, 2000).  In 
other studies (Aloisi et al., 1994; Aloisi et al., 2004), females had higher flexion and 
licking duration than males following formalin.  Licking duration was reduced by 
testosterone in females to a “male-like” level (Aloisi et al., 2004); the authors speculated 
that this was [indirect] evidence that testosterone limits the licking response in males.  
Supraphysiological testosterone added to intact males did not alter licking, but this 
negative result could be due to a ceiling effect.  Another study showed gonadectomy for 3 
months (i.e. longer than the current study) in female rats increased rubbing of the 
formalin-injected lip, but no change in flinches of an injected paw (Pajot et al., 2003).  A 
different study demonstrated that E2 increases formalin-induced paw licking behavior in 
male rats (Ceccarelli et al., 2004) – possibly corroborating the current findings – but was 
in males, not females.  A few studies showed an anti-nociceptive effect of estradiol 
administration on formalin-related behaviors, but, in contrast to the current study, these 
were done with longer, continuous supplementation of estradiol in younger rats (Kuba et 
al., 2005; Kuba et al., 2006; Mannino et al., 2007).  The current study demonstrated that 
E2 supplementation increased formalin-induced flinching behavior in females – a finding 
that is difficult to directly compare or contrast with any of these previous studies because 
they differ in the hormone manipulation, formalin dose, age and sex of rats.  In addition, 
Aloisi et al. (1995) reported that sex differences found in formalin-induced behaviors 
were dependent on the stimulus level (formalin dose).  Other reports have demonstrated 
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stimulus-intensity dependence for sex differences in behavioral responses to other 
noxious stimuli [for review, see (Aloisi, 1997)].  This stimulus-intensity dependence is a 
characteristic that likely extends to sex-hormone modulation of nociception – an idea to 
which the findings of the current study point, with the positive result at 5% but negative 
result at 1.25% formalin.  Another caveat to consider when performing and analyzing 
studies of sex hormone modulation in pain-related behavior is the sex differences 
themselves, which may or may not be due to differences in response to the pain, but to 
the other experimental parameters (Aloisi, 1997).  Thus, the current results add to the 
existing body of data pertaining to sex hormone modulation of persistent inflammatory 
nociception by demonstrating an effect of acute, direct manipulation of estradiol in 
female rats on behavior evoked by 5% formalin. 
 The force/time traces demonstrate activity of the rats and that the force on the 
plate changed over time.  These changes in force over time are related to behavior and are 
the basis for Fourier-transformation of the data. 
 Fourier-transformation-based power spectral analysis was performed on the 
force/time traces of actometry over the entire 60-minute period following formalin 
injection.  Based on the difference in power spectra between control rats and those 
injected with formalin, three specific frequency bands (ranges) were designated for 
further comparison of behavioral power.  The frequency band designations were:  Low:  
0.3-1.5 Hz; Peak:  4.4-5.4 Hz; and High:  2.4-9.3 Hz (Figures 25 and 26).  The power 
differences were more pronounced in the 5% formalin-injected rats, which formed the 
primary basis for the selection of these specific power bands.   
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 Results for 5% formalin revealed an increase in power for formalin-treated rats in 
the Peak frequency band (Figure 28), but not at the Low or High frequency band.  These 
data demonstrate that 5% formalin induced an increase in a behavior(s) that is 
represented by power in the 4.4-5.4 Hz frequency band.  This increase was accompanied 
by an apparent loss of power in the low-frequency band.   
 Specific behaviors are associated with power in restricted frequency bands.  The 
few well-defined examples include licking (4-7 Hz), respiration (1-2 Hz), heartbeat (6-8 
Hz), and whisking (5-7 Hz).  Locomotion is typically large amplitude and very low 
frequency (< 2 Hz).  Accordingly, the increased power in the 4.4-5.4 Hz frequency band 
may represent increased licking and whisking behaviors, and perhaps an increased 
respiratory rate in 5% formalin-injected rats.  The concomitant loss of power in the low 
frequency band may reflect a shift in frequency in locomotive movements, which may be 
altered by flinching behaviors being superimposed on normal locomotion.   
 In the E2-supplementation experiment with actometry, estradiol injection lowered 
power in the Low (0.3-1.5 Hz) frequency band with 1.25% formalin, indicating estrogen 
decreased a behavior(s) represented in the Low frequency band (Figure 29).  However, 
1.25% formalin itself did not change this value (Figure 27).  This frequency band 
corresponds to locomotive behaviors in the rat; a loss of power here may indicate that 
estrogen modifies locomotive behaviors during formalin-evoked nociception.  Whereas 
estrogen did not enhance the numbers of 1.25% formalin-evoked flinches, it may 
nonetheless modify the locomotive behaviors that accompany inflammatory nociception.  
For example, freezing behavior may be enhanced, or the frequency (Hz) of locomotion 
between flinches increased (out of the low frequency band) in these subjects.   
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 Spatial plots from actometer force/time recordings of female rats over one hour 
demonstrate movement of the rats across the force plate area and that movement changed 
over time (Figure 30).  Movement across different portions of the force plate grid 
provides the basis for the analysis of total distance traveled and demonstrate the utility of 
the actometer.   
 Analysis of total distance traveled from actometer recordings revealed that 5% 
formalin-treated rats had higher total distance traveled over Naïve rats (Figure 31, panel 
B), indicating this formalin stimulus level evoked more locomotion than rats that were 
not enduring a noxious stimulus.  The increased locomotion observed with formalin may 
be an escape-related behavior whereby the rats to try to avoid the noxious stimulus.   
 Actometry also revealed behavioral differences in total distance traveled between 
formalin-injected and control groups at 5%, but not 1.25% formalin.  Total distance 
traveled may provide an adequate measure of pain-related behavior at 5% formalin, but 
any interpretation of total distance measures with regard to nociception-related behavior 
must consider the importance of stimulus-intensity effects.  These results suggest a 
stimulus-intensity threshold associated with formalin-evoked measures of total distance 
traveled.  Alternatively, the actometry methods used may not be sensitive enough to 
detect any putative, subtle changes in these behaviors elicited by lower formalin doses.   
 Not many studies have investigated locomotor activity or exploration after 
formalin.  A very relevant study characterized many behaviors over a time course and 
several concentrations of formalin in adult rats (Abbott et al., 1999); the report 
demonstrated a formalin concentration-dependent decrease in “active behaviors.”  
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However, when comparing the highest concentration vs. the next lower concentration 
used, “active behaviors” in the first part of the second phase increased – opposite the 
trend.  In addition, the highest concentration used in that study was 2%, which is lower 
than the concentration in the current study (5%) where a difference in distance traveled 
was observed, making it difficult to extrapolate the results for comparison.  Also, 
locomotor activity (walking) was summed with other “active behaviors” for analysis.  
One study in P25 rat pups showed increased locomotion with increasing formalin (Teng 
& Abbott, 1998).  Another report showed a decrease in “exploratory behavior” due to 
formalin in males (Abbott et al., 1995), but it is unclear whether “exploratory behavior” 
is equivalent to locomotion.  All of these previous reports observed the time spent in (or 
frequency of occurrence of) the behavioral category, which may be a different measure of 
ambulation than distance traveled (as in the current study) since there may be differences 
or variations in the rate (speed) of locomotion, between subjects or over time.  One study 
investigated distance traveled as well as locomotion following formalin and demonstrated 
an increase in these end points compared to baseline (Mena et al., 1996), which supports 
the findings of the current study that showed increased distance traveled following 5% 
formalin.  On another point of interest, it is evident from these studies that 
pharmacological manipulations within the formalin model can bring about modulation of 
these end points that does not correlate with pain scores.  For example, in one study 
analgesics decreased the pain score but increased locomotor activity (Abbott et al., 1995); 
in a different study, a low or high dose of naloxone both decreased locomotor activity 
even though the low dose induced analgesia and the high dose caused hyperalgesia 
(Mena et al., 1996).  Differences in experimental parameters used can, therefore, 
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potentially complicate or limit interpretation of results for locomotor-type end points with 
regard to any differences, or the power to detect such differences, in intensity of the 
nociceptive experience.  In addition, there are sex differences in the behavioral responses 
to noxious stimuli (Aloisi, 1997), and the current study used only female rats.  For these 
reasons, caution must be used when using these actometry end points as specific 
measures of pain-related behaviors.  
 All these data taken together indicate that estrogen can increase nociception-
related behaviors and, thus, presumably nociception in an activational manner; however 
effects of estradiol on nociception (and/or related behaviors) are dependent on the 
intensity of noxious stimulus.  Thus, it is evident that estrogen, by acting in an acute, 








ESTRADIOL DOES NOT ALTER A MARKER OF NOCICEPTION IN 
SPINAL CORD FOLLOWING FORMALIN INJECTION IN FEMALE 
RATS:  STUDIES OF FOS EXPRESSION 
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5.1  Abstract 
 Many studies have demonstrated activational effects of estrogen, including 
modulation of pain sensation in females.  Previous results from our laboratory 
demonstrated that a single injection of estradiol in ovariectomized female rats, mimicking 
a proestrus surge, enhances formalin-evoked pain-related behaviors.  We hypothesized 
that estradiol would increase a formalin-evoked marker of nociception, Fos (the protein 
product of the immediate-early gene c-fos), in the spinal cord.  This study was designed 
to explore whether the appearance of estrogen’s modulation of Fos was dependent on the 
intensity of the inflammatory formalin stimulus.  Fos expression in spinal cord neurons 
was characterized following formalin injection using (fluorescent) immunohistochemistry 
in female rats, and the effect of estradiol on this Fos expression was also investigated.  
Thus, adult female rats were ovariectomized and, six days later, injected subcutaneously 
with 10 µg/kg estradiol benzoate or vehicle.  Twenty-four hours later, solutions 
containing formalin (1.25% or 5.0%) were injected into the right hind paw.  Following 
formalin injection, rats were anesthetized, and lumbar spinal cords were removed by 
laminectomy.  The number of neurons in the lumbar spinal cord dorsal horn expressing 
Fos was quantified by immunohistochemistry.  Results revealed that formalin evoked 
concentration-related numbers of Fos-positive neurons in the ipsilateral lumbar spinal 
dorsal horn.  A time-course experiment showed overall Fos expression in laminae I-VI at 
two hours to be approximately as high if not higher than earlier time points.  No 
differences due to estradiol were observed in the number of Fos-positive neurons in 
laminae I-VI for 1.25% or 5% formalin.  This implied that estradiol was not modulating 
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nociception at the level of the peripheral nervous system or spinal cord, indicating other 
anatomical sites may be more likely targets of estrogen modulation. 
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5.2  Introduction 
 Estrogens appear to have activational, often pro-nociceptive (pain-potentiating) 
effects on innervation, synapse formation, and sensory function.  Several previous reports 
suggest that elevated serum estrogen levels enhance persistent inflammatory nociception.  
However, there are no reports of direct, systematic investigation into identification of the 
anatomical sites of estrogens’ action in the nervous system to enhance nociception and 
pain.  We hypothesized that sex differences in pain sensation are due, at least in part, to 
activational effects of estradiol on peripheral, spinal and/or supraspinal sites involved in 
the transmission and perception of nociceptive stimuli.  To determine whether spinal 
activation– as an initial site of investigation – in response to inflammatory pain was 
increased by estrogen, the current study addressed the levels of Fos (a biomarker of 
neuronal activation) in the spinal cord dorsal horn evoked by intraplantar formalin (a 
model of persistent inflammatory pain). 
 The rostro-caudal distribution of Fos-positive neurons across spinal segments 
following plantar hind paw formalin injection is highest at the L3-L5 levels (Presley et 
al., 1990).  The current study was designed to focus investigation of hind paw 
inflammation-driven changes in neuronal activation in as restricted and relevant an area 
of the spinal cord as possible.  Accordingly, Fos expression was measured primarily at 
the L4-L5 spinal segments. 
 The distribution of Fos-positive neurons across spinal dorsal horn laminae 
following noxious stimulation has been previously described (Harris, 1998; Hunt et al., 
1987; Kaneko et al., 2000; Khanna et al., 2004; Presley et al., 1990) and is suggested to 
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correspond to different functions of the laminae.  A genetic study showed that variations 
in the degree of nociception-related licking behavior across mouse strains correlated with 
the number Fos-positive neurons in spinal laminae V-VI (Bon et al., 2002).  These 
previous descriptions of the laminar organization and Fos expression in the spinal cord 
provided rationale for the method of quantification of Fos within divided groups of the 
dorsal laminae used in the current study. 
 A previous time course study showed that maximum Fos-positive neuron counts 
in the dorsal spinal cord following formalin injection occurred 2 hours after initiation of 
the inflammatory stimulus (Presley et al., 1990).  The current study set out to verify that 
this 2 hour time point would be optimal for Fos quantification. 
 Previous studies have demonstrated stimulus-intensity dependence of the level of 
Fos immunoreactivity in the spinal cord following formalin injection (Fukuda et al., 
2001; Kaneko et al., 2000; Khanna et al., 2004).   
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5.3  Materials & methods 
 Adult female Sprague-Dawley rats (~75 days old, 200-230 g, Harlan, 
Indianapolis, IN) were divided into two groups: 1) ovariectomized (OVX) receiving 
estradiol, and 2) OVX receiving an equivalent volume of vehicle.  Estradiol 
supplementation was followed 24 hours later by an injection of either 100 μL of 5% 
formalin or 50 μL of 1.25% formalin into the right plantar hind paw as a model of 
persistent inflammatory pain.   
5.3.1  Hormone manipulation 
 For ovariectomy (OVX), rats were anesthetized with a mixture of ketamine (64 
mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 mg/kg; i.p.).  
Under aseptic conditions, a ventral midline incision (~1.5 cm) was made into the lower 
abdominal cavity.  Both ovaries were externalized, fallopian tubes and blood vessels 
ligated with silk suture just proximal to the ovaries, and the ovaries excised.  Adipose 
tissue, fallopian tubes, and blood vessels were reinserted into the abdominal cavity.  
Muscle and skin layers were individually closed with suture.  Six days later, rats received 
a single subcutaneous injection into the left flank of 10 μg/kg estradiol benzoate (Sigma, 
E-9000) at 10 μg/mL in vehicle (10% ethanol/90% corn oil), or an equivalent volume of 
vehicle.  This dose of estradiol was chosen to mimic the surge in estradiol observed 
during proestrus in rats [see (Butcher et al., 1974; Medlock et al., 1991; Nag & Mokha, 




5.3.2  Spinal cord collection 
 Two hours after formalin injection (or 3 minutes, 1 or 2 hours for the time 
course), rats were anesthetized with ketamine/xylazine, and perfused transcardially with 
ice-cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in 
PBS, pH 7.4.  Lumbar spinal cords were subsequently removed by laminectomy.  Spinal 
cords were post-fixed in PFA at 4 °C, then in 30% sucrose at 4 °C before freezing.   
5.3.3  Immunohistochemistry for Fos 
 For fluorescent immunohistochemistry, frozen lumbar spinal cords were cut into 
20 μm-thick sections and placed on charged glass microscope slides.  Slides were washed 
in 0.4% Triton X-100 in PBS (PBST), pH 7.4, blocked with 5% normal donkey serum 
plus 1% BSA in PBST, incubated with primary rabbit anti-Fos polyclonal IgG antibody 
(1:1000, Calbiochem, Ab-5, Cat. No. PC38) overnight at 4 °C.  They were then incubated 
with secondary fluorescein (FITC)-conjugated donkey anti-rabbit IgG antibody (1:200, 
Jackson ImmunoResearch, Code No. 711-095-152) for 1 hour at room temperature, then 
mounted with Vectashield Hard Set mounting medium with DAPI (Vector Laboratories, 
Cat. No. H-1500).  Sections were fluorescently co-labeled for NeuN to verify neuronal 
identification (not shown).  Slides were then viewed on a Nikon 80i fluorescent 
microscope system, and neurons with Fos-positive immunofluorescence counted in 
ipsilateral laminae I-VI of sections at least 60 μm apart in spinal segments L4-L5, with at 
least five sections counted and averaged for each rat.  Laminar divisions and spinal 
segments were based on gross landmarks of the lumbar enlargement according to Paxinos 
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& Watson (2005).  Comparison of Fos immunoreactivity with DAPI staining during 
counting was used to confirm that only neurons displaying intact nuclei were quantified.   
5.3.4  Data Analyses 
 All data represent the mean ± SEM.  Data were statistically analyzed using 
Student’s t-tests with the significance level set to p ≤ 0.05.   
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5.4  Results 
 Formalin-evoked inflammatory nociception of the hind paw elicited robust Fos 
expression in neurons throughout the ipsilateral, lumbar spinal cord dorsal horn two 
hours after injection into the hind paw (Figures 32, 35 and 36).  Figure 32 shows 
representative photomicrographs of fluorescent immunohistochemical staining for Fos in 
lumbar spinal cord dorsal horns following injection of 100 μL of 5% formalin into the 
right hind paw.  Formalin-evoked Fos expression was visible throughout the upper 
laminae of the ipsilateral dorsal horn (for laminar divisions, see Figure 33); Fos staining 
in the contralateral dorsal horn was sparse.  Also, there was a prevalence of Fos-positive 
neurons in the medial part of the dorsal horn and less so laterally (see Figure 32).  
Additionally, results revealed that the magnitude of the number of Fos-positive neurons 
in the ipsilateral spinal cord dorsal horn evoked by plantar formalin was proportional to 
the stimulus intensity (Figures 35 and 36). 
 A time course of 1.25% formalin-evoked Fos immunohistochemistry in the spinal 
dorsal horn rats is shown in Figure 34.  Results demonstrated the changing pattern of Fos 
expression over time at 3 minutes, 1 and 2 hours.  Ipsilateral to the inflamed hind paw, 
there was a generally increasing number of Fos-positive neurons over the observed time, 
for estradiol- or vehicle-treated rats.  Overall, Fos expression in laminae I-VI at two hours 
was higher than earlier time points.  Relatively lower numbers of Fos-positive neurons 
were found on the contralateral side, accompanied by a smaller range of expression over 
time.  Results suggest a peak in contralateral Fos expression at 1 hour. 
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 Comparing rats receiving estradiol (OVX + E2; n = 6) with those receiving 
vehicle (OVX + Veh; n = 5), data showed that estradiol administration did not alter the 
number of Fos-positive neurons in spinal cord laminae I-II, III-IV, V-VI, or total across 
laminae I-VI for 5% formalin (Figure 35).  The hypothetical possibility of a ceiling 
effect on the number of Fos-positive neurons at 5% formalin prompted further 
investigation of the same comparison at a lower, 1.25%, formalin dose.  This experiment 
revealed that 1.25% formalin also elicited robust Fos expression in the ipsilateral dorsal 
horn, with a pattern similar to that observed with 5% formalin, except relatively lower in 
magnitude.  At this 1.25% formalin stimulus intensity, results again revealed no 
difference due to estradiol for any of the laminar regions examined (Figure 36; n = 8 per 




Figure 32.  Representative photomicrographs of fluorescent immunohistochemical staining for Fos in 
lumbar spinal cord dorsal horns following formalin.  Spinal cords were collected two hours after injection 
of 100 μL of 5% formalin into the right hind paw.  Lumbar spinal cords were cut into 20 μm-thick sections, 
probed with primary rabbit anti-Fos antibody (1:1000, Calbiochem), and labeled with FITC-conjugated 
donkey anti-rabbit antibody (1:200, Jackson).  Note that formalin-evoked Fos expression is visible 
throughout the upper laminae of the ipsilateral (right) dorsal horn (panel B); Fos staining in the 




Figure 33.  Representative example of spinal cord dorsal horn immunohistochemistry for Fos, showing 




Note:  The figure caption is located on the subsequent page.  
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Figure 34.  Time course of 1.25% formalin-evoked Fos immunohistochemistry in the spinal dorsal horn.  
Female rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 10 µg/kg 
estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), rats 
were injected with 50 μL of 1.25% formalin into the right hind paw, and spinal cords were collected 0.05, 1 
and 2 hours later.  Following immunohistochemical staining for Fos, sections in spinal segments L4-L5 
were viewed on a fluorescent microscope, and neurons in laminae I-VI of the spinal cord dorsal horn 
exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  Data represent the 




 Number of Fos-positive Neurons 





26.4 ± 7.5 
21.9 ± 3.9 
40.3 ± 4.2 
88.6 ± 14.1 
33.4 ± 5.4 
25.1 ± 4.7 
36.3 ± 4.1 
94.7 ± 13.4 
 
Figure 35.  Effect of estradiol on 5% formalin-evoked Fos immunohistochemistry in the ipsilateral spinal 
dorsal horn.  Rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 10 
µg/kg estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), 
rats were injected with 100 μL of 5% formalin into the right hind paw, and spinal cords were collected two 
hours later.  Following immunohistochemical staining for Fos, sections in spinal segments L4-L5 were 
viewed on a fluorescent microscope, and neurons in laminae I-VI of the ipsilateral spinal cord dorsal horn 
exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  Note that estradiol 
administration did not alter Fos expression in any of the laminar regions examined.  Data represent the 
mean ± SEM (Significance level set to p ≤ 0.05, unpaired Student’s t-test; n:  Veh = 5; E2 = 6). 
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 Number of Fos-positive Neurons 





17.5 ± 2.9 
15.1 ± 2.6 
25.6 ± 2.6 
59.6 ± 6.8 
16.5 ± 0.9 
12.4 ± 2.2 
21.0 ± 3.3 
49.9 ± 5.6 
 
Figure 36.  Effect of estradiol on 1.25% formalin-evoked Fos immunohistochemistry in the ipsilateral 
spinal dorsal horn.  Rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 
10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after 
OVX), rats were injected with 50 μL of 1.25% formalin into the right hind paw, and spinal cords were 
collected two hours later.  Following immunohistochemical staining for Fos, sections in spinal segments 
L4-L5 were viewed on a fluorescent microscope, and neurons in laminae I-VI of the ipsilateral spinal cord 
dorsal horn exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  Note 
that estradiol administration did not alter Fos expression in any of the laminar regions examined.  Data 




5.5  Discussion 
 Formalin-evoked inflammatory nociception of the hind paw elicited robust Fos 
expression in neurons throughout the ipsilateral, lumbar spinal cord dorsal horn two 
hours after injection (Figures 32, 35 and 36).  The magnitude of the number of Fos-
positive neurons in the ipsilateral spinal cord dorsal horn evoked by plantar formalin was 
directly related to the stimulus intensity.  This result is consistent with many previous 
reports that have characterized the activation of neuronal Fos expression as a biomarker 
of nociceptive activation.  Several previous studies have demonstrated the level of Fos 
immunoreactivity in the (dorsal) spinal cord to be stimulus-intensity dependent for 
formalin (Fukuda et al., 2001; Kaneko et al., 2000; Khanna et al., 2004) and other 
noxious stimuli (Abbadie et al., 1994; Bester et al., 1997; Bullitt et al., 1992; Buritova et 
al., 1998; Hunt et al., 1987; Willcockson et al., 1995). 
 The time-course experiment showed overall Fos expression in laminae I-VI at two 
hours to be approximately as high, if not higher, than earlier time points (Figure 34), an 
observation consistent with previous reports in the literature (Presley et al., 1990).  This 
result verified 2 hours post-injection as an optimal time point for further experiments 
involving Fos quantification for investigating potential estradiol effects on spinal 
nociceptive neuronal activation. 
 The overall medial-lateral distribution pattern of Fos expression in the dorsal 
spinal cord was more medial than lateral (unpublished observations; for example, see 
Figure 32), which is similar to the pattern of spinal Fos expression after formalin 
observed by Presley et al. (1990).  This pattern of Fos expression in spinal neurons relates 
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to the known somatotopic input to the spinal cord from hind paw peripheral afferents 
(Bullitt, 1991; Presley et al., 1990). 
 Elevated Fos expression levels were associated with formalin-evoked nociception 
overall.  Contrary to the working hypothesis, the administration of estradiol did not 
significantly alter numbers of nociception-evoked Fos-positive neurons in the ipsilateral 
lumbar spinal cord dorsal horn at either formalin concentration (Figures 35 and 36).  Our 
previous results have demonstrated that estrogen supplementation enhances formalin-
evoked flinching behavior (see Chapter 4, Figure 19).  Together, these observations 
support the conclusion that, whereas estrogen enhances pain-related behaviors evoked by 
persistent inflammatory nociception, estrogen may not significantly modulate the 
intensity of nociceptive neuronal activation in the peripheral nervous system (primary 
sensory neurons) or spinal cord.  Conversely, this finding suggests that estrogen may be 
enhancing inflammatory nociception primarily via actions at other anatomical sites, such 
as supraspinal sites, where pain sensation is modified subsequent to spinal transmission.  
The convergence of the neuronal activity that provides the substrate for interpretation of 
pain intensity and subsequent motor responses may occur at sites farther along 
nociceptive neuronal pathways than the first synaptic connection in the spinal cord dorsal 
horn.  Alternatively, peripheral or spinal enhancement of nociception within the context 
of the formalin model may not be manifested as a change in spinal Fos.  One potential 
explanation for this is the manifestation of a “ceiling effect” whereby the dynamic range 
of Fos expression in the “positive” spinal nociceptive neurons is limited, and is 
maximized following moderate nociceptive activation, without additional cells available 
for “recruitment” under the effects of estrogen.  However, this interpretation is less likely 
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because, based on the established data demonstrating the relationship of Fos expression 
in spinal neurons with noxious peripheral stimulation, and the fact that peripheral 
nociceptors must signal through the spinal cord, if there was peripheral modulation of 
nociception, it would likely be seen as a change in the degree of spinal Fos-positive 
neurons.  
 In conclusion, these data demonstrate the response of spinal neurons to noxious, 
persistent, inflammatory stimulation as manifested by the expression of Fos, a biomarker 
of neuronal activation.  Acute estradiol treatment did not alter the number of Fos-positive 
neurons in the spinal cord within two stimulus intensities.  Thus, it appears that the 
peripheral nervous system and spinal cord may not be primary targets for estrogen acting 








FORMALIN HAS MINIMAL DETECTABLE EFFECT ON AND 




6.1  Abstract 
 These experiments were undertaken to characterize the activation of ERK (as 
phospho-ERK, pERK) as an alternative to Fos as a marker for neuronal activation in the 
spinal cord following formalin injection.  We hypothesized that estradiol would increase 
pERK in the spinal cord.  Accordingly, adult female rats were ovariectomized and, six 
days later, injected subcutaneously with 10 µg/kg estradiol benzoate or vehicle.  Twenty-
four hours later, solutions containing 1.25% or 5.0% formalin were injected into the right 
hind paw.  Following formalin injection, spinal cords were collected.  The number of 
neurons in the lumbar spinal cord dorsal horn expressing pERK was quantified by 
immunohistochemistry.  Alternatively, fresh-frozen lumbar enlargements of spinal cords 
were dissected into dorsal, ipsilateral quarters and homogenized for pERK quantification 
by western blotting.  Results of immunohistochemistry revealed that minimal numbers of 
pERK-positive neuronal cell bodies were visible in all laminar regions examined, they 
had minimal change in number over the time course, and no difference due to estradiol 
was observed.  Western blot analysis showed no difference in pERK activation between 
no-formalin control and any time point following formalin, and no change between time 
points.  These observations led to the conclusion that quantification of ERK activation by 
either of these methods was not adequately sensitive to use as a marker for neuronal 
activation in the spinal cord under these conditions. 
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6.2  Introduction 
 Estrogens appear to have activational, often pro-nociceptive (pain-potentiating) 
effects on innervation, synapse formation, and sensory function.  Several previous reports 
suggest that elevated serum estrogen levels enhance persistent inflammatory nociception.  
However, there are no reports of direct, systematic investigation into identification of the 
anatomical sites of estrogens’ action in the nervous system to enhance nociception and 
pain.  We hypothesized that sex differences in pain sensation are due, at least in part, to 
activational effects of estradiol on peripheral, spinal and/or supraspinal sites involved in 
the transmission and perception of nociceptive stimuli.  To determine whether spinal 
activation– as an initial site of investigation – in response to inflammatory pain was 
increased by estrogen, the current study addressed the levels of pERK (a biomarker of 
neuronal activation) in the spinal cord dorsal horn evoked by intraplantar formalin (a 
model of persistent inflammatory pain).  Previous studies have observed activation of 
ERK (as pERK) in the spinal cord following noxious stimulation, including formalin, 
although with mixed results (Fukuda et al., 2009; Ji et al., 1999; Li et al., 2010; Svensson 
et al., 2006).   
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6.3  Materials & methods 
 Adult female Sprague-Dawley rats (~ 11-12 weeks old, 200-230 g, Harlan, 
Indianapolis, IN) were divided into two groups: 1) ovariectomized (OVX) receiving 
estradiol, and 2) OVX receiving an equivalent volume of vehicle.  Estradiol 
supplementation was followed 24 hours later by an injection of either 100 μL of 5% or 50 
μL of 1.25% formalin into the right plantar hind paw as a model of persistent 
inflammatory pain.  Separate sets of animals were used for these experiments; the rats 
treated with 100 μL of 5% formalin were prepared for western blot analysis following 
investigation of Fos immunohistochemistry in similarly-treated animals (see Chapter 5).  
Subsequently, a lower concentration of formalin was selected to address perceived 
limitations of the 5% stimulus (see Chapter 5 discussion, page 127).  Accordingly, 
immunohistochemical analysis of spinal pERK in rats treated with 50 μL of 1.25% 
formalin was conducted in alternate sections from the same rats used for analysis of Fos 
immunostaining (see Chapter 5).   
6.3.1  Hormone manipulation 
 For ovariectomy (OVX), rats were anesthetized with a mixture of ketamine (64 
mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 mg/kg; i.p.).  
Under aseptic conditions, a ventral midline incision (~1.5 cm) was made into the lower 
abdominal cavity.  Both ovaries were externalized, fallopian tubes and blood vessels 
ligated with suture just proximal to the ovaries, and the ovaries excised.  Adipose tissue, 
fallopian tubes, and blood vessels were reinserted into the abdominal cavity.  Muscle and 
skin layers were individually closed with suture.  Six days later, rats received a single 
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subcutaneous injection into the left flank of 10 μg/kg estradiol benzoate (Sigma, E-9000) 
at 10 μg/mL in vehicle (10% ethanol/90% corn oil), or an equivalent volume of vehicle.  
This dose of estradiol was chosen to mimic the surge in estradiol observed during 
proestrus in rats [see (Butcher et al., 1974; Medlock et al., 1991; Nag & Mokha, 2006; 
Viau & Meaney, 1991; Zoubina et al., 2001)].   
6.3.2  Spinal cord collection 
 6.3.2.1  For immunohistochemistry 
 Three minutes (or 0.05, 1 or 2 hours for the time course) after injection of 50 μL 
of 1.25% formalin, rats were anesthetized with ketamine/xylazine, and perfused 
transcardially with ice-cold phosphate-buffered saline (PBS) followed by 4% 
paraformaldehyde (PFA) in PBS, pH 7.4.  Lumbar spinal cords were subsequently 
removed by laminectomy.  Spinal cords were post-fixed in PFA at 4 °C, then in 30% 
sucrose at 4 °C before freezing. 
 6.3.2.2  For western blotting 
 Either without formalin injection or 5 or 40 minutes after injection of 100 μL of 
5% formalin into the right hind paw, rats were decapitated.  Spinal cords were then 
removed by hydraulic extrusion with 0.9% saline, and immediately frozen.   
6.3.3  Immunohistochemistry for pERK 
 Frozen, fixed lumbar spinal cords were cut into 20 μm-thick sections and placed 
on charged glass microscope slides.  For fluorescent immunohistochemistry, slides were 
washed in 0.1% Tween-20 in Tris-buffered saline, pH 7.6 (TBST), blocked with 5% 
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normal donkey serum in TBST, and incubated with primary rabbit anti-pERK 
monoclonal IgG (1:100, Cell Signaling Technology, #4370) overnight at 4 °C.  Then they 
were incubated with secondary fluorescein (FITC)-conjugated donkey anti-rabbit IgG 
antibody (1:200, Jackson ImmunoResearch, Code No. 711-095-152) for 1 hour at room 
temperature and then mounted with Vectashield Hard Set mounting medium with DAPI 
(Vector Laboratories, Cat. No. H-1500).  Sections were fluorescently co-labeled for 
NeuN to verify neuronal identification (not shown).  Slides were then viewed on a Nikon 
80i fluorescent microscope system, and neurons with Fos- or pERK-positive 
immunofluorescence counted in ipsilateral laminae I-VI of sections at least 60 μm apart 
in spinal segments L4-L5, with at least five sections counted and averaged for each rat.  
Comparison of pERK immunoreactivity with DAPI staining during counting was used to 
confirm that only neurons displaying intact nuclei were quantified.   
6.3.4  Western blotting for pERK 
 Lumbar enlargements of fresh-frozen spinal cords were dissected into ipsilateral, 
dorsal quarters, homogenized and lysed.  Homogenates were blotted by electrophoresis, 
then probed with primary rabbit anti-pERK antibody (1:200, #4376, Cell Signaling 
Technology), and labeled with HRP-conjugated bovine anti-rabbit secondary antibody 
(1:2000, #sc2374, Santa Cruz Biotechnology) and chemiluminescent substrate.  Then 
blots were stripped and re-probed for total ERK with rabbit anti-ERK primary antibody 
(1:1000, #9102, Cell Signaling Technology) and labeled with HRP-conjugated bovine 
anti-rabbit secondary antibody (1:10000, #sc2374, Santa Cruz Biotechnology) and 
chemiluminescent substrate.  Blots were exposed to photographic film, and the film 
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developed and digitally photographed.  Ovariectomized rats that received estradiol or 
vehicle were included together within all of the treatment groups/time points. 
6.3.5  Data analyses 
 All data represent the mean ± SEM.  Data were statistically analyzed by Student’s 
t-test or one-way ANOVA with the significance level set to p ≤ 0.05.  Photomicrographs 
of western blots were analyzed using quantitative densitometry to measure the area under 
the density curves for each relevant band in the western blots using ImageJ software 
(NIH).   
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6.4  Results 
 Immunohistochemistry following formalin showed there were a few pERK-
expressing neurons visible, mostly in the upper laminae, of the ipsilateral (right) dorsal 
horn (Figure 37), although positive pERK staining was sparse in general across laminae 
I-VI.   
 Figure 38 shows the results of a pilot study investigating the time course of 
pERK immunohistochemistry in the spinal dorsal horn evoked 3 minutes, 1 and 2 hours 
after 1.25% formalin.  Minimal numbers of pERK-positive neuronal cell bodies were 
found in laminae I-II, III-IV, V-VI or total across I-VI, and they had minimal change in 
number over the time course (n:  Vehicle:  0.05 h = 3, 1 h = 1, 2 h = 2; E2:  0.05 h = 3, 1 
h = 1, 2 h = 1).  At the three-minute time point after 1.25% formalin, estradiol did not 
alter the number of pERK-positive neurons in laminae I-II, III-IV, V-VI or total across I-
VI (Figure 39;Student’s t-test; n = 3 per group). 
 Figure 40 shows photomicrographs of representative western blots for ERK in 
spinal cord homogenates following 5% formalin.  They demonstrate that pERK1, 
pERK2, total ERK1 and total ERK2 were all present and detectable by the western 
blotting method.  Results of western blotting revealed no effect of formalin on pERK 
levels in the dorsal spinal cord at five or forty minutes (Figure 41;one-way ANOVA; n = 




Figure 37.  Representative photomicrograph of fluorescent immunohistochemical staining for pERK in 
ipsilateral lumbar spinal cord dorsal horn following formalin.  Spinal cords were collected three minutes 
after injection of 100 μL of 5% formalin into the right hind paw.  Subsequently, 20 μm-thick sections were 
cut from the lumbar enlargement, probed with primary rabbit anti-pERK antibody (1:100, #4370, Cell 
Signaling Technology), and labeled with FITC-conjugated donkey anti-rabbit antibody (1:200, Jackson).  
Note there were few pERK-expressing neurons visible in the upper laminae of the ipsilateral (right) dorsal 
horn, although positive pERK staining was sparse throughout the upper dorsal horn.  Digital 




Note:  The figure caption is located on the subsequent page.  
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Figure 38.  Time course of 1.25% formalin-evoked pERK immunohistochemistical staining in the spinal 
dorsal horn.  Female rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 
10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after 
OVX), rats were injected with 50 μL of 1.25% formalin into the right hind paw, and spinal cords were 
collected 0.05, 1 and 2 hours later.  Following immunohistochemical staining for pERK in spinal segments 
L4-L5, sections were viewed on a fluorescent microscope, and neurons in laminae I-VI of the spinal cord 
dorsal horn exhibiting NeuN- and pERK-positive immunoreactivity and DAPI staining were counted.  Data 




 Number of pERK-positive Neurons 





0.7 ± 0.4 
0.2 ± 0.1 
0.3 ± 0.2 
1 ± 0.4 
1 ± 0.4 
0.3 ± 0.1 
0.4 ± 0.1 
2 ± 0.6 
 
Figure 39.  Effect of estradiol on 1.25% formalin-evoked pERK immunohistochemistry in the ipsilateral 
spinal dorsal horn.  Female rats were ovariectomized (OVX) and, six days later, received a single s.c. 
injection of 10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days 
after OVX), rats were injected with 50 μL of 1.25% formalin into the right hind paw, and spinal cords were 
collected 3 minutes later.  Following immunohistochemical staining for pERK in spinal segments L4-L5, 
sections were viewed on a fluorescent microscope, and neurons in laminae I-VI of the ipsilateral spinal 
cord dorsal horn exhibiting NeuN- and pERK-positive immunoreactivity and DAPI staining were counted.  
Minimal numbers of pERK-positive neurons were observed in all laminae, and estradiol did not alter the 
number of pERK-positive neurons in any of the laminar regions examined.  Data represent the mean ± 





Figure 40.  Photographs of representative western blots for ERK in ipsilateral dorsal spinal cord following 
5% formalin.  Female rats were ovariectomized (OVX) and, six days later, received a single s.c. injection 
of 10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after 
OVX), spinal cords were collected either without formalin injection or 5 or 40 minutes after injection of 
100 μL of 5% formalin into the right hind paw.  Ipsilateral dorsal quarters of the lumbar enlargements of 
spinal cords were homogenized and lysed.  Homogenates were blotted by electrophoresis, then probed with 
primary rabbit anti-pERK antibody (1:200, #4376, Cell Signaling Technology), and labeled with HRP-
conjugated bovine anti-rabbit secondary antibody (1:2000, #sc2374, Santa Cruz Biotechnology) and 
chemiluminescent substrate.  Blots were then stripped and re-probed for total ERK with rabbit anti-ERK 
primary antibody (1:1000, #9102, Cell Signaling Technology) and labeled with HRP-conjugated bovine 
anti-rabbit secondary antibody (1:10000, #sc2374, Santa Cruz Biotechnology) and chemiluminescent 






Figure 41.  Time course of ERK activation in ipsilateral dorsal spinal cord following 5% formalin.  Female 
rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 10 µg/kg estradiol 
(E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), spinal cords were 
collected either without formalin injection or 5 or 40 minutes after injection of 100 μL of 5% formalin into 
the right hind paw.  Ipsialteral dorsal quarters of the lumbar enlargements were homogenized and lysed.  
Homogenates were blotted by electrophoresis, then probed with primary rabbit anti-pERK antibody (1:200, 
#4376, Cell Signaling Technology), and labeled with HRP-conjugated bovine anti-rabbit secondary 
antibody (1:2000, #sc2374, Santa Cruz Biotechnology) and chemiluminescent substrate.  Blots were then 
stripped and re-probed for total ERK with rabbit anti-ERK primary antibody (1:1000, #9102, Cell 
Signaling Technology) and labeled with HRP-conjugated bovine anti-rabbit secondary antibody (1:10000, 
#sc2374, Santa Cruz Biotechnology) and chemiluminescent substrate.  Blots were exposed to photographic 
film, and the film developed and digitally photographed.  The digital photographs were analyzed by 
densitometry using ImageJ software.  Results revealed no effect of formalin on pERK levels at five or forty 





6.5  Discussion 
 Following formalin, minimal numbers of pERK-positive neurons were found in 
laminae I-VI, and they did not change in number over the time course examined (Figures 
37, 38 and 39).  In addition, results of western blotting revealed no effect of formalin on 
pERK levels in the dorsal spinal cord (Figure 41).  These observations led to the 
conclusion that quantification of ERK activation by either of these methods, IHC or 
western blotting, was not adequately sensitive to observe nociception-evoked changes in 
neuronal activation in the spinal cord under these conditions. 
 These results are difficult to compare to one previous study of ERK activation in 
the superficial spinal cord following noxious stimulation with formalin (Ji et al., 1999).  
An immunohistochemical time course in that study showed activation of pERK above 
baseline that peaked at three minutes post-formalin and then fell to lower levels for up to 
an hour later.  They showed a similar time course of spinal pERK after capsaicin 
injection, another inflammatory, noxious chemical.  The results of that study suggest that 
pERK could be a useful and sensitive marker for nociceptive activation in the spinal cord 
following this kind of stimulation.  However, their method of pERK quantification may 
have (it is unclear) summed the total number of positive neurons over eight sections per 
rat, as opposed to taking the average number per section, as did the current study.  In 
addition, that study only had 2-3 rats per group, and used a larger section thickness (30 
µm) than the current study (20 µm).  These factors make it difficult to compare these 
studies and complicate the interpretation of whether either method of pERK 
quantification is an adequate proxy for the degree of spinal activation. 
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 Another, later study more clearly demonstrated activation of pERK in the spinal 
cord after formalin injection compared with baseline control using western blotting 
(Svensson 2006).  Despite this, similar to the current study, a different 
immunohistochemical study failed to demonstrate a difference in spinal pERK following 
formalin compared to control, although it measured pERK at a later time point (Fukuda et 
al., 2009). 
 Given the rapid onset of ERK activation, pERK levels may be more 
representative of the noxious stimulation that occurs in that early time period, such as the 
mechanical nociception due to the needle prick or the initial, direct chemical activation of 
nociceptors.  Furthermore, pERK is likely less representative of the degree of activation 
that occurs at later time points during persistent, inflammatory nociception, when 
sensitization of the spinal cord is being manifested.  Although activation of ERK may 
have a role in the early response to noxious stimulation that leads to the later sensitization 
(Alter et al., 2010; Choi et al., 2006; Ji et al., 1999; Karim et al., 2006; Karim et al., 2001; 
Polgar et al., 2007; Svensson et al., 2006), this does not necessarily mean that it is an 
adequate marker for the degree of activation that occurs during the later period, after the 
nervous system has been sensitized.  For example, spinal pERK was not elevated three 
days after formalin injection, when formalin-induced secondary mechanical hyperalgesia 
was present (Li et al., 2010).  Thus, pERK may not be the best marker for the degree of 
nociceptive activation that occurs with persistent, noxious, inflammatory stimuli. 
 In conclusion, approaches used in this study to address pERK, including both 
immunohistochemical and western-blot techniques, revealed that estradiol did not modify 
nociception-evoked levels of ERK activation in the ipsilateral lumbar spinal cord dorsal 
145 
horn.  This result indicates that, at this formalin stimulus condition, estrogen modulation 
of spinal pERK expression was not apparent.  Our previous results have demonstrated 
that estrogen supplementation enhances formalin-evoked flinching behavior (see Chapter 
4, Figure 19).  Taken together, these observations support the conclusion that while 
estrogen enhances pain-related behaviors evoked by persistent inflammatory nociception, 
estrogen may not significantly alter the intensity of neuronal activation of primary 
sensory or spinal neurons.  Interpretation of this negative result is hindered by the 
limitation that formalin elicited minimal pERK-positive neurons in the spinal cord.  
Beacuse of this, peripheral or spinal enhancement of nociception within the context of the 
formalin model may not be manifested as a measurable change in spinal pERK, possibly 
because the range of pERK expression elicited by formalin is too small to observe any 
modulation by estrogen.   
 Finally, the findings of this study and the previous study addressing Fos activation 
suggested that estrogen may primarily be enhancing inflammatory nociception via actions 
at supraspinal sites where pain sensation is modified subsequent to spinal transmission.  
Based on this possibility, the subsequent study was designed to address the activation of 
several candidate higher brain centers by formalin and the modification of its effects by 








ESTROGEN MODIFIES PERSISTENT INFLAMMATORY 
NOCICEPTION IN THE BRAIN:  STUDIES OF FOS EXPRESSION IN 
SPECIFC BRAIN REGIONS FOLLOWING FORMALIN INJECTION 
IN FEMALE RATS 
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7.1  Abstract 
 This study explored whether nociceptive activation of higher brain centers is 
increased by estrogen supplementation.  Previous results from our laboratory and other 
studies have indicated estrogen can enhance formalin-evoked pain-related behaviors.  We 
hypothesized that an estradiol surge would modify formalin-evoked levels of a marker of 
nociception, Fos, in supraspinal brain regions.  Using immunohistochemistry for Fos, 
brain structures investigated were some known to be important for processing the 
affective component of pain:  hippocampus, amygdala and nucleus accumbens.  To test 
this hypothesis, adult female rats were ovariectomized and, six days later, injected 
subcutaneously with 10µg/kg estradiol benzoate or vehicle.  Twenty-four hours later, 50 
µL of 1.25% or 100 µL of 5% formalin was injected into the right hind paw.  Two hours 
following formalin injection, brains were removed and frozen.  Brains were subsequently 
cut into coronal sections, and the number of Fos-expressing neurons in the nucleus 
accumbens, amygdala and hippocampus was quantified by immunohistochemistry.  Pilot 
studies hand-quantified fluorescent immunohistochemistry of Fos at control and different 
doses of formalin, and revealed no differences due to estrogen.  An improved method of 
immunohistochemistry (colorimetric with image analysis) was then employed which had 
the purpose of establishing a relationship of Fos expression to formalin dose and control 
conditions.  Results revealed that formalin (1.25%) alone increased Fos in the right 
nucleus accumbens; no changes due to formalin alone were observed in hippocampal 
dentate gyrus or ventral CA1, or central amygdala.  Formalin (1.25%) increased Fos in 
left nucleus accumbens in the presence of estradiol, but did not change Fos in absence of 
E2.  Estradiol decreased Fos in right ventral CA1 in the presence of 5% formalin; but 
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estradiol made no difference in the absence of formalin.  Also, estradiol did not alter Fos 
expression in the dentate gyrus or central amygdala and, thus, may not modify 
nociception in those regions.  Overall, these findings support the hypothesis that estrogen 
enhances inflammatory nociception at supraspinal sites.   
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7.2  Introduction 
 Previous investigations in our laboratory and several previous reports have 
demonstrated that elevated serum estrogen levels enhance persistent inflammatory 
nociception [see Chapter 4, (Bradshaw et al., 2000; Fillingim et al., 1997; Hellstrom & 
Anderberg, 2003; Isselee et al., 2002; Lautenbacher & Rollman, 1993; LeResche et al., 
2003; Meisler, 1999; Somerville, 1972; Tall & Crisp, 2004)].  However, there are no 
reports of direct, systematic investigation into identification of the anatomical sites of 
estrogens’ action in the nervous system to enhance nociception and pain.  Previous 
findings indicated no difference due to estradiol in number of Fos-expressing neurons in 
the dorsal spinal cord following intraplantar formalin, suggesting supraspinal sites of 
action (see Chapter 5).  We hypothesized that sex differences in pain sensation are due, at 
least in part, to activational effects of estradiol on supraspinal sites involved in the 
transmission and perception of nociceptive stimuli.  The relationship of Fos expression to 
intraplantar formalin stimulus has been described for some supraspinal sites, including 
the hippocampal dentate gyrus (inverse) and ventral CA1 (inverse) (Khanna et al., 2004).  
To determine if supraspinal activation in response to inflammatory pain is increased by 
estrogen, the current study quantified the number of Fos-expressing neurons in the 
amygdala, hippocampus and nucleus accumbens following intraplantar formalin (a model 
of persistent inflammatory pain) as initial sites of investigation. 
 These sites were selected for investigation based on the predominance of 
inflammatory nociception-evoked changes in neurokinin-1 receptor (NK-1) and brain-
derived neurotrophic factor (BDNF) gene expression previously determined in the 
McCarson laboratory.  While investigating the effects of formalin-evoked nociception on 
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the plasticity of gene expression in the rat brain, Amy Allen, Ph.D., discovered that 
chemogenic inflammatory stimuli alter BDNF and NK-1 receptor gene expression in 
limbic brain structures associated with the regulation of affect (data from Dr. Allen’s 
results are represented in Figure 42).  The direction of these changes (increase versus 
decrease) were not consistent across all brain regions studied; NK-1 and BDNF gene 
expression was robustly down-regulated in the hippocampus and amygdala following 
formalin-evoked nociception, but were markedly increased in the nucleus accumbens 
following the same treatment.  These changes suggest communication between signaling 
pathways that regulate BDNF and NK-1 receptor gene expression in limbic brain 
structures during inflammatory nociception.  The regional differences in BDNF and NK-
1 receptor gene expression may underlie long-term changes in sensory processing and 
mood associated with chronic pain.   
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Figure 42.  Histogram showing BDNF and NK-1 receptor mRNA levels in the nucleus accumbens, 
amygdala, and hippocampus of male rats after an inflammatory stimulus.  A) BDNF gene expression levels 
B) NK-1 receptor gene expression levels.  Note that formalin treatment for 24 hours resulted in a 
significant increase in BDNF and NK-1 gene expression in the nucleus accumbens and significant 
decreases in the amygdala and hippocampus.  All values are shown as pg specific mRNA/ng -actin 
mRNA (Mean  S.E.M.; n = 6) *p < 0.05 vs. control rats (ANOVA and Fisher’s PLSD test).   
 
 Based on these observations, the amygdala, hippocampus and nucleus accumbens 
were selected for analysis of Fos expression following formalin-evoked inflammatory 
nociception.  In addition, these structures have functional roles in processing negative 
affect or nociception, and undergo structural and functional changes in affective disorders 
(Ferre et al., 2007; Khanna & Sinclair, 1992; Knyihar & Csillik, 2006; Koyanagi et al., 
2008; Magnusson & Martin, 2002; Mayberg, 1997; Millan, 1999; Neugebauer, 2007; 
Neugebauer et al., 2004; Phelps & LeDoux, 2005; Ploghaus et al., 2001; Porro, 2003; 
Price, 2000, 2002; Price et al., 2006; Sheline et al., 1996; Zubieta et al., 2003; Zubieta et 
al., 2001).  Also, there is considerable plasticity in these structures both with regard to 
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nociceptive/affective function as well as interaction with estrogen (Cooke & Woolley, 
2005; Desmond & Levy, 1997; Maren, 2005; McEwen, 2001; McEwen & Magarinos, 
2001; Neugebauer, 2007; Neugebauer et al., 2004; Price, 2000, 2002; Price et al., 2006; 
Woolley, 1998, 2000; Woolley & McEwen, 1992), making these structures logical 
choices for investigating potential estrogen modulation of nociception.   
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7.3  Materials & methods 
 Adult female Sprague-Dawley rats (~11 weeks old, 200-250 g, Harlan, 
Indianapolis, IN) were used in these experiments.  Two types of experiments were 
performed:  formalin-only or estradiol-supplementation experiments.  Rats in the 
formalin-only experiments were ovariectomized but received no further hormone 
manipulation; for the colorimetric immunohistochemistry experiments, data from rats that 
received vehicle in the estradiol-supplementation experiments were included in the 
formalin-only experimental results. 
 Rats in the estradiol-supplementation experiments were divided into four groups:  
1) ovariectomized (OVX) receiving estradiol (E2) and no formalin (restraint-only); 2) 
OVX receiving an equivalent volume of vehicle and no formalin (restraint-only); 3) OVX 
receiving E2 and formalin injection; and 4) OVX receiving vehicle and formalin 
injection.  Some preliminary experiments did not include the two restraint-only treatment 
groups (groups 1 and 2 above).   
7.3.1  Hormone manipulation 
 For ovariectomy (OVX), rats were anesthetized with a mixture of ketamine (64 
mg/kg, i.p.; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (5.3 mg/kg; i.p.).  
Under aseptic conditions, both ovaries were externalized and excised.  Muscle and skin 
layers were individually closed.  Six days later, rats in the estradiol-supplementation 
experiments received a single subcutaneous injection into the left flank of 10 μg/kg 
estradiol benzoate (Sigma, E-9000) at 10 μg/mL in vehicle (10% ethanol/90% corn oil), 
or an equivalent volume of vehicle.   
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7.3.2  Pain model (Formalin injection) 
 Approximately 24 hours after estradiol or vehicle injection (or seven days after 
OVX), rats received an injection of 50 μL of 1.25% formalin or 100 μL of 5% formalin 
into the right plantar hind paw as a model of persistent inflammatory pain.  Restraint-only 
control rats were manually restrained and hind paw handled as if injecting, but received 
no needle prick or injection.   
7.3.3  Tissue collection 
 7.3.3.1  Brains 
 Two hours after formalin injection, rats were anesthetized with 
ketamine/xylazine, and perfused transcardially with ice-cold phosphate-buffered saline 
(PBS) followed by 4% paraformaldehyde (PFA) in PBS, pH 7.4.  Brains were 
subsequently removed and post-fixed overnight in PFA at 4 °C, then in 30% sucrose at 4 
°C for a few days before freezing. 
 7.3.3.2  Uteri 
 Approximately 24 hours after estradiol or vehicle injection (seven days after 
OVX), a separate group of rats were weighed then decapitated, adipose tissue was 
removed from uteri, and uteri were excised at the base and weighed wet.   
7.3.4  Immunohistochemistry for Fos 
 Frozen brain coronal sections at approximate Bregma +2.3 through +0.8 mm, 
−1.6 through −3.1 mm, and −4.8 through −6.3 mm [based on “The Rat Brain in 
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Stereotaxic Coordinates” by Paxinos & Watson (2005)] were prepared at 20 μm using a 
cryostat and mounted on microscope slides.   
 7.3.4.1  Fluorescent immunohistochemistry 
 Coronal sections were collected at Bregma −1.6 through −3.1 mm (amygdala and 
rostral hippocampus for dentate gyrus and CA1/2/3), and −4.8 through −6.3 mm (caudal 
hippocampus for ventral dentate gyrus and ventral CA3) [based on “The Rat Brain in 
Stereotaxic Coordinates” by Paxinos & Watson (2005)].  Sections were probed with 
primary rabbit anti-Fos antibody (1:1000, Calbiochem), and labeled with FITC-
conjugated donkey anti-rabbit antibody (1:200, Jackson), as described for spinal cord 
sections (see Chapter 5).  Sections were then viewed on a fluorescent microscope, and 
neurons in CA1, CA2, CA3 and dentate gyrus (DG) of the hippocampus and basolateral 
and basomedial (combined), central and lateral nuclei of amygdala exhibiting NeuN- and 
Fos-positive immunoreactivity and DAPI staining were counted for the entirety of each 
region, with 2-8 sections averaged per rat.  Anatomical regions were defined based on 
Paxinos & Watson (2005).   
 7.3.4.2  Colorimetric immunohistochemistry and automated image analysis 
 Coronal sections were collected at Bregma +2.3 through +0.8 mm (nucleus 
accumbens), −1.6 through −3.1 mm (hippocampal dentate gyrus and central amygdala), 
and  Bregma −4.8 through −6.3 mm (hippocampal ventral CA1).  Sections were 
incubated one hour at room temperature with a rabbit polyclonal anti-Fos primary 
antibody (1:1000, Calbiochem, La Jolla, CA).  Sections were then incubated with 
secondary antibody (1:200, goat anti-rabbit, Vector Laboratories, Burlingame, CA)for 30 
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minutes at room temperature, coupled with avidin DH: biotinylated horseradish 
peroxidase H complex (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA), 
and visualized with diaminobenzidine (ImmPACT DAB Peroxidase Substrate, Vector 
Laboratories, Burlingame, CA), according to our optimized protocol based on the 
manufacturer’s instructions.  Anatomical regions were defined based on Paxinos & 
Watson (2005).  Digital photomicrographs of each region were taken at 40X 
magnification using a Nikon 80i light microscope.  One image sampling area was chosen 
for each region of interest as follows:  A) nucleus accumbens:  dorsomedial to the 
anterior commissure so that the anterior commissure is just out of frame; B) central 
amygdala:  to include the lateral-most portion of the central nucleus; C) dentate gyrus 
(anterodorsal hippocampus):  to include both aspects of the granular layer at the 
ventromedial “corner” of the dentate gyrus near the 3rd ventricle; and D) ventral CA1 
(posterior hippocampus):  within one to two frames dorsal of the “turn” of the granular 
layer where its orientation changes from more medio-lateral to dorso-ventral (or vice 
versa).  Images were always oriented with the shorter (top-bottom) dimension 
approximately parallel with the dorso-ventral axis.  An automated image analysis macro 
with the software ImageJ was used, which included, for all images, thresholding of 
intensity – based on the modal pixel intensity value of the entire image – and positive 
area size limits (to exclude areas too small or large to be neuronal nuclei) before 
automated counting.  The threshold for positivity was determined empirically and set to 
pixel intensity ≤ (darker than) 81% of the modal pixel intensity value of the (each) entire 
image.  The positive area size limits were set to include pixel area sizes that were 
calculated to be equivalent to the area occupied by circles with diameters of 5-15 μm.  
157 
Limitations were also made on the relative circularity of shape of these areas.  Immuno-
positive cells were counted and averaged per image for sections (at least 60 μm between 
sections) within the rostral-caudal extent for each supraspinal site (one image per region 
of interest, per section) from each rat, with 3-18 sections averaged per rat.  The average 
number of immuno-positive cells in sections without primary antibody was subtracted 
from other average values for each rat.  After group averaging, data were normalized to 
the control group value for the left or right side independently of one another.  Data are 
expressed as the mean  SEM for each group.   
7.3.5  Statistical analyses 
 All data represent the mean  SEM.  Data were statistically analyzed by Student’s 
t-test or one-way ANOVA with a post hoc (Holm-Sidak) multiple comparisons test, with 




Figure 43.  Illustration of sampling locations and anatomy for automated image analysis of Fos 
immunohistochemistry.  Sagittal view of rat brain showing where coronal sections were sampled through 
three main areas: A) Bregma +2.3 through +0.8 mm (Nucleus Accumbens), B) Bregma −1.6 through −3.1 
mm (hippocampal dentate gyrus and central amygdala), and C) Bregma −4.8 through −6.3 mm 
(hippocampal ventral CA1).  Coordinates based on “The Rat Brain in Stereotaxic Coordinates” by Paxinos 




7.4  Results 
7.4.1  Fluorescent immunohistochemistry for Fos 
 The current study used fluorescent immunohistochemistry to investigate the 
regulation of Fos expression in brain regions evoked by two intensities of a nociceptive 
formalin stimulus compared with a restraint-only control.  This project was also designed 
to investigate the impact of acute E2 supplementation on Fos expression in the same 
brain structures.  Brain structures investigated were CA1, CA2, CA3 and dentate gyrus of 
the hippocampus, as well as basolateral and basomedial (combined), central and lateral 
nuclei of the amygdala.  The results of this study demonstrated the presence of Fos-
positive neurons in all of the regions investigated (Figure 44).  Analysis of the numbers 
of Fos-positive cells revealed that formalin did not change Fos expression in the 
amygdala or hippocampus (Figures 45 and 46).  In addition, the results of this 
experiment did not reveal any estradiol-evoked modification of Fos expression in the 
amygdala or hippocampus following 1.25% formalin injection in the hind paw (Figures 
47 and 48).  As is typical for sections stained by fluorescent IHC, the fluorescent labeling 
of the Fos targets remained visible for only a short period of time (days) before their 
integrity was lost).  For this reason, the resulting sample numbers in this experiment were 
small, and may have precluded the observation of significant formalin- or estradiol-
evoked effects.  Accordingly, fluorescent IHC was not pursued further in favor of 
colorimetric IHC, which would provide relatively longer-lasting stained sections – a 
quality desired for a more comprehensive and time-consuming investigation of Fos 





Figure 44.  Representative photomicrographs of fluorescent immunohistochemical staining for Fos in rat 
brain following formalin-evoked inflammatory nociception.  Brains were collected two hours after injection 
of 50 μL of 1.25% formalin into the right hind paw.  Brains were cut into 20 μm-thick sections, probed 
with primary rabbit anti-Fos antibody (1:1000, Calbiochem), and labeled with FITC-conjugated donkey 
anti-rabbit antibody (1:200, Jackson).  Note that Fos expression was visible in the granular layer of the 
hippocampal dentate gyrus (A) and CA1/2/3 regions (B) as well as the lateral and central amygdala (C).  




Figure 45.  Fos immunohistochemistry in the hippocampus following 1.25% or 5% formalin-evoked 
inflammatory nociception.  Data collected using manual counting of fluorescence-positive cell bodies.  
Female rats were ovariectomized (OVX) and, seven days later, rats were either injected into the right hind 
paw with 50 μL of 1.25% formalin, 100 μL of 5% formalin or received sham restraint only (no formalin), 
and brains were collected 2 hours later.  Following immunohistochemical staining for Fos, 20-μm sections 
were viewed on a fluorescent microscope, and neurons in CA1, CA2, CA3 and dentate gyrus (DG) of the 
hippocampus exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  Note 
that Fos-positive neurons were present in each of the regions examined.  Data represent the mean ± SEM 





Figure 46.  Fos immunohistochemistry in the amygdala following 1.25% or 5% formalin-evoked 
inflammatory nociception.  Data collected using manual counting of fluorescence-positive cell bodies.  
Female rats were ovariectomized (OVX) and, seven days later, rats were either injected into the right hind 
paw with 50 μL of 1.25% formalin, 100 μL of 5% formalin or received sham restraint only (no formalin), 
and brains were collected 2 hours later.  Following immunohistochemical staining for Fos, 20-μm sections 
were viewed on a fluorescent microscope, and neurons in basolateral & basomedial (combined), central and 
lateral amygdala exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  
Note that Fos-positive neurons were present in each of the regions examined.  Data represent the mean ± 






Figure 47.  Effect of estradiol on Fos expression in hippocampus following 1.25% formalin-evoked 
inflammatory nociception.  Data collected using manual counting of fluorescence-positive cell bodies.  
Female rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 10 µg/kg 
estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), rats 
were injected with 50 μL of 1.25% formalin into the right hind paw, and brains were collected 2 hours later.  
Following fluorescent immunohistochemical staining for Fos, 20-μm sections were viewed on a fluorescent 
microscope, and neurons in CA1, CA2, dorsal CA3, ventral CA3, dorsal dentate gyrus (DG) and ventral 
dentate gyrus of the hippocampus exhibiting NeuN- and Fos-positive immunoreactivity and DAPI staining 
were counted.  Data represent the mean ± SEM (Significance level set to p ≤ 0.05, unpaired Student’s t-test; 
n:  CA1, CA2, dorsal CA3, dorsal DG:  6 per group; ventral CA3:  Left – Vehicle = 2, E2 = 6, Right – 





Figure 48.  Effect of estradiol on Fos expression in amygdala following 1.25% formalin-evoked 
inflammatory nociception.  Data collected using manual counting of fluorescence-positive cell bodies.  
Female rats were ovariectomized (OVX) and, six days later, received a single s.c. injection of 10 µg/kg 
estradiol (E2) or vehicle.  Twenty-four hours after estradiol (E2) injection (seven days after OVX), rats 
were injected with 50 μL of 1.25% formalin into the right hind paw, and brains were collected 2 hours later.  
Following immunohistochemical staining for Fos, 20-μm sections were viewed on a fluorescent 
microscope, and neurons in basolateral & basomedial (combined), central and lateral amygdala exhibiting 
NeuN- and Fos-positive immunoreactivity and DAPI staining were counted.  Data represent the mean ± 
SEM (Significance level set to p ≤ 0.05, unpaired Student’s t-test; n = 6 per group). 
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7.4.2  Colorimetric immunohistochemistry for Fos 
 The continuation of the study used colorimetric IHC to investigate the 
relationship between Fos expression in brain regions and the inflammatory nociception 
evoked by two levels of formalin stimulus versus restraint-only controls.  Brain regions 
investigated were nucleus accumbens, central amygdala, dentate gyrus and ventral CA1 
of hippocampus.  Results of colorimetric IHC showed that 1.25% formalin increased Fos-
positive neurons in the right nucleus accumbens.  There was no change in the number of 
Fos-positive neurons for 1.25% or 5% formalin in the dentate gyrus, ventral CA1, central 
amygdala, or left nucleus accumbens (Figure 52).   
 This project also investigated the impact of acute E2 supplementation on Fos 
expression in the (same four) aforementioned brain structures.  The results of this 
analysis revealed that in the left nucleus accumbens, 1.25% formalin increased the 
number of Fos-positive neurons in E2-treated, but not vehicle-treated, rats.  This group 
with 1.25% formalin and E2 also had higher numbers of Fos-positive neurons than that of 
the control group receiving sham restraint and no E2 (vehicle).  No other differences 
were found between any treatment groups for the dentate gyrus, ventral CA1, central 
amygdala, or right nucleus accumbens (Figure 53).   
 Furthermore, the results of this study also revealed that, in the right ventral CA1, 
E2 treatment decreased the number of Fos-positive neurons in 5% formalin-treated rats.  
Also, the group receiving 5% formalin and no E2 (vehicle) treatment had more Fos-
positive neurons than the group that received sham restraint and E2, but this comparison 
is not relevant to the hypothesis.  No other differences were found between any treatment 
166 





Figure 49.  Illustration of sampling regions and anatomy for automated image analysis of Fos 
immunohistochemistry & representative photomicrographs of immunohistochemical staining for Fos.  
Illustrations (left) of coronal sections through sampling locations [modified from “The Rat Brain in 
Stereotaxic Coordinates” by Paxinos & Watson (2005)].  The box indicates the approximate image 
sampling area for each structure.  Coronal sections at A) Bregma +2.3 through +0.8 mm (Nucleus 
Accumbens), B) Bregma −1.6 through −3.1 mm (hippocampal dentate gyrus and central amygdala), and C) 
Bregma −4.8 through −6.3 mm (hippocampal ventral CA1) were prepared at 20 μm using a cryostat and 
visualized with diaminobenzidine.  Digital photomicrographs (right) of each region were captured at 40X 




Figure 50.  Representative photomicrograph of DAB immunohistochemical staining for Fos in brain (right 
dentate gyrus) following formalin.  Sections were prepared at 20 μm and probed with a rabbit anti-Fos 
primary antibody (1:1000, Calbiochem).  Sections were then labeled with secondary antibody (1:200, goat anti-
rabbit, Vector Laboratories), and visualized with avidin DH: biotinylated horseradish peroxidase H complex 
(Vectastain Elite ABC Kit, Vector Laboratories) and diaminobenzidine.  Digital photomicrograph taken at 




Figure 51.  Example of automated image analysis.  Panels (A) through (C) show the same representative 
photomicrograph at various steps through the automated image analysis method.  Following 
immunohistochemical staining for Fos with DAB, digital photomicrographs of each region were taken at 40X 
magnification (A).  An automated image analysis macro with the software ImageJ was used, which included, 
for all images, thresholding of intensity (B) and positive area size limits (to exclude areas too small or large to 
be nuclei) before automated counting (C).  A) An original example photomicrograph.  B) After thresholding.  





Figure 52.  Fos immunohistochemistry in brain regions following no injection, 1.25% or 5% formalin.  
Data collected using automated image analysis of DAB staining.  Female rats were ovariectomized (OVX) 
and, seven days later, rats were either injected into the right hind paw with 50 μL of 1.25% formalin, 100 
μL 5% formalin or received sham restraint only (no formalin), and brains were collected 2 hours later.  
Sections were prepared at 20 μm, and, following immunohistochemical staining for Fos with DAB, digital 
photomicrographs of the left and right dentate gyrus were taken at 40X magnification.  An automated image 
analysis macro with the software ImageJ was used for automated counting of Fos-positive cells.  Note that 
1.25% formalin increased Fos-positive neurons in the right nucleus accumbens.  There was no change in 
Fos-positive neuron counts for any other stimulus in any other region examined.  Data represent the mean ± 
SEM (Statistically significant comparisons are marked with brackets; p ≤ 0.05, one-way ANOVA with 







Figure 53.  Effect of estradiol on Fos expression in brain regions following 1.25% formalin.  Data 
collected using automated image analysis of DAB staining.  Female rats were ovariectomized (OVX) and, 
six days later, received a single s.c. injection of 10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after 
estradiol (E2) injection (seven days after OVX), rats were injected with 50 μL of 1.25% formalin into the 
right hind paw, and brains were collected 2 hours later.  Sections were prepared at 20 μm, and, following 
immunohistochemical staining for Fos with DAB, digital photomicrographs of the left and right dentate gyrus 
were taken at 40X magnification.  An automated image analysis macro with the software ImageJ was used for 
automated counting of Fos-positive cells.  Note that, in the left nucleus accumbens, 1.25% formalin 
increased Fos-positive neuron counts in E2-treated rats.  This 1.25%/E2 group also had higher counts than 
that of the control group receiving sham restraint and no E2 (vehicle).  No other differences were found 
between any treatment groups for any of the regions examined.  Data represent the mean ± SEM 
(Statistically significant comparisons are marked with brackets; p ≤ 0.05, one-way ANOVA with Holm-






Figure 54.  Effect of estradiol on Fos expression in brain regions following 5% formalin.  Data collected 
using automated image analysis of DAB staining.  Female rats were ovariectomized (OVX) and, six days 
later, received a single s.c. injection of 10 µg/kg estradiol (E2) or vehicle.  Twenty-four hours after 
estradiol (E2) injection (seven days after OVX), rats were injected with 100 μL of 5% formalin into the 
right hind paw, and brains were collected 2 hours later.  Sections were prepared at 20 μm, and, following 
immunohistochemical staining for Fos with DAB, digital photomicrographs of the left and right dentate gyrus 
were taken at 40X magnification.  An automated image analysis macro with the software ImageJ was used for 
automated counting of Fos-positive cells.  Results revealed that, in the right ventral CA1, E2 treatment 
decreased Fos-positive neuron counts in 5% formalin-treated rats.  Also, the group receiving 5%/vehicle 
treatment had higher counts than the sham/E2 group.  No other differences were found between any 
treatment groups for any of the regions examined.  Data represent the mean ± SEM (Statistically significant 
comparisons are marked with brackets; p ≤ 0.05, one-way ANOVA with Holm-Sidak post-hoc test.  The 




7.5  Discussion 
 The current data add significantly to our understanding of the alteration of central 
nervous system activation by persistent inflammatory nociception.  Potential central sites 
of nociception-evoked activation have been suggested by previous Fos-labeling (Bon et 
al., 2002; Ceccarelli et al., 1999; Doyle & Hunt, 1999; Harris, 1998; Herrera & 
Robertson, 1996; Kaneko et al., 2000; Khanna et al., 2004; Kovacs, 1998; Menetrey et 
al., 1989; Presley et al., 1990; Sandner et al., 1993) and gene expression studies (Allen & 
McCarson, 2005; Duric & McCarson, 2005, 2006b, 2007; McCarson & Krause, 1994, 
1995; Neugebauer et al., 2004).  The current study investigated formalin-evoked Fos 
expression in supraspinal regions that had not been previously investigated in peer-
reviewed publications, such as the nucleus accumbens, as well as some that had, such as 
the hippocampal dentate gyrus and ventral CA1 and central amygdala (Aloisi et al., 2000; 
Aloisi et al., 1997; Ceccarelli et al., 1999; Khanna et al., 2004; Neugebauer et al., 2004).   
7.5.1  Fluorescent immunohistochemistry for Fos 
 The current study used fluorescent immunohistochemistry to investigate the 
regulation of Fos expression in brain regions evoked by two intensities of a nociceptive 
formalin stimulus compared with a restraint-only control.  This project was also designed 
to investigate the impact of acute E2 supplementation on Fos expression in the same 
brain structures.  Brain structures investigated were CA1, CA2, CA3 and dentate gyrus of 
the hippocampus, as well as the basolateral and basomedial (combined), central and 
lateral nuclei of the amygdala.  The results of this study demonstrated the presence of 
Fos-positive neurons in all of the regions investigated.  These results also revealed that 
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formalin did notchange Fos expression in the amygdala orhippocampus and that estradiol 
did not modify the Fos expression in the amygdala or hippocampus evoked by 1.25% 
formalin injection in the hind paw.  Due to limitations, fluorescent IHC was not pursued 
further in favor of colorimetric IHC.  
7.5.2  Colorimetric immunohistochemistry for Fos: 
 The use of automated, quantitative image analysis for colorimetric 
immunohistochemistry provides a more unbiased, and likely more precise, quantification 
method than manual counting.  Computer image analysis can arguably more accurately 
and reproducibly (precisely) make a determination of intensity relative to the threshold of 
intensity for positivity, for each instance and from sample to sample.  It also allows for 
high-throughput analysis, as multiple images can be analyzed in a relatively short time 
period compared to manual counting. 
 This study was the first of its kind to report Fos expression in the nucleus 
accumbens following intraplantar formalin-evoked nociception.  Current results 
demonstrated that inflammatory nociception evoked by intraplantar injection of 1.25% 
formalin increased Fos-positive neurons in the right nucleus accumbens (Figure 52).  
This may indicate that an increase in Fos in the nucleus accumbens reflects increased 
activation (nociception).  The increase in Fos in the accumbens is consistent with 
previous gene expression studies.  In a related study, the number of Fos-positive neurons 
in the core of nucleus accumbens was reported as higher than control following injection 
of formalin into low back skin or muscle (Ohtori et al., 2000).  However, this study was 
performed in anesthetized rats, complicating comparison to the current study.  
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Nonetheless, it supports the findings of the current study that formalin-evoked 
nociception increases Fos expression in the nucleus accumbens.  Moreover, Dr. Allen’s 
dissertation showed that NK-1 and BDNF gene expression were markedly increased in 
the nucleus accumbens 24 hours following intraplantar formalin (Figure 42), supporting 
a role of this structure in pain processing that involves increased expression of gene 
products that typically mediate neuronal excitation.  The change in expression of these 
genes in the nucleus accumbens may also partially represent plasticity-mediated 
sensitization of the central nervous system that occurs with persistent nociception, and 
similar changes may occur in chronic pain conditions.  The results of the current study 
support the addition of the nucleus accumbens to the list of brain structures that manifest 
altered gene (Fos) expression from nociceptive activation.   
 The current study did not demonstrate a formalin-induced change in Fos 
expression in the dentate gyrus or ventral CA1; these results were not consistent with 
previous reports, which demonstrated formalin-induced decreased Fos expression in these 
regions (Ceccarelli et al., 1999; Khanna et al., 2004).  One report mentioned Fos 
expression “tended” to decrease in the dorsal dentate gyrus and ventral CA1 (in OVX 
females) following formalin, but statistical significance of these comparisons were not 
reported (Aloisi et al., 2000); thus, those data may support the current negative findings.  
Allen & McCarson (2005) found that formalin injection decreased BDNF expression in 
whole hippocampus, but only in rats with E2 supplementation, not ovariectomized ones.  
Dr. Allen showed in her dissertation that hippocampal NK-1 receptor expression was also 
decreased by formalin (Figure 42).   
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 The current study did not find a change in Fos expression in the central amygdala 
due to formalin.  This is consistent with one previous publication which found no change 
in c-fos mRNA in the central amygdala following intraplantar formalin, whereas changes 
were demonstrated in the basolateral and lateral amygdala (Nakagawa et al., 2003).  In 
contrast, the number of Fos-positive neurons in the central amygdala was reported as 
higher than control following injection of formalin into low back skin or muscle (Ohtori 
et al., 2000).  However, this study was performed in anesthetized rats, and control 
conditions were different, complicating comparison to the current study.  Additionally, 
Traub et al. (1996) showed that noxious colorectal distention increased Fos expression in 
the central amygdala.  However, that pain model may activate different neural substrates 
or pain-processing mechanisms than the formalin model, as the processing in the 
amygdala differs with the type of painful stimulus (Neugebauer, 2007).  In a model of 
arthritic persistent pain, expression of metabotropic glutamate receptors were up-
regulated in the central amygdala, demonstrating plasticity induced by the model 
consistent with pharmacological observations of enhanced sensitivity (Neugebauer et al., 
2004).  NK-1 and BDNF gene expression were robustly down-regulated in the amygdala 
following formalin-evoked nociception (Figure 42).  Therefore, pain of different origins 
is capable of modulating gene expression in the central amygdala, but the current study 
corroborates the previous report in that Fos expression in the central amygdala was not 
altered by the formalin model.   
 It was observed in the left nucleus accumbens that inflammatory nociception 
evoked by intraplantar injection of 1.25% formalin increased Fos-positive neuron counts 
in E2-treated, but not vehicle-treated, rats (Figure 53).  This observation indicated a 
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“permissive” effect of E2 on nociceptive activation of these neurons, supporting an E2-
facilitated activation of the left nucleus accumbens by formalin.  This result supports the 
hypothesis suggesting the existence of supraspinal sites of action, namely the nucleus 
accumbens, through which E2 potentiates inflammatory nociception.  However, caution 
should be used when interpreting the direction of change (increase or decrease) on 
nociception in the left accumbens, because, even though the current results indicated an 
increase in Fos in the right accumbens correlated with nociception (Figure 52), the 
relationship of Fos expression to nociceptive neuronal function may not necessarily be 
the same for left and right accumbens.  The current study implicates the nucleus 
accumbens as a supraspinal site of action of E2-mediated increased persistent 
inflammatory nociception. 
 Notably, the results of this study revealed that, in the right ventral CA1, E2 
treatment decreased the number of Fos-positive neurons in 5% formalin-treated rats 
(Figure 54).  This indicates that E2 modified nociception-related neuronal activity in the 
ventral CA1; thus the ventral CA1 was a probable supraspinal site of action where E2 
increases nociception.  Therefore, the current results further support the hypothesis that 
E2 increases inflammatory nociception by acting at supraspinal sites.  Allen & McCarson 
(2005) found that formalin injection decreased BDNF expression in whole hippocampus, 
but only in rats with E2 supplementation, not ovariectomized ones.  This indicated an 
interaction of E2-mediated signaling with formalin-evoked nociceptive processing that 
suppressed the level of BDNF in the hippocampus.  Because E2 changed BDNF and Fos 
expression in the same direction (decrease), their expression levels may have similar 
functional implications for the hippocampus, or neurons within the hippocampus.  
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However, the function of these BDNF- or Fos-positive neurons must be delineated before 
solid conclusions can be made in terms of contribution to overall nociception.  Dr. Allen 
showed in her dissertation that hippocampal NK-1 receptor expression was also 
decreased by formalin (Figure 42).  Previous reports have demonstrated formalin-
induced decreased Fos expression in the ventral CA1 (Ceccarelli et al., 1999; Khanna et 
al., 2004).  Thus, it appears that a decrease in Fos in the ventral CA1 may indicate the 
occurrence of pro-nociceptive processing in the ventral CA1.  These arguments support 
the conclusion that, since E2 decreased formalin-evoked Fos expression in the ventral 
CA1, estradiol increased pro-nociceptive processing in the ventral CA1. 
 These findings support the hypothesis that activational effects of estrogen may 
contribute to sex differences in chronic pain syndromes by acting at supraspinal sites in 











8.1  Effects of androgens on pain-related behaviors  
 These experiments used gonadectomy alone or with testosterone supplementation 
to manipulate androgen status in an acute manner in adult, male rats, and subsequently 
tested the impact of this androgen manipulation on behavioral responses in several pain 
models.  Results of androgen manipulation revealed that androgen has activational effects 
on pain of phasic thermal and persistent neuropathic origin, but perhaps not persistent 
inflammatory origin.  These results provide evidence that androgens, as well as estrogens, 
may contribute to sex differences in pain sensation.  The lack of evidence for androgen-
mediated effects on nociceptive behavior in the formalin model prompted subsequent 
focus on estrogen manipulation in females. 
 
8.2  ERK as a marker of nociceptive activation 
 Levels of ERK in the spinal cord were quantified at several time points following 
injection of formalin into the rat hind paw, using immunohistochemistry for pERK-
positive neurons or western blotting for pERK.  Observations of levels of ERK led to the 
conclusion that quantification of ERK activation by either of these methods was not 
adequately sensitive to use as a marker for neuronal activation, or estrogen modulation 





8.3  Estrogen modifies formalin-evoked flinching but not spinal Fos expression 
 These experiments used ovariectomy with estradiol supplementation to 
manipulate estrogen status in an acute manner in adult, female rats, and subsequently 
tested the impact of this estrogen manipulation on behavioral responses (paw flinching 
and actometry end points) to formalin injection into the hind paw – a model of persistent, 
inflammatory pain.  Results of the behavioral analyses indicate that a proestrus-like surge 
in serum estrogen can modify (increase) inflammatory nociception-related behaviors and, 
thus, presumably nociception in an activational manner.  However effects of estradiol on 
nociception (and/or related behaviors) may be dependent on the intensity of noxious 
stimulus.  Results of estradiol manipulation confirmed the hypothesis that a single 
injection of estradiol significantly enhances late-phase formalin-induced hind paw 
flinching at 5% formalin (Figure 19).  By demonstrating an effect of acute, direct 
manipulation of estradiol in female rats on behavior evoked by 5% formalin, these results 
support the conclusion that estradiol activationally increases persistent, inflammatory 
nociception. 
 However, the administration of estradiol did not significantly alter numbers of 
nociception-evoked Fos-positive neurons in the ipsilateral lumbar spinal cord dorsal horn 
at either formalin concentration (Figures 35 and 36).  Together, these observations 
support the conclusion that, whereas estrogen enhances pain-related behaviors evoked by 
persistent inflammatory nociception, estrogen may not significantly modulate the 
intensity of nociceptive neuronal activation in the peripheral nervous system (primary 
sensory neurons) or spinal cord.  Thus, it appears that the peripheral nervous system and 
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spinal cord may not be primary targets for estrogen acting to increase inflammatory 
nociception.   
 The current findings also suggest that estrogen may be enhancing inflammatory 
nociception primarily via actions at other anatomical sites, such as supraspinal sites, 
where pain sensation is modified subsequent to spinal transmission.  Accordingly, 
subsequent investigation was aimed at determining modulatory effects of estradiol at 
supraspinal sites.   
 
8.4  Selection of supraspinal sites for investigation 
 Hypothetically, limbic and cortical areas involved in affective processing may be 
important for sex differences or sex hormone modulation of pain.  This notion, in part, 
guided the selection of supraspinal sites for investigation in this project.  The incidence of 
affective/emotional disorders in women and the cyclic nature of their onset, severity and 
duration suggest that hormonal modulation in affective centers could be a mechanism that 
enhances pain sensation.  Sensitization of the limbic system by estrogen and a heightened 
impact on the affective component of pain may underlie the disproportionate burden of 
mood disorders and certain chronic pain syndromes (e.g., depression and fibromyalgia) in 
women.   
 Synaptic plasticity associated with long-term potentiation occurs in limbic centers 
such as the amygdala (Maren, 2005) and hippocampus.  There is extensive literature on 
plasticity and long-term potentiation in the hippocampus.  The amygdala is deeply 
involved in emotional processing (Phelps & LeDoux, 2005).  Limbic structures have 
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functional roles in processing negative affect or nociception and undergo structural and 
functional changes in affective disorders (Ferre et al., 2007; Khanna & Sinclair, 1992; 
Knyihar & Csillik, 2006; Koyanagi et al., 2008; Magnusson & Martin, 2002; Mayberg, 
1997; Millan, 1999; Neugebauer, 2007; Neugebauer et al., 2004; Ploghaus et al., 2001; 
Porro, 2003; Price, 2000, 2002; Price et al., 2006; Sheline et al., 1996; Zubieta et al., 
2003; Zubieta et al., 2001).  Also, there is considerable plasticity in these structures both 
with regard to nociceptive/affective function as well as interaction with estrogen (Cooke 
& Woolley, 2005; Desmond & Levy, 1997; McEwen, 2001; McEwen & Magarinos, 
2001; Neugebauer, 2007; Neugebauer et al., 2004; Price, 2000, 2002; Price et al., 2006; 
Woolley, 1998, 2000; Woolley & McEwen, 1992), making these structures logical 
choices for investigating potential estrogen modulation of nociception.   
 
8.5  Estrogen and nociception in the hippocampal ventral CA1 
 Results showed that estradiol decreased Fos in right ventral CA1 in the presence 
of 5% formalin (Figure 54); no difference in Fos due to estradiol in the absence of 
formalin was observed.  These results, combined with the observations of E2-mediated 
increased flinching behavior and lack of E2 effect on spinal Fos expression (as discussed 
above), support the hypothesis that E2 increases persistent, inflammatory nociception 
primarily at supraspinal sites of action.  Furthermore, the ventral CA1 is a probable target 
for this pro-nociceptive effect of E2.   
 The finding of an E2-induced difference in Fos in the ventral CA1 elicited by 5% 
formalin, but not 1.25% formalin, is consistent with the observation of an E2-induced 
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increase in flinching at 5% formalin but not 1.25% formalin.  These results indicate E2 
increases inflammatory nociception in a stimulus-intensity dependent manner.  This 
could mean there is a threshold effect for E2 to influence nociception, especially for any 
particular structure.  E2 may affect neurons, signaling mechanisms, pathways, or 
synapses that are involved in processing of higher, but not lower, intensity stimulation.   
 Estradiol, in the presence of 5% formalin, changed Fos expression in the same 
direction (decreased) as formalin was previously reported to have in the ventral CA1 
(Khanna et al., 2004), thus appearing to have a pro-nociceptive effect there.  Also, 
reduced activity (reduced Fos immunoreactivity) in the ventral CA1 is consistent with 
mechanisms of depression; persistent inflammatory nociception or immobilization stress 
will drive down NK-1 and BDNF gene expression throughout the hippocampus (Duric & 
McCarson, 2005).   
 The lack of a formalin-only-induced change in Fos in ventral CA1 in the current 
data limit interpretation of the estradiol-induced change in Fos.  Differences in control 
group conditions and findings of sex differences in previous reports [see (Aloisi et al., 
2000; Aloisi et al., 1997; Ceccarelli et al., 1999; Khanna et al., 2004)] make it difficult to 
provide context for interpretation of the current Fos expression data in terms of influence 
(interaction) of E2 or gonadal hormones on (with) formalin-/noxious stimulus-induced 
nociception or related neuronal activity. 
 Finally, from these data we can at least conclude that the ventral CA1 has 
modified neuronal activity due to E2.  Whether this activity is pro- or anti-nociceptive is 
unclear.  In all, these data support the existence of supraspinal site(s) of E2-mediated 
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modulation of/increases in nociception.  The ventral CA1 is implicated as such a site of 
E2-mediated modulation; or E2-mediated modulation could be due to action at another 
(supraspinal) site that modifies activity in the ventral CA1.   
 The CA1 subdivision is the main output of the hippocampus (Witter, 2006).  
Major output targets of the CA1 include the cingulate cortex, anterior thalamus, 
prefrontal cortex, mammillary bodies, subicular complex, nucleus accumbens, and 
entorhinal cortex.  In addition, the anterior thalamus in turn projects to cingulate cortex.   
 The cingulate cortex is a very important pain and affective processing center 
(Price et al., 2006; Rainville, 2002; Zubieta et al., 2003; Zubieta et al., 2001).  It receives 
spinothalamocortical nociceptive input.  The experience of pain involves interaction of 
processing at many nervous system sites, including the cingulate cortex.  There is 
correlation between the activity in the cingulate and ratings of pain intensity as well as 
ratings of pain unpleasantness (affect) (Rainville, 2002).  Also, specific manipulation of 
pain affect produced specific modulation of activity in the cingulate and pain 
unpleasantness (Rainville, 2002).  Several areas within the cingulate cortex undergo pain-
related activation.  Part of the cingulate may also contribute to motor control during pain.  
The cingulate appears to be a center for processing motor, behavioral, cognitive, and 
affective responses to pain, as well as modulation of pain.  Thus, the cingulate cortex is a 
key area for processing nociception and behavior in animals and pain affect in humans.  
Therefore, modulation of output to the cingulate, from places such as the CA1, likely has 
an impact on the (affective) processing of pain/nociception. 
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 The CA1 region of the hippocampus has direct & indirect (through the subicular 
complex, entorhinal cortex, or cingulate cortex) output to the prefrontal cortex (PFC) 
(Conde et al., 1995; Laroche et al., 1990; Tierney et al., 2004).  The direct pathway is 
excitatory and can undergo long-term potentiation (Laroche et al., 1990).  The prefrontal 
cortex has functions in the affective and cognitive aspects of pain (Price et al., 2006; 
Price & Drevets, 2010), and afferent pathways to the PFC from limbic structures such as 
the CA1 may regulate sensorimotor gating (Miller et al., 2010).  Thus, modulation of 
CA1 activity, as shown by an estradiol-mediated effect in the current study, possibly 
modulates signaling in the PFC and, through this, impacts nociception and potentially 
pain sensation.  Modulation of the PFC is another possible avenue through which 
estradiol could mediate increases in nociception.   
 The CA1 output to nucleus accumbens also has high significance in terms of 
potential impact on pain processing.  The accumbens is another structure that has 
important function in the processing of pain and affect (see p. 188).  Thus, modulation of 
output from the CA1 to the accumbens is another possible way estrogen could increase 
nociception. 
 In addition, hippocampal output to the forebrain and hypothalamus may influence 
descending modulation of nociception.  These targets of hippocampal output have 
descending projections to the periaqueductal gray that could serve to integrate and relay 
descending modulation of nociception (Marchand & Hagino, 1983).   
 Electrophysiological and pharmacological data reveal decreased activity in (some) 
CA1 neurons in response to noxious stimulation (Khanna & Sinclair, 1992).  
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Pharmacological blockade in the hippocampus that is relevant to this phenomenon 
decreased nociception-related behavior (Rodgers & Brown, 1976).  Other evidence 
implies that CA1 neurons may also have an opioid-mediated inhibitory role in pain 
processing (Roumy & Zajac, 1998).  These observations are consistent with a decrease in 
Fos expression in the CA1 being correlated with increased nociception, as in the current 
study with E2 and in the report by Khanna et al. (2004). 
 
8.6  Estrogen and nociception in the nucleus accumbens 
 It was observed in the left nucleus accumbens that inflammatory nociception 
evoked by intraplantar injection of 1.25% formalin increased Fos-positive neuron counts 
in E2-treated, but not vehicle-treated, rats (Figure 53).  This observation indicated a 
“permissive” effect of E2 on nociceptive activation of these neurons, supporting an E2-
facilitated activation of the left nucleus accumbens by formalin.  Formalin (1.25%) alone 
increased Fos expression in the right nucleus accumbens in the formalin-only study, 
indicating the involvement of the nucleus accumbens (core) in nociceptive function (at 
least in formalin-induced nociceptive processing).  However, caution should be used 
when interpreting the direction of change (increase or decrease) pertaining to nociception 
in the left accumbens, because the relationship of Fos expression to nociceptive neuronal 
function may not necessarily be the same for left and right accumbens.  Nonetheless, this 
result supports the hypothesis suggesting the existence of supraspinal sites of action, 
namely the nucleus accumbens, through which E2 potentiates inflammatory nociception.  
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Thus, the current study implicates the nucleus accumbens as a supraspinal site of action 
of E2-mediated increased persistent inflammatory nociception.   
 The nucleus accumbens is part of a neural network loop with the pallidum, 
thalamus, and prefrontal cortex that overlaps and is interconnected with a loop involving 
the amygdala, striatum, pallidum, and thalamus (Price & Drevets, 2010).  The accumbens 
(ventral striatum) receives direct input from the spinal cord (Newman et al., 1996) and 
amygdala (Price & Drevets, 2010).  The amygdala also receives direct projections from 
the spinal cord (Newman et al., 1996).  These observations support the assertion that the 
limbic system (including the accumbens) plays an important role in mediating pain.   
 Recent studies have established a function of the nucleus accumbens in pain 
modulation.  Through indirect connection with the PFC, which participates in descending 
modulation of pain, the accumbens could participate in the descending modulation of 
nociception.   
 The nucleus accumbens clearly regulates outflow of pain-modulatory information 
from the limbic system.  This influence can be inhibitory or facilitatory, and both 
excitatory (e.g. NMDA) and inhibitory (e.g. dopamine receptor D2, cholecystokinin, 
endogenous opioid) mechanisms exist within the nucleus accumbens.  The nucleus 
accumbens is an important pain & affect processing center (Knyihar & Csillik, 2006; 
Koyanagi et al., 2008; Magnusson & Martin, 2002; Millan, 1999; Ohtori et al., 2000; 
Zubieta et al., 2001, 2002).  Pharmacological studies support the existence of adenosine 
and opioid signaling in the accumbens that contribute to nociceptive sensory and 
affective processing (Ferre et al., 2007; Zubieta et al., 2001).  The nucleus accumbens 
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(core) appears to have an anti-nociceptive function in processing nociception elicited by 
formalin injection (Altier & Stewart, 1997; Lapeyre et al., 2001; Magnusson & Martin, 
2002; Taylor et al., 2003).  Magnusson & Martin (2002) demonstrated that blockade of 
activity by microinjection of local anesthetic into the accumbens core, but not shell, 
enhanced formalin-induced nociception.   
 Fos expression could reflect activity in cells of either excitatory or inhibitory 
function, or both.  Thus, if estradiol increases nociception, estradiol-mediated increased 
activity (Fos) in the nucleus accumbens could represent increased activity of inhibitory 
inter-neurons within the accumbens, resulting in decreased output of neurons with anti-
nociceptive function and, therefore, a pro-nociceptive effect.  Alternatively, estradiol may 
be increasing nociception by acting on a different supraspinal structure, and the increased 
activity (Fos) in the accumbens may represent increased compensatory, anti-nociceptive 
processing.   
 The E2-facilitated increase in Fos expression in the accumbens evoked by 1.25% 
formalin, with no estradiol-mediated change in the degree of flinching behavior, may 
mean E2 increases nociception, but that this effect is masked by nociceptive or behavioral 
output processing at other centers.  Also, the lack of an E2-mediated change in Fos 
expression elicited by 5% formalin, along with an E2-mediated increase in flinching, may 
mean E2 does not modulate nociception in the accumbens at higher concentrations 
(stimulus levels), or that E2 does modulate nociception in the accumbens, but this effect 
is not manifested as a change in Fos expression.  This dichotomy may speak to a 
limitation of the use of Fos immunohistochemistry as a proxy for the degree of activity, at 
least in this structure.   
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8.7  Fos as a marker of nociceptive activation 
 There are limitations for using Fos expression or behavior as proxies of the 
nociceptive experience.  The response level or range of Fos expression in a given site in 
the nervous system may limit the ability to observe modulation of neuronal activity.  
There are thresholds or ceilings to the expression of Fos elicited by a stimulus.  There 
may be differences in these thresholds or ceilings on Fos expression in each respective 
structure versus other structures or versus behavioral output.  The level of Fos expression 
represents activation of a given structure, whereas behavior represents the net output of 
all processing in all relevant nervous system centers.  Also, it is possible that modulation 
of behavior could occur without modulation of overall nociception, or vice versa.   
 The specific contributions of each of the brain regions where Fos expression is 
altered by formalin-evoked inflammation to the overall perception of pain have not been 
fully elucidated.  Accordingly, the functional implications of Fos expression in these 
brain areas remain somewhat undefined.  Fos-expressing neurons in each location could 
have differential effects (e.g. excitation/inhibition, nociception/anti-nociception), and it 
remains unclear whether Fos expression only reflects afferent input, or represents altered 
sensitivity to the input and/or the degree of activity (output) of the labeled neurons.  In 
addition, estrogen may be acting directly in these structures, or indirectly by acting on 
other centers that modulate neuronal activity in these structures.   
 Potential limitations of the brain Fos study include the following: 1) “signal” 
might be diluted with sections over the rostral-caudal extent of a structure, if Fos-
expressing neurons (or neurons that respond to stimulus/modulated by E2) are not 
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homogeneously spread throughout the structure (i.e., located within a smaller rostral-
caudal extent than that examined).  2) Also, one sampling region is only part of the 
structure and may not represent neuronal/Fos activation for the whole structure (as 
opposed to counting Fos-positive neurons across the entire structure within each section).  
These two aspects represent differences between the current study and other previous 
studies.   
 Why does E2 modulation of gene expression occur in sites where no modification 
of nociception-evoked Fos was observed?  Nociception-evoked gene expression in the 
spinal cord dorsal horn has been shown to be modulated by estrogen status.  For example, 
basal and nociception-evoked expression of the brain-derived neurotrophic factor 
(BDNF) gene in the spinal cord is modified by estrogen (Allen & McCarson, 2005). 
 First, the observations of BDNF (and NK-1) were made with a different (longer 
OVX, longer & constant E2) estrogen treatment than current experiments where Fos was 
quantified.  These differences in experimental parameters could bring about different 
modulation of the nervous system, and, thus, the observed dichotomy in these end points. 
 In addition, observations of BDNF (and NK-1) were made at 24 hours following 
formalin; observation of Fos was made at 2 hours.  Used at these different time points, 
they (or any measures) may be markers of different phenomena.  For example, different 
sensitizing changes to the nervous system may be present at 24 hours; these changes 
might be more representative of sensitivity to subsequent stimulation.  The expression of 
Fos at 2 hours is likely more representative of sensitization that takes place during the 
initial inflammatory insult.  Both aspects are important in terms of estrogen sensitizing 
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the nervous system, but modulation that impacts the initial insult (which is probably in 
place beforehand) is perhaps more powerful or important regarding sensitization than 
modulation that only occurs upon subsequent stimulation. 
 Perhaps its most distinguishing property, the quantification of Fos is a marker of 
function; i.e., it represents the degree of neuronal activity or metabolism.  BDNF and 
NK-1 are biomolecules that have function in neuronal signaling, but, standing alone, are 
not functional markers.  Compensatory changes could take place in other facets of 
signaling or neuronal function, a possibility which blurs the interpretation of such end 
points.   
 Obviously, there are inherent obstacles to the use of biomolecular end points 
(such as these) as proxies of the degree on neuronal activity.  It is important to recognize 
that any potential relationship between immediate-early gene expression and other, 
subsequent events like signaling cascade modification or regulation of evoked gene 
expression remains largely undefined.  Ultimately, perhaps the most interpretable 
measures of neuronal activity are electrophysiological recording or functional imaging.   
 
8.8  Comparison with previous reports 
 Differences in control group conditions and findings of sex differences in 
previous reports make it difficult to give context to interpretation of the current Fos 
expression data in terms of (regarding) influence (interaction) of E2 or gonadal hormones 
on (with) formalin-/noxious stimulus-induced nociception or related neuronal activity.  
There are differences in the manipulation of control groups between the current study and 
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other relevant studies, and among other studies; for example, some control groups 
received essentially no manipulation (Ceccarelli et al., 1999), paw manipulation but no 
needle prick/injection (current study), needle prick into the paw but no injection (Aloisi et 
al., 2000), or injection of saline (Khanna et al., 2004).  Another difference between this 
study and others is the sex of the subjects; the current study was performed with females, 
but the study by Khanna et al. (2004) was with males.  Relevant to this, sex differences 
have been found in the end points used (e.g. hippocampal Fos expression) following 
stimulation with formalin (Aloisi et al., 1997; Ceccarelli et al., 1999). 
 Another aspect that sets the current study apart from others is the timing of the 
estradiol manipulation.  Previous studies typically used longer durations of ovariectomy 
and longer treatment with estradiol before the nociceptive stimulus was applied.  For 
example, work in Dr. Amy Allen’s dissertation used an OVX duration of two weeks and 
then sustained estradiol treatment for two weeks before application of formalin.  The 
current study used an OVX period of six days and then a single injection of estradiol 24 
hours before formalin, in order to model more acute effects of estradiol.  Different dose 
and timing of estradiol manipulation regimens may employ different estrogen signaling 
mechanisms (e.g. genomic vs. rapid, membrane signaling) and potentially different 
effects on neuronal activity.   
 Other bodies of work have focused on organizational differences, which take 
place during development and result in permanent sex differences.  For example, studies 
have shown that aspects of opioid anti-nociception were modified by organizational 
effects of sex hormones (Cataldo et al., 2010; Craft & Ulibarri, 2009).  Investigations 
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such as these into this organizational type of sex steroid effect are in contrast with the 
plasticity-driven, activational effects that are the focus of this dissertation project.   
 Some other studies have used chronic inflammation models of chronic pain, such 
as subcutaneous injection of complete Freund’s adjuvant (CFA), to study nociceptive 
activation and plasticity in specific sites of the nervous system.  The CFA model does not 
evoke stereotyped behaviors like the formalin model does, but manifests hyperalgesia to 
subsequent phasic stimulation.  This is in contrast to the use of formalin in this project; 
formalin produces persistent activation, but is used as an acute stimulus.   
 Similar to this dissertation project, Dr. Amy Allen’s dissertation work 
investigated estradiol modulation of gene expression in response to noxious stimulation 
with formalin in specific nervous system sites.  Dr. Allen demonstrated some estradiol-
mediated changes in gene expression in relevant brain regions (Allen & McCarson, 
2005).   
 
8.9  Future studies 
 As with most scientific inquiries, results of this project open the door for more 
inquiry.  Future or further studies could microinject E2 into the structures investigated 
herein to determine how E2 modulation in these structures affects nociception and related 
behavior.  Recapitulation of the behavioral enhancement or changes in Fos expression by 
local E2 effects would confirm these structures as sites of action for E2-mediated 
enhancement of nociception.   
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 To better define the contribution of each structure to formalin-induced 
nociception and behavior, as well as give more context to Fos expression in these areas, 
experiments could modify activity in specific sites using microinjection of local 
anesthetic or agonists or antagonists of specific neuronal signaling molecules.   
 More studies are needed to determine the function of Fos-positive neurons in 
these structures.  For example, pertinent information would be the mode of output of 
these neurons (excitatory or inhibitory), their connectivity, and the function of their 
projection targets.   
 The current project focused on investigating sites involved in emotional/affective 
processing.  Alternatively, future investigation of potential sites of action of estradiol 
could be sensory/discriminative sites, such as the ventral posterolateral thalamus, primary 
or secondary sensory cortex, etc.  In addition, other sites involved in affective processing 
of pain as well as higher level integration of sensory, cognitive and affective components 
of pain (e.g. cingulate cortex, prefrontal cortex) could be investigated.   
 Investigations could be undertaken into the signaling mechanisms of estrogen-
mediated modulation of nociception in specific nervous system sites that have been 
identified as participating in such modulation.   
 Other investigations, similar to this project, could be made into identifying 




8.10  Final conclusions 
 The results of this research project demonstrate that nociception-evoked levels of 
Fos expression in higher brain centers, unlike those in the spinal cord, are modified by 
estrogen status in female rats.  Together with observations that estrogen enhances pain-
related behaviors, these results suggest that estrogen enhances inflammatory nociception 
via actions at higher brain centers.   
 The results of these studies reveal the nucleus accumbens and the ventral CA1 
region of the hippocampus as supraspinal structures where estrogen modifies 
nociception-evoked neuronal activity.  Both centers are involved in the regulation of 
affect, and thereby may contribute to the emotional component of pain sensation.  
Modulation of pain processing in these structures may also contribute to sex differences 
in the sensory and affective experiences of pain.   
 The results of these studies also demonstrate that activational, rather than 
organizational, effects of estrogen at supraspinal sites of action modify nociception.  
These activational effects may contribute to sex differences in pain sensation and/or the 
disproportionate severity or incidence of some pain syndromes in women.   
 Experiments in this dissertation represent only a small glimpse of what impact sex 
steroids are capable of having on pain processing.  They demonstrate what impact sex 
steroids can have on processing pain of specific types.  This knowledge still needs to be 
reconciled with the impact that sex steroids do have on pain processing.  There are 
limitations which prevent the making of generalizations based on these, or any, data 
pertaining to sex steroid modulation of pain.  Many factors that contribute to these 
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limitations include, but are not limited to, the timing with respect to the noxious 
stimulation, duration and level of steroid presence, the type (modality) of pain, location 
on the body, etc., as well as more generic factors, such as sex, age, genetics, and lifestyle.   
 Certainly, the knowledge gained from this research contributes to a more 
complete understanding of modulation of pain by sex hormones.  Knowledge of the 
specific roles of sex hormones in pain perception will eventually lead to more efficacious 
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